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Every year more than 10 million people develop cancers globally. Ovarian
cancer, specifically, results in more than 22,000 new cases and 16,000 deaths from this
disease yearly, more than any other cancer of the female reproductive system. In
addition, because of non-specific symptoms and poor screening techniques, most ovarian
cancer cases are discovered after the disease is in an advanced state. Consequently,
aggressive and effective treatment options that incur minimal toxic effects to healthy
tissue are in great need.
In the present research, stealth biodegradable nanoparticles were developed as
vehicles for the controlled and targeted delivery of chemotherapeutic agents for the
treatment of ovarian cancer. The design of this delivery system consisted of
nanoparticles of biodegradable polymers of the poly(lactic-co-glycolic acid) family
loaded with the chemotherapeutic agent doxorubicin or the imaging agents rhodamine
6G, indocyanine green or gadopentetic acid. Nanoparticles were modified by
incorporation of functional poly(ethylene glycol) on their surface to improve the stability
viii
of the colloidal suspension, increase their circulation lifetime in vivo, and provide a site
for conjugation of targeting agents specific to ovarian tissue. Various methods were
evaluated for this surface modification, including the use of polymer blends, the chemical
conjugation of the polymers, and the polymerization of lactide and glycolide monomers
initiated by heterofunctional poly(ethylene glycol). Nanoparticles incorporating
poly(ethylene glycol) presented improved characteristics compared to unmodified
particles including smaller size, higher stability and slower release of the
chemotherapeutic agent doxorubicin The actual drug or agent content was decreased in
the case of doxorubicin and rhodamine, but increased for indocyanine green as a result of
improved agent-polymer interactions.
Poly(ethylene glycol)-containing nanoparticles were conjugated to monoclonal
antibody mAb106-105, which is specific to the extracellular domain of human follicle-
stimulating hormone (FSH) receptors. These receptors are only expressed in ovarian
cells in women, thus providing a system that is highly specific to ovarian tissue. The
interaction and therapeutic potential of nanoparticles with or without targeting antibodies
were tested on OVCAR-3, Caov-3, and MDA-MB-231 cancer cells.
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Cancer is a disease that affects millions of people across the globe every year.
The World Health Organization estimated that more than 10 million people developed a
malignant tumor and more than 6.5 million people died from this disease during the year
2000 (Ferlay, Bray et al. 2004). In the United States, cancer is the second cause of death
from disease after heart disease, accounting for more than half a million deaths every
year. According to the American Cancer Society Cancer Statistics, the overall cost for
cancer for the United States in 2004 was $189.8 billion: $69.4 billion for direct medical
costs, $16.9 billion for indirect morbidity costs, and $103.5 billion for indirect mortality
costs (American Cancer Society 2005). Most importantly, while mortality rates of other
major chronic diseases, such as heart and cerebrovascular disease, decreased significantly
in the past half century, cancer mortality rates have remained approximately constant
(American Cancer Society 2005). This is a troubling fact because it suggests that recent
detection and treatment options have not been able to improve mortality rates
substantially.
Ovarian cancer, specifically, currently accounts for 3% of the estimated new cases
and 6% of the deaths associated with cancer in women in the United States, which
equates to approximately 22,200 cases and 16,200 deaths every year (American Cancer
Society 2005). Death rates for ovarian cancer have remained almost constant since the
1950’s, and the relative five-year survival rate from 1995 to 2000 was 44%, compared to
88% for breast cancer (American Cancer Society 2005). Unfortunately, symptoms of
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ovarian cancer are not specific and current screening methods are not very sensitive.
This results delayed detection, usually after the cancer is in an advanced state and has
metastasized, and consequently after the chance of survival has been sharply reduced.
The three main treatment options for ovarian cancer patients are surgery,
chemotherapy, and radiation therapy. In all cases, the extent of treatment depends on the
type of cancer, the stage of the disease, the patient’s overall state of health, and personal
considerations. In most cases, however, a combination of surgical and chemotherapeutic
treatments is utilized. All of these treatment options may lead to permanent menopause
and infertility. Chemotherapeutic treatments in general lack specificity because they
target all proliferating cells by inhibiting DNA synthesis or interfering with processes of
cell division or metabolism (Twardowski and Margolin 2002). As a consequence,
chemotherapy leads to the damage of healthy tissue, especially of the normally dividing
cells of the bone marrow, skin, and gastro-intestinal mucosa, among other tissues. In
addition, neoplastic cells readily mutate, and many cancers develop resistance to
chemotherapeutic agents (Twardowski and Margolin 2002). The poor specificity of
chemotherapeutic agents commonly prevents aggressive and effective treatment of the
cancer.
Targeted delivery of imaging and therapeutic agents with the use of biodegradable
nanoparticles promises to improve early detection of the cancer, reduce dose-limiting side
effects during treatment, and improve the efficacy of the treatment by controlling the
spatial and temporal distribution of the imaging agent or drug in vivo. To date, most
delivery systems for ovarian cancer have targeted the folate receptors (Li 1998; Sudimack
and Lee 2000) and luteinizing hormone-releasing hormone receptors (Wang, Lin et al.
2003; Yang, Chan et al. 2006) that are overexpressed in ovarian cancer cells. However,
because these receptors are also expressed in numerous other healthy tissues, only limited
3
specificity can be achieved. There is, as a result, a great need for the development of a
system that can more specifically target ovarian cancer tissue.
1.1 OVERALL RESEARCH OBJECTIVES
The development of an alternative formulation for targeted delivery of imaging
and chemotherapeutic agents to ovarian cancer cells based on the concepts of
biomaterials, controlled drug delivery and targeted drug delivery could result in a system
that overcomes some of the problems associated with current methods. Specifically, the
main objectives of the research project described here were to develop, characterize and
evaluate an injectable, long-circulating, controlled release system based on biodegradable
polymeric nanoparticles that directs imaging and chemotherapeutic agents to ovarian
tumors. To achieve the desired specificity of this formulation to ovarian cancer cells
these nanoparticles are targeted the follicle stimulating hormone (FSH) transmembrane
receptors which are solely expressed in the ovaries and testis (Richards and Midgley
1976; Kangasniemi, Kaipia et al. 1990; Simoni, Gromoll et al. 1997; Meduri, Charnaux et
al. 2002). Importantly, expression of FSH receptors has also been observed to occur in
samples of numerous types of ovarian epithelial cancers as described in Chapter 2
(Nakano, Kitayama et al. 1989; Zheng, Lu et al. 2000; Parrott, Doraiswamy et al. 2001;
Syed, Ulinski et al. 2001; Wang, Lin et al. 2003). It is expected, consequently, that the
increased and spatially restricted expression of these receptors in ovarian cancer cells
could enhance targeted delivery of imaging and therapeutic agents.
The design of the developed nanoparticles consists of a core of the biodegradable
polyesters poly(lactide-co-glycolide) or poly(lactic acid) and free pendant chains of
functional poly(ethylene glycol) onto which targeting moieties are conjugated, as
depicted in Figure 1.1. The imaging or chemotherapeutic agents to be delivered are
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encapsulated within the biodegradable core and are released through a combination of
diffusion across the polymeric matrix and degradation of the same.
The system developed is designed to be more efficacious than the current method
of systemic bolus administration of chemotherapy and other targeted delivery systems
because:
- By releasing the chemotherapeutic agent over time through controlled release, the
concentration of this agent is more easily maintained within the therapeutic
window for extended periods. This protects the patient from exposure to high
concentration bolus doses which are commonly near toxic levels while still
delivering therapeutic levels, results in the need for fewer administrations, and
increases patient compliance and quality of life during treatment.
- Targeting the nanoparticles loaded with chemotherapeutic agents to cellular
receptors of such strict expression profiles as the FSH receptors will provide an
extremely specific system that will deliver antineoplastic agents only to the
location where they are needed. Consequently, the toxicity that is traditionally
induced in other tissues of the body will be significantly reduced. It will then be
possible to provide more aggressive chemotherapeutic treatment while
minimizing serious side effects to the patient. Additionally, the fact that more of
the drug injected is put into intimate contact with the tumor means that therapy
will be more efficacious.
- Inclusion of poly(ethylene glycol) chains on the surface of the nanoparticles will
result in delayed opsonization, reduced uptake by the reticuloendothelial system,
and consequent increased time of residence in the circulation. This alteration
increases the likelihood that the therapeutic agent will reach its target without the
5
need for chemical modification of the drug which may interfere with its in vivo
activity.
1.2 SPECIFIC RESEARCH AIMS
The specific aims that were addressed in this project were the following:
(i) To prepare, characterize and optimize formulations of biocompatible,
biodegradable nanoparticles of poly(lactic-co-glycolic acid) (PLGA) loaded
with chemotherapeutic agents for therapeutic purposes. Specifically, the
chemotherapeutic agent used was doxorubicin, which is currently used in the
treatment of recurrent ovarian cancer. Nanoparticles were prepared by oil-in-
water nanoprecipitation of a polymer/drug solution upon addition to an aqueous
phase. Nanoparticles were characterized with respect to size, loading,
encapsulation efficiency, morphology, zeta potential, and in vitro drug release
kinetics.
(ii) To prepare and characterize the formulation of biocompatible,
biodegradable nanoparticles of poly(lactic-co-glycolic acid) loaded with
fluorescent or electron-dense agents for characterization purposes.
Encapsulation of fluorescent or electron-dense agents within nanoparticles was
sought for use in studying the interactions of the nanoparticles with the target
cells through fluorescence microscopy and electron microscopy, respectively.
The hypothesis here was that if these nanoparticle formulations had similar
properties to those loaded with chemotherapeutic agents, then they would be
useful for monitoring cellular and tissue uptake and distribution of therapeutic
nanoparticles both in vitro and in vivo. Rhodamine 6G, indocyaninie green and
gadopentetic acid were used as fluorescent and electron dense agents.
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Nanoparticles were characterized with respect to loading, encapsulation
efficiency, particle size and morphology.
(iii) To modify the initial formulations by including poly(ethylene glycol) (PEG)
free chains at the surface of the nanoparticles to provide stealth properties.
This modified formulation can present enhanced properties such as increased
lifetime in the circulation and distinct biodistribution in vivo, and provides the
possibility for attachment of targeting moieties at the surface of the nanoparticles.
Incorporation of functional PEG on the formulation was attempted through
polymer blending, polymer conjugation and co-polymerization techniques.
Nanoparticle preparation and cryoprotection variables were optimized.
(iv) To incorporate targeting agents specific to ovarian cancer cells on the surface
of the nanoparticles. A monoclonal antibody specific to the extracellular portion
of the FSHR receptor was introduced on the surface of the nanoparticles through
chemical conjugation to the functionalized end of the poly(ethylene glycol)
chains. Conjugation of the targeting agents was verified and optimized.
(v) To examine the specificity of cellular uptake, and intracellular distribution of
the various formulations of nanoparticles in vitro. Cellular studies were
carried out in ovarian epithelial cancer cell lines expressing the FSH receptors, in
addition to a non-ovarian cancer cell line. Comparative nanoparticle uptake
experiments in the different cell lines were performed in order to verify the
specificity of the targeted formulation to ovarian cancer cells.
(vi) To determine the therapeutic efficacy of the targeted delivery system in vitro.
The above mentioned types of cells were exposed to the targeted nanoparticles
loaded with chemotherapeutic agents. Cytotoxicity studies revealed the degree of
therapeutic effect of the various formulations: free drug, blank nanoparticles,
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drug-loaded nanoparticles with or without PEG modification, and drug-loaded
nanoparticles with the targeting agent.
1.3 OVERVIEW
Chapter 2 describes background information relevant to the drug delivery system
developed. Chapter 3 describes the preparation, characterization and in vitro evaluation
of poly(lactic-co-glycolic acid) nanoparticles loaded with the chemotherapeutic agent
doxorubicin. Chapter 4 describes the preparation and characterization of nanoparticles
loaded with the imaging agents rhodamine 6G, indocyanine green and gadopentetic acid
for in vitro and in vivo visualization. Chapter 5 describes the various strategies that were
used to incorporate poly(ethylene glycol) on the surface of the nanoparticles to improve
the stability of the formulation and provide a site for conjugation of targeting agents .
Chapter 6 describes the preparation of targeted nanoparticles containing poly(ethylene
glycol) and antibodies for targeting. Chapter 7 describes the results of in vitro evaluation
of the various formulations on ovarian cancer cells. Finally, Chapter 8 summarizes the
conclusions and future prospects for this research project.
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Figure 1.1 Design and Expected Mechanism of Action of Targeted Biodegradable
Nanoparticles. Nanoparticles Concentrate at the pathological tissue
because of the highly permeable vasculature of cancerous tissue, and
specifically interact with the targeted follicle stimulating hormone
receptors. The imaging or chemotherapeutic agents loaded within the
nanoparticles are released in a controlled manner either intracellularly
after receptor-mediated endocytosis, as shown, or extracellularly in close
proximity to the cancer cells.
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2.1 CONTROLLED DRUG DELIVERY
The properties of the nanoparticle-based system developed in this research are
based on the concepts of controlled drug delivery and targeted delivery. Controlled drug
delivery utilizes the combination of a bioactive agent with a non-active substance
(carrier) in such a way that the drug is released from the carrier in a predetermined
manner, whether at a constant rate in what is known as zero-order release, in a cyclic
manner, or in response to an external trigger such as a change in pH, ionic strength or
temperature of the medium (Brannon-Peppas 1997; Stayton, El-Sayed et al. 2005; Wei,
Zeng et al. 2005; Peppas 2006; Sawant, Hurley et al. 2006). The benefits offered by
controlled drug delivery over traditional pharmaceutical administration include
maintenance of the drug levels within desired limits, maximal use of the pharmaceutical,
the need for fewer doses, and better patient compliance (Brannon-Peppas 1997). In
addition, association of the drug with a carrier may provide enhanced protection to the
active agent from degradation in the physiological environment, and improve the stability
of the agent that is required for formulation and administration.
Examples of currently researched methods for drug delivery include prodrugs,
dendrimers, liposomes, micelles, hydrogels, implantable systems, micro- and
nanofabricated systems, Microparticles, and nanoparticles. Prodrugs are generated
through the chemical conjugation of an active agent with a carrier molecule, which could
be a polymer or lipid (Lee, Lu et al. 2002; Mhaka, Denmeade et al. 2002). Dendrimers
are highly branched macromolecules of very small size, and monodistributed molecular
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weight that can be used to deliver high payloads of drugs through conjugation of the
active agent with the numerous surface or interior functional groups (Kukowska-Latallo,
Candido et al. 2005). Both prodrugs and dendrimers have the disadvantage of chemically
modifying the active agent, possibly affecting its in vivo activity. Liposomes consist of
vesicles formed by phospholipids bilayers, and which deliver the drug into cells by fusing
with cellular membranes (Torchilin, Narula et al. 1996; Schiffelers, Koning et al. 2003).
Micelles consist of self-assembled vesicles formed by lipids or other amphiphilic
molecules (including polymers), and which can be used for encapsulation and isolation of
hydrophobic molecules from the surrounding hydrophilic physiological environment
(Yoo and Park 2001; Yoo and Park 2004; Lee, Na et al. 2005; Liu, Tong et al. 2005;
Venkatraman, Jie et al. 2005; Nasongkla, Bey et al. 2006). Liposomes and micelles offer
advantages such as prolonged circulation time, altered pharmacokinetics, and the ability
to encapsulate highly hydrophobic drugs, but do not usually provide controlled release
over time. Hydrogels are materials capable of uptaking significant amounts of water and
swelling in result to changes in the surrounding environment, resulting in increased pore
sizes that allow controlled release of its contents (Torres-Lugo, Garcia et al. 2002;
Peppas, Wood et al. 2004; Blanchette and Peppas 2005). Drug delivery systems based on
hydrogels have been shown to result in low drug burst effects, but do not usually provide
long term drug release. Implantable systems can provide long term drug release, but
require invasive interventions for implantation and removal, thus resulting in lower
patient acceptability (Desai, Mallery et al. 2007; Huolman and Ashammakhi 2007;
Kontakis, Pagkalos et al. 2007).
Micro- and nanofabricated systems have only recently been researched for drug
delivery. Although these techniques can produce drug carriers with specific geometrical,
structural and functional properties (Betancourt and Brannon-Peppas 2006), the costs
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associated with their production may limit their applications. Microparticles (Brannon-
Peppas 1995; Kasturi, Sachaphibulkij et al. 2005; Lin, Ng et al. 2005) and nanoparticles
(Couvreur, Dubernet et al. 1995; Yoo, Oh et al. 1999; Janes, Fresneau et al. 2001;
Brannon-Peppas and Blanchette 2004; Betancourt, Brown et al. 2007)encapsulate drugs
in either a reservoir or matrix arrangement, in which the drug is either localized to the
center of the particle and surrounded by a polymer layer, or dispersed throughout a
polymeric matrix, respectively. Depending on the conformation, and on the material
used to fabricate the micro- or nanoparticle, these systems may lead to various drug
release kinetic profiles –including constant (zero-order) release– as a result of the
combined effects of drug diffusion and carrier degradation (Brannon-Peppas 1997).
Nanoparticles, in addition, because of their small size, are able to circulate through
capillaries, preferentially escape into tumor tissue because of the enhanced permeability
and retention effect (EPR), and may be taken up by cells for intracellular drug delivery,
as will be discussed in the “targeted drug delivery” section. It is these properties of
nanoparticles that were exploited for the development of the targeted delivery system in
this project.
2.1.1 Biomaterials for Drug Delivery
Numerous biopolymers, both synthetic and natural, have been studied for drug
delivery applications. As for any other device used for in vivo applications, drug delivery
systems must result in low or preferably non-detectable adverse physiological reactions
such as immunogenicity and toxicity. Natural polymers include cellulose, chitosan,
hyaluronic acid, chondroitin sulfate, gelatin, collagen, alginate, carrageenan, dextran,
proteins and DNA (Janes, Calvo et al. 2001; Friess 2004). Synthetic polymers include
poly(lactic-co-glycolic acid) (PLGA) and other lactide- or glycolide-derived polymers,
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polyethylene glycol (PEG), poly(acrylic acids), poly(acrylates), poly(acrylamides),
poly(anhydrides), poly(caprolactone), poly(urethanes), among others (Brannon-Peppas
1997; Huh, Cho et al. 2003). Synthetic polymers have a number of benefits including
high control of polymer properties, such as molecular weight and functionality, and
feasible commercial-scale production. In addition, although both synthetic and natural
polymers may activate the complement system, natural polymers can also lead to cellular
and humoral immune response as a result of the recognition of foreign organism markers.
The system developed in this research utilizes poly(lactide-co-glycolide) (PLGA),
the copolymer of lactide and glycolide, as the main component for the preparation of
nanoparticles for delivery of chemotherapeutic or imaging agents. PLGA is a
biodegradable polymer that has been approved by the FDA for use as suture material and
in various drug delivery systems, including Lupron Depot® formulation of leuprolide
acetate for the treatment of prostate cancer and endometriosis (TAP Pharmaceutical
Products), Nutropin Depot® PLGA formulation of human growth hormone (Genentech),
Sandostatin® Depot PLGA microsphere formulation for inhibition of human growth
hormone secretion (Novartis), ProLease® (Alkermes) and Trelstar® Depot (Debiopharm)
(Shive and Anderson 1997; Dechy-Cabaret, Martin-Vaca et al. 2004). PLGA degrades
by hydrolysis of its ester bonds into lactic acid and glycolic acid, both of which are
further metabolized into carbon dioxide and water through the Kreb’s cycle (Lewis 1990;
Brannon-Peppas 1995). The degradation of this family of polymers can be tailored
according to the co-monomer ratio, with a longer degradation time required with
increased lactic acid content. Degradation increases under extreme pH conditions. At
low pH degradation occurs through random chain cleavage which forms insoluble
oligomers and few carboxylic acid groups. In basic conditions, degradation occurs
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through preferential cleavage of terminal ester bonds which results in rapid formation of
soluble monomers and carboxylic acid groups (Abdelwahed, Degobert et al. 2006).
PLGA microparticles have been formulated in the past as carriers for oral,
mucosal and subcutaneous administration (Shive and Anderson 1997; Blanco and Alonso
1998; Fattal, Pecquet et al. 2002; Murillo, Goni et al. 2002; Freitas, Merkle et al. 2005).
Polymeric biodegradable nanoparticles, specifically those prepared from PLGA, have
only been utilized as drug delivery systems fairly recently (Brannon-Peppas 1995;
Panyam and Labhasetwar 2003; Feng, Mu et al. 2004; Astete and Sabliov 2006). These
were developed from the modification of well-known microparticle preparation
techniques (Jain 2000). PLGA nanoparticles degrade through bulk or uniform
degradation throughout the polymeric matrix (Brannon-Peppas 1995; Brannon-Peppas
1997). The research group of Dr. Brannon-Peppas has reported on the optimization
(Birnbaum, Kosmala et al. 2000) and scale up production (Brannon-Peppas and
Birnbaum 2000) of PLGA nanoparticles to up to 100g per batch, thus demonstrating the
feasibility of their production for clinical and commercial applications.
2.1.2 Poly(ethylene glycol) (PEG) in Drug Delivery
Unmodified polymeric nanoparticles administered through intravenous injection
are known to be rapidly cleared from the circulation by organs of the reiculoendothelial
system, namely the Kuppfer cells in the liver and the macrophages in the spleen (Fawaz,
Bonini et al. 1993; Brannon-Peppas and Blanchette 2004). For example, polystyrene
particles as small as 60 nm are known to be removed from the circulation within minutes
(Gref, Domb et al. 1995). Poly(ethylene glycol) (PEG) has been shown to increase
circulation time in the blood, modify the biodistribution, and provide shielding from
recognition by the immune system to biologically active agents (Stolnik, Dunn et al.
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1994; Gref, Luck et al. 2000; Mehvar 2000; Hu, zhai et al. 2002; Otsuka, Nagasaki et al.
2003). PEG is a hydrophilic, biocompatible, non-biodegradable polymer that has been
approved by the FDA for a number of biomedical applications, including suppositories
(Graham 1987), contraceptive sponges (Nakaoka, Tabata et al. 1997), and wound healing
membranes (Park, Jang et al. 2007). PEG is known to bind 2 to 3 water molecules per
ethylene oxide unit, effectively increasing its hydrodynamic size to up to 10 times that of
a soluble polymer of comparable molecular weight. Because of this, PEG coating
sterically stabilizes the nanoparticles and hinders their interaction with plasma proteins
and the immune system. The effect of PEGylation on the serum half life has been shown
to correlate with the molecular weight of the PEG chains. Half lives of up to 20 hours
have been observed with the use of 190 kDa PEG chains (Yokoyama and Okano 1996).
Although PEG is not biodegradable, PEG molecules of less than about 30 kDa can be
excreted from the body through renal clearance.
2.1.3 Targeted Drug Delivery
Targeted delivery utilizes unique phenotypic features of diseased tissues and cells
in order to concentrate the drug at the location where it is needed. Targeted delivery can
be divided into passive and active targeting. Passive targeting tries to minimize non-
specific interactions between the drug carrier and non-target sites in the body by detailing
its physiochemical properties such as size, morphology, hydrophilicity, and surface
charge (McDonald and Baluk 2002; Torchilin 2002). When targeting tumor tissue, the
enhanced permeability and retention effect (EPR) acts as a passive targeting approach
because it allows passage of drug carriers ranging in size from 10 to 500 nm through the
highly-permeable blood vessels that supply growing tumors, and leads to entrapment of
large molecules as a result of deficient lymphatic drainage (Yokoyama and Okano 1996;
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McDonald and Baluk 2002). In fact, it has been reported that the intra-cellular openings
in vascular endothelium of tumor blood vessels can be of up to 2 μm in diameter, and that
the vessel porosity in tumor vasculature can be up to an order of magnitude higher than
that of normal blood vessels (McDonald and Baluk 2002). The abnormal architecture of
tumor vasculature is a result of the process of neovascularization directed by tumor
factors, a process that is crucial for tumor growth and metastasis (Folkman, Merler et al.
1971; Folkman 2003). The ability of therapeutic NPs to utilize the EPR can translate into
improved anti-tumor efficacy, better use of the encapsulated pharmaceutical agent, and
increased patient compliance and quality of life.
Active targeting utilizes biologically specific interactions including antigen-
antibody and ligand-receptor binding, and may seek drug uptake by receptor-mediated
endocytosis through association of the drug or drug carrier with such antigen or ligand
(Torchilin 2002; Fahmy, Samstein et al. 2005). Receptor-mediated endocytosis
commonly occurs through clathrin-coated vesicles, and is carried out in mammalian cells
continuously for the uptake of nutrients, and for modulation of signal transduction
through the up- or down-regulation of signaling receptors (Conner and Schmid 2003).
Signaling receptors, such as the ones that are targeted with the present nanoparticles, are
commonly endocytosed in response to elevated hormone levels as a feedback regulation
mechanism. Targeted delivery avoids the need for high systemic drug levels for the drug
to be effective, and consequently offers a more economic alternative for treatment.
Targeted delivery is not only useful for therapeutic purposes, but has also been
researched for its ability to concentrate imaging or contrast agents for the detection of
malignancies and for monitoring the effects of therapeutic agents (Brannon-Peppas and
Blanchette 2004; Gao, Cui et al. 2004).
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Most systems for targeted delivery to cancer have utilized drug conjugates,
liposomes or micelles. Recently, however, various nanoparticle-based targeted systems
have been developed. Table 2.1 and Table 2.2 summarize some of the targeted drug
delivery systems or polymeric nanoparticle systems, respectively, for cancer treatment
that have been recently reported. To date, the vast majority of systems developed for
targeted drug delivery for the treatment of ovarian cancer target the folate receptor with
monoclonal antibodies or folic acid itself (Sudimack and Lee 2000; Turk, Waters et al.
2004; Yoo and Park 2004). Folate receptors are overexpressed in many tumor types,
including more than 90% of ovarian carcinomas (Sudimack and Lee 2000; Yoo and Park
2004). However, folate receptors are also expressed on epithelial cell in the placenta,
breast, lung, kidney, proximal tubles, choroid plexus, fallopian tubes, uterus, endocervix,
and salivary glands (Veggian, Fasolato et al. 1989; Weitman, Lark et al. 1992), as well as
in myelomonocytes and lymphoid cells (Shen, Ross et al. 1994; Ross, Wang et al. 1999).
Consequently, such systems will result in significant effects to these non-cancerous
tissues when administered systemically in vivo. Other systems have been designed to
target the Luteinizing Hormone-Releasing Hormone (LHRH) receptors (Arencibia,
Schally et al. 2001; Dharap, Qiu et al. 2003; Dharap, Wang et al. 2005) but run into the
same type of limitations as folate targeting.
As mentioned in Chapter 1, the system developed in the present project was
designed to actively target the follicle stimulating hormone (FSH) receptors for the
treatment of ovarian cancer by taking advantage of their exquisite ovarian-specific
expression profile.
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2.1.4 Multi-Drug Resistance and Drug Delivery Systems
Many types of tumor cells have developed resistance to treatment with
commonly-used chemotherapeutic agents with unrelated structures, including
doxorubicin. This multi-drug resistance is associated with the overexpression of
transmembrane ATP-binding transporters such as the P-glycoprotein (Pgp) and multidrug
resistance-related proteins (Yoo and Park 2004). These transport proteins are able to
excrete drugs that have diffused into the plasma membrane.
Drug delivery systems promise to increase therapeutic efficacy of
chemotherapeutic agents by delivering the drugs intracellularly to the cytoplasm or
endosomal compartments, thus avoiding recognition and excretion by these transporters
in the plasma membrane (Torchilin 2002). For example, folate-decorated doxorubicin
loaded nano-aggregates were found to be more effective than the free drug in vitro and in
vivo with human squamous carcinoma KB cells which are known to present severe multi-
drug resistance (Wong, Rauth et al. 2006). Solid lipid nanoparticles with doxorubicin
were seen to be eight times more effective than the free drug in multidrug resistant breast
cancer cells MDA435/LCC6/WT (Lee, Na et al. 2005). Doxorubicin-loaded pH sensitive
nanoparticles made from blends of poly(L-histidine)-poly(ethylene glycol)-folate and
poly(lactic acid)-PEG-folate resulted in 90% cytotoxicity of doxorubicin-resistant MCF-
7 cells and significantly improved in vivo therapeutic effect in a MCF-7 mice xenograft
model (Lu, Zheng et al. 2000). In all three examples, increased therapeutic effect was
attributed to bypass of Pgp efflux pump and consequent high drug concentrations
intracellularly.
As part of the present research project, we investigated the therapeutic efficacy of
targeted nanoparticles targeted to the follicle stimulating hormone receptor in multi-drug
resistant ovarian cancer cells, as discussed in Chapter 7.
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2.2 CONTRAST AGENTS IN MOLECULAR AND CLINICAL IMAGING
Clinical imaging is an important aspect of cancer detection and therapeutic
monitoring. Depending on the imaging modality, imaging tests can show the location
and some of the properties of a mass in the body. Ultrasound, for example, can be used
to determine whether a mass is solid or fluid. Computer Tomography (CT) scans can
give information about mass location and size. Magnetic Resonance Imaging (MRI)
produces images from variables that are determined by the chemical characteristics of
tissue, and consequently provides detailed anatomical information. Nuclear imaging,
which includes Positron Emission Tomography (PET) and Single Photon Emission
Computed Tomography (SPECT), can provide molecular information because it utilizes
radioactively-labeled materials that specifically accumulate at sites of disease. However,
this imaging modality provides images of considerable low resolution (5 to 7 mm) when
compared to CT and MRI images (~ 1mm). Despite the valuable information that all of
these imaging modalities provide in the clinical setting, to date only invasive biopsies are
able to reliably reveal whether a growth is cancerous.
Contrast agents have been extensively used in clinical settings to provide
enhanced specificity and contrast for imaging with the above-mentioned imaging
systems. In MRI specifically, various negative and positive contrast agents, which result
in dark and bright images respectively, are clinically used and many more are being
researched. Example of novel negative MRI contrast agents are superparamagnetic iron
oxide nanoparticles (Chertok, Moffat et al. 2007; Kumar, Leuschner et al. 2007; Liu,
Dahnke et al. 2007; Morello, Burrill et al. 2007). Positive contrast agents are commonly
small molecular weight compounds with unpaired electron spins in their outer shells,
such as compounds of the paramagnetic metal ion gadolinium, manganese or iron
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(D'Arceuil, de Crespigny et al. 2004; Lee and Koretsky 2004; Lee, Silva et al. 2005;
Silva, Lee et al. 2007). Commercially available gadolinium-based positive contrast
agents include Magnevist® (Schering, Germany), Gadovist® (Schering, Germany), and
Optimark® (Mallinkrodt, USA). The active agent in Magnevist®, which was the first
MRI contrast agent approved for clinical use, is gadopentetic acid (Gd-DTPA), a chelate
complex of the gadolinium ion. Magnevist® distributes in the intravascular and
extracellular fluid spaces, does not cross the blood brain barrier, and is excreted rapidly
by glomerular filtration via the kidneys. Contrast agents are also being developed for use
in molecular imaging, including its application in targeted drug delivery (Lanza, Winter
et al. 2004).
Encapsulation of contrast agents within drug delivery systems, such as the
targeted nanoparticles here developed, will change their biodistribution and
pharmacokinetics according to those of the carrier. Nanoparticles loaded with imaging
agents could be used for in vivo detection and monitoring of tumors, as well as for
monitoring the retention, biodistribution, and tumor uptake of the nanocarriers. In
addition, because of the increased circulation time and the narrow spatial localization
offered by the targeted nanoparticles, it is expected that they could provide a significant
increase in tumor-specific image contrast in vivo.
2.3 OVARIAN CANCER
Ovarian tissue contains three main types of cells: germ cells, stromal cells, and
epithelial cells. Germ cells are responsible for the production of oocytes (eggs). Stromal
cells surround the germ cells and produce most of the female hormones (estrogen and
progesterone). Epithelial cells line the ovary. Ovarian tumors are classified according to
the type of cell in which they originate. Germ cell tumors account for less than 5% of
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ovarian tumor cases, and usually occur in young women (American Cancer Society
2005). Since up to 70% of patients with germ cell tumors are diagnosed during the first
stage of the disease, the outcomes are generally positive. There are two types of germ
cell tumors: dysgerminomonas, the most common, and nondysgerminomatous.
Stromal tumors normally develop in post-menopausal women and also account
for about 5% of all ovarian cancers (American Cancer Society 2005). These tumors are
formed from the cells of the sex cord or early connective tissue, and commonly include
granulosa cells, Sertoli cells, thecal cells, and fibroblasts. Granulosa cell tumors are the
most prevalent of the stromal tumors, and are commonly accompanied by elevated levels
of the tumor marker inhibin in the circulation. Inhibin is responsible for the inhibition of
follicle stimulating hormone (FSH) secretion.
Cancers originating in the epithelial lining of the ovaries account for 90% of
ovarian cancers (Nitta, Katabuchi et al. 2001). Epithelial tumors can be further classified
into serous, endometroid, mucinous, and clear cells tumors. Ovarian epithelial cells are
involved in secretion of lysosomal enzymes to digest the follicular stroma during
ovulation and are degraded during this process. The rapid rate of epithelial cell
proliferation during healing after ovulation has been suggested to be a possible source of
mutagenic potential (Lu, Zheng et al. 2000).
Numerous factors have been associated with the risk for ovarian cancer. Elevated
levels of the pituitary gonadotropins luteinizing hormone and follicle stimulating
hormone, such as in postmenopausal women or women treated for infertility, have been
connected with a higher risk for ovarian cancer (Dias, Lindau-Shepard et al. 1998; Choi,
Choi et al. 2004). In contrast, reduced gonadotropin levels, such as in women who have
had multiple pregnancies, are breast feeding, use oral contraceptives, or are receiving
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estrogen replacement therapy, are associated with a reduced risk (Dias, Lindau-Shepard
et al. 1998; Lu, Zheng et al. 2000; Nitta, Katabuchi et al. 2001).
Early detection of tumors in general is usually regarded as the best method for
increased patient survival because it improves the chances of successful treatment. In
fact, the 5-year survival rate for patients diagnosed during stage I of ovarian cancer is
more than 90%, compared to 30-60% and 20% for stages III and IV, respectively
(American Cancer Society 2005). However, less than 20% of cases are discovered at an
early stage because of the non-specific symptoms and poor detection methods. The
symptoms associated with ovarian tumors usually include abdominal fluid buildup,
unusual vaginal bleeding, pelvic pressure, back or leg pain, and digestive symptoms such
as gas, bloating and indigestion. These symptoms, unfortunately, are often caused by
conditions other than cancer and commonly delay identification of the tumor until it has
spread beyond the ovaries.
Regular gynecological exams commonly fail to identify ovarian tumors because
the ovaries are internal organs that are difficult to palpate. Although a number of
screening tests are available, these were found not to lower the number of deaths caused
by ovarian cancer in studies, and, consequently, are only performed on women with
known high risk of developing ovarian tumors. Screening tests for epithelial ovarian
cancer include transvaginal sonography for ultrasound-based detection of masses –
whether cancerous or not–, and blood tests for quantifying levels of cancer antigen CA-
125 which have been correlated with ovarian cancer (Jacobs and Bast 1989). The CA-
125 test is very non-specific because a number of other gynecological conditions in
addition to hepatitis, pancreatitis, cirrhosis, and other cancers may result in elevated
levels of this marker. There are no tests available for screening for germ cell or stromal
tumors.
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Treatment options for ovarian cancer patients include surgery, chemotherapy, and
radiation therapy. In all cases, the extent of treatment depends on the type of cancer, the
stage of the disease, the patient’s overall state of health, and personal considerations. In
most cases, however, a combination of surgical and chemotherapeutic treatments is
utilized. Surgical options include uni- or bilateral oophorectomy, salpingectomy, and/or
hysterectomy, corresponding to the removal of the ovaries, fallopian tubes and uterus,
respectively. Cytoreduction or debulking of the tumor is also performed in order to
improve the patient’s prognosis. For stages III and IV the recommended surgical
treatment includes removal of the uterus, both fallopian tubes, both ovaries, and omentum
(fatty tissue from upper abdomen), in addition to tumor cytoreduction. Such treatment
completely eliminates the possibility of the patient ever becoming pregnant. After
surgery, combination chemotherapy is most commonly used, as will be described in the
following section.
Progress in the development of better treatments for ovarian cancer has been slow
because of numerous factors. There are no acceptable animal models that develop
ovarian epithelial cancers (Choi, Choi et al. 2004). Existing models are frequently
deemed not relevant as this disease almost never occurs in non-primate animals (Nitta,
Katabuchi et al. 2001). Little information has been gathered regarding the formation and
progression of human epithelial ovarian cancer as a result of late diagnosis and
consequent lack of human tissue at the early stages of the disease (Nitta, Katabuchi et al.
2001). Also, even though ovarian surface epithelial cells have been cultured and
characterized, their growth is not adequate for in vitro investigations (Nitta, Katabuchi et
al. 2001). A recent achievement has been the immortalization of normal ovarian
epithelial cells for research purposes (Nitta, Katabuchi et al. 2001). In addition,
xenograft models of human ovarian cancer have been reported to result in the formation
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of intraperitoneal carcinomatosis and metastasis in similarity to human tumors which
suggest that these models may provide valuable information for future studies (Nitta,
Katabuchi et al. 2001).
2.3.1 Chemotherapeutic Treatment of Ovarian Cancer
Combination chemotherapy is the standard therapeutic approach for the treatment
of epithelial cancerous tumors. As first-line therapy, a taxane such as paclitaxel in
combination with a platinum compound such as cisplatin is indicated. Recurrent
epithelial tumors are treated with either additional cycles of the above chemotherapeutic
combination, or with agents such as topotecan, doxorubicin, liposomal doxorubicin
(Doxil®), cyclophosphamide, vinorelbine (Navelbine®), hexamethylmelamine,
ifosfamide, etoposide, or topotecan with fluorouracil (American Cancer Society 2005).
There are no standard chemotherapy treatments for recurrent stromal cancer, but some of
the antineoplastic agents used are vincristine, cisplatin, doxorubicin, and
cyclophosphamide (American Cancer Society 2005). Doxorubicin was utilized in for the
preparation of therapeutic targeted nanoparticles in this research project.
2.4 FOLLICLE STIMULATING HORMONE AND RECEPTOR
The follicle stimulating hormone (FSH) is one of the two glycoprotein hormones
secreted by the pituitary gland, commonly referred to as gonadotropin hormones, that
regulate the function of the gonads (testes and ovaries) (Dias, Lindau-Shepard et al.
1998). The other gonadotropin hormone is the luteinizing hormone (LH). FHS is
essential for female fertility as it is key for the formation and development of follicles,
but not for male fertility (Vannier, Loosfelt et al. 1996; Lindau-Shepard, Brumberg et al.
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2001; Choi, Choi et al. 2004). FSH acts through receptors on granulosa cells in females
and on Sertoli cells in males (Vannier, Loosfelt et al. 1996). Structurally, it is composed
of two subunits ( and and two glycosilation sites on each unit (Dias, Lindau-Shepard
et al. 1998).
The follicle stimulating hormone receptor (FSHR) is a transmembrane protein
from the family of G protein-coupled signaling surface receptors (Lu, Zheng et al. 2000).
Its transmembrane domain its composed of seven -helices (Vannier, Loosfelt et al.
1996; Lindau-Shepard, Brumberg et al. 2001). The size of FSHR is of 74 kDa as
determined by Western Blot using a monoclonal antibody against the receptor (Vannier,
Loosfelt et al. 1996). The protein consists of 695 amino acids (Lindau-Shepard,
Brumberg et al. 2001). Specifically, it has been determined that the extracellular domain
comprises approximately 346 amino acids (residues 18–364) and contains the N-terminus
of the protein, the transmembrane domain contains 264 amino acids (residues 365-629),
the intracellular region consists of 65 amino acids (residues 630-695) and contains the C-
terminal end of the protein, and the signal peptide consists of amino acids 1-17 (Vannier,
Loosfelt et al. 1996; Lindau-Shepard, Brumberg et al. 2001).
The extracellular region has a leucine-rich repeat segment located within amino
acid residues 200-500 (Jiang, Dreano et al. 1995). Such leucine-rich repeats are believed
to be involved in protein-protein interaction and, consequently, to home the binding site
for FSH. Further studies have shown that the binding site is in close proximity to amino
acid residues 300-315 (Lindau-Shepard, Brumberg et al. 2001). Binding of FSH to FSHR
results in a conformational change that activates a signaling pathway through the
intracellular G-protein. This pathway consists of activation of adenylyl cyclase (cAMP)
followed by indirect activation of mitogen activated protein (MAP) kinases (Vannier,
Loosfelt et al. 1996).
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2.4.1 Expression and Function of FSHR in Ovarian Cancer
In this project, the possibility of using the FSH receptor for ovarian-specific
delivery of anti-tumor agents loaded in biodegradable nanoparticles was investigated.
FSH receptors have one of the most restricted cell distribution patterns, being expressed
only in the ovaries and testis (Richards and Midgley 1976; Kangasniemi, Kaipia et al.
1990; Simoni, Gromoll et al. 1997; Meduri, Charnaux et al. 2002). Expression levels of
FSHR on ovarian cells in vitro and in vivo both in healthy and diseased conditions have
been studied in numerous reports. Studies have identified high affinity binding sites for
FSH on samples of human serous and mucinous cystoadenomas of epithelial origin and
on samples of theca/theca-granulosa cell tumors (Nakano, Kitayama et al. 1989).
Additionally, FSH receptors have been identified on many ovarian cancer cell lines
(Parrott, Doraiswamy et al. 2001; Syed, Ulinski et al. 2001). In one study, expression of
FSHR was detected in 100% of ovarian epithelial inclusions, 100% of cystoadenomas,
94% of borderline tumors and 60% of carcinomas (Zheng, Lu et al. 2000). Increasing
levels of FSHR expression were observed with increased malignancy level from
precursor lesions to ovarian inclusions, benign ovarian epithelial tumors and borderline
ovarian epithelial tumors, in that order (Wang, Lin et al. 2003). However, the same
group also observed that FSHR expression decreased as the level of malignancy
increased from borderline ovarian epithelial tumors to ovarian carcinomas (Wang, Lin et
al. 2003).
Because of varying expression of FSHR in tumors with malignancy stage, a role
of FSH and FSHR on the development of the tumor has been suggested. The effect of
FSH exposure and FSHR expression on the presentation of oncogenes has been
investigated previously in vitro. After transfection of immortalized ovarian surface
epithelial cells IOSE-80 with an FSHR overexpression vector, overexpression of
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epidermal growth factor receptor (EGFR), c-myc and HER-2/neu oncogenes but not of
K-Ras oncogene were observed (Choi, Choi et al. 2004). This study also found that
overexpression of FSHR resulted in increased phosphorilzation of ERK1/2 but not of p38
or pJNK (Choi, Choi et al. 2004). A separate study reported that exposure of normal
ovarian cells, immortalized ovarian surface epithelial cells and some ovarian cancer cells
to FSH results in increased growth in a dose and time-dependent manner (Parrott,
Doraiswamy et al. 2001; Syed, Ulinski et al. 2001). These results suggest that FSHR
expression may be associated with an increased oncogene activation and proliferation in
preneoplastic and ovarian cancer cells.
Despite the fact that the role of FSHR in tumor development is not completely
clear to date, the fact that the expression of this receptor is limited to ovarian tissue offers
a possibility for enhancing the specificity of delivery of therapeutic nanoparticles to
ovarian cancer.
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Table 2.1 Targeted drug delivery systems reported in the literature. Abbreviations: 5-
fluorodeoxyiridine (5-FU), epidermal growth factor (EGF), epidermal
growth factor receptor (EGFR), poly(ethylene glycol) (PEG).
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CHAPTER 3
FORMULATION, CHARACTERIZATION AND IN VITRO
EVALUATION OF DOXORUBICIN LOADED NANOPARTICLES
3.1 INTRODUCTION
Chemotherapeutic agents commonly lead to the damage of healthy cells,
especially those of the bone marrow, skin, and gastro-intestinal mucosa because they act
on rapidly-proliferating cells by inhibiting DNA synthesis and interfering with the
processes of cell division and metabolism (Twardowski and Margolin 2002). Engineered
drug delivery systems for cancer treatment aim to increase the therapeutic efficacy of
chemotherapeutic agents while minimizing their interaction with non-pathological sites in
the body by modifying their biodistribution and controlling the rate at which the agent is
released from the carrier to the systemic circulation or tissues. The design and
consequent physiochemical properties of the drug carrier determine the results observed
in vivo.
DOX (M.W. 580 g/mol), known under the trade name of Adriamycin® (Pharmacia
& Upjohn, Kalamazoo, MI), is an anthracycline antibiotic that blocks DNA synthesis and
transcription by intercalating between DNA nucleotides interacting specifically with
guanine and cytosine, inhibits the action of Topoisomerase II, and generates damaging
radicals from its metabolism (Blasiak, Gloc et al. 2002). DOX has been clinically used
for the treatment of lymphoma, acute leukemia, soft tissue sarcoma, and breast, ovarian,
testicular, lung, bladder, and gastric cancers (IARC 1976). DOX is usually administered
intravenously at a maximum bolus dose of 60-90 mg/m2 at 21-day intervals (IARC 1976).
A maximum lifetime dose of 550 mg/m2 is allowed because of known cumulative
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cardiotoxicity associated with anthracycline treatment (Lum, Svec et al. 1985). In
addition to cardiotoxicity, DOX is also known to cause severe myelosupression, which
limits the aggressiveness and extent of treatment possible.
Development of drug delivery systems for the controlled delivery of DOX has
been the focus of much research to date. In fact Doxil® (ALZA Corporation), a
controlled release injectable formulation based on pegylated DOX-loaded liposomes, is
approved by the FDA for the treatment of AIDS-related Kaposi’s sarcoma and refractory
ovarian cancer. This formulation efficiently targets tumors by taking advantage of the
enhanced permeability and retention effect, and has shown to result in drastically
different toxicity profiles than free DOX. Specifically, Doxil is known to cause dose-
limiting toxicity to the skin and musosa, while significantly reduced myelosuppression,
alopecia and cardiotoxicity (Gabizon 2001). DaunoXome® (Gilead Sciences Ltd.) is a
similar liposomal formulation of the antineoplastic anthracycline antibiotic daunorobicin.
DaunoXome is indicated for the treatment of advanced AIDS-related Kaposi’s sarcoma.
Another formulation of DOX that has proven efficacious in in vitro and in vivo animal
studies for the treatment of chemoresistant hepatocellular carcinoma consists of DOX-
loaded polyisohexylcyanoacrylate nanoparticles (Barraud, Merle et al. 2005) and is
currently undergoing phase I/II clinical trials in Europe under the name of Transdrug®
(Bioalliance Pharma, France).
DOX formulations based on the biodegradable polymers poly(lactic acid) or
PLGA have also been reported in the literature. These formulations include DOX-loaded
microparticles (Ike, Shimizu et al. 1991; Lin, Ng et al. 2005; Tan, Lin et al. 2005), PLGA
NPs, PLGA-PEG micelles, and PLGA-vitamin E tocopheryl polyethylene glycol
succinate NPs with DOX covalently conjugated to the PLGA polymer (Yoo, Oh et al.
1999; Yoo and Park 2001; Yoo and Park 2004; Zhang, Lee et al. 2007), pH sensitive
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DOX-loaded micelles of poly(L-histidine)-PEG-folate and PLA-PEG-folate blends (Lee,
Na et al. 2005), self-assembled NPs of PLGA-g-pullulan loaded with DOX (Jeong, Na et
al. 2006), and multifunctional micelles of PLA-PEG loaded with superparamagnetic iron
oxide NPs and DOX (Nasongkla, Bey et al. 2006), among others. Microparticle
formulations have limited clinical potential because they must be locally administered or
implanted. Formulations in which DOX is chemically conjugated to the drug carrier are
often problematic because modification of the drug may lead to changes in its in vivo
activity and creates the risk for creation of non-biocompatible products of drug-polymer
metabolism.
In this chapter, the preparation, characterization, and in vitro evaluation of DOX-
loaded PLGA NPs is described. DOX NPs were prepared through a nanoprecipitation
technique followed by solvent evaporation. DOX NPs were characterized with respect to
size, morphology, zeta potential, loading, encapsulation efficiency, and release profile.
The therapeutic efficacy and cellular interaction of DOX NPs was studied in vitro in
MDA-MB-231 breast cancer cells. Encapsulation of DOX within PLGA NPs will protect
the patient from toxic effects associated with high-concentration bolus doses because the
NPs will release the drug in a controlled manner so that its available concentration is
maintained within therapeutic levels –above the minimum effective concentration but
below the toxic concentration— for longer periods of time.
3.2 METHODS
3.2.1 Materials
PLGA (molecular weight 11 kD) with 50/50 lactide/glycolide molar percent and
carboxylic acid end group was purchased from Medisorb (Cincinnati, OH, USA).
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Doxorubicin hydrochloride was purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Bovine serum albumin, phosphate buffer saline (PBS) packs (0.01M buffer, 0.138M
NaCl, 0.0027M KCl, pH 7.4) and 3,3-dimethyl glutaric acid were purchased from
Sigma/Aldrich (St. Louis, MO, USA). All solvents were of at least ACS grade.
3.2.2 Preparation of Blank and DOX-Loaded NPs
PLGA NPs with no drug (blank NPs) or with DOX were prepared through a
modified oil-in-water (o/w) nanoprecipitation technique (Fessi, Devissaguet et al. 1986).
This technique has been used in the past for the preparation of NPs and nanocapsules
with various polymers and drugs (Stolnik, Dunn et al. 1994; Barichello, Morishita et al.
1999; Furtado Mosquera, Legrand et al. 2000; Peltonen, Koistinen et al. 2003; Arica and
Lamprecht 2005; Leo, Contado et al. 2006). DOX was dissolved in methanol at
concentration of 2.2mg/l, 4.2 mg/ml and ~5.8mg/ml for 2.1, 3.9 and 5.3 wt.% targeted
loadings (i.e. the desired weight percent of DOX in the NPs assuming a 100%
encapsulation efficiency). Separately, 100 mg of PLGA were dissolved in 3ml of
acetone. The organic phase was formed by combining 1.0 ml of the DOX solution and
the 3ml of PLGA solution. This phase was added to 10 ml of an aqueous phase
containing 10 mg/ml bovine serum albumin (BSA) as a suspension stabilizer, followed
by sonication for 30 seconds. NPs form spontaneously as a result of the migration of the
water-miscible acetone and methanol into the water phase, and the consequent
precipitation of PLGA in the form of NPs. The solvents were removed by stirring under
vacuum for 45 minutes at room temperature. NPs were recovered by centrifugation for
10 minutes at 48k g in a Beckman J2-21 refrigerated centrifuge (Beckman Instruments
Inc., Palo Alto, CA, USA), and washed three times by resuspending the pellet in 10 ml of
10 mg/ml BSA solution followed by centrifugation to remove any unencapsulated DOX.
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Supernatants were collected for analysis. NPs were frozen in a -20°C freezer overnight,
lyophilized without any cryoprotectant using a Freeze Dryer 4.5 (Labconco, Kansas City,
MO, USA), and stored at -20°C for further use. All characterization and evaluation
studies described below were done utilizing lyophilized NPs. Blank NPs were similarly
prepared, except that no DOX was utilized in the formulation.
3.2.3 Physiochemical Characterization of NPs
The yield of the formulation was determined by weighting the total mass of NPs
recovered after lyophilization, and comparing it to the mass of polymer and drug used
during preparation. A Coulter® NanoSizerTM (Coulter Electronics LTD., Harpenden
Herts, UK) was utilized to determine the size and relative polydispersity of freeze-dried
NPs resuspended in de-ionized water with sonication. Each batch was sized three times
independently. The polydispersity index provides an indication of the variation in the NP
size for each batch of NPs. This index, as given by the NanoSizer, ranges from 0 to 9,
where 0 indicates a monodispersed distribution and 9 a distribution in which the ratio of
the largest to the smallest particle is 5 or more.
The morphology of the NPs was studied with a Hitachi 4500 scanning electron
microscope (SEM). NPs were resuspended in water with sonication, mounted onto a
carbon conductive tab (Ted Pella, Inc., Redding, CA, USA), dried at room temperature
overnight, and sputter coated with metal plasma prior to SEM imaging. A Phillips EM
208 transmission electron microscope (TEM) was used to confirm NP size and to study
their internal structural features. NPs were resuspended in water, applied to a 300 mesh
copper TEM grid with a carbon film (Electron Microscopy Sciences, Hatfield, PA, USA),
and stained with uranyl acetate (J. T. Baker Chemical Co., Phillipsburg, NJ, USA).
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The surface charge of NPs was studied through zeta potential measurements with
a ZetaPlus (Brookhaven Instruments Corporation, Holtsville, NY, USA). NPs were
resuspended at a concentration of 1mg/ml by sonication in a 1mM KCl solution (pH 7.5).
A minimum of 9 zeta potential readings were obtained per batch.
3.2.4 DOX Encapsulation Efficiency and Loading
Drug loading (the weight percent of DOX in the final NP formulation) and
encapsulation efficiency ( EE ; percent of the DOX that was actually encapsulated out of
that used for the preparation of DOX NPs) were assessed by two methods: (i) quantifying
the amount of DOX recovered from wash supernatants (
TSSUPERNATANDOX
M ) and assuming that
the rest of the drug used during preparation (
PREPDOX
M ) had been encapsulated, and (ii) by
dissolving a known mass of NPs ( NPsM ) with a mixture of dichloromethane and
methanol (60:40 v/v%), filtering through a 0.45 μm nylon syringe filter to remove
insoluble fractions and determining the mass of DOX found in the solution (
inNPsDOX
M ).
Absorbance at 480 nm was used to determine these concentrations based on standard
curves (r2 > 0.99).


















Dissolved blank NPs did not show absorbance at 480nm.
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3.2.5 In Vitro DOX Release
Drug release studies were performed in vitro in 10mM phosphate buffered saline
(PBS, pH 7.4) or isotonic 10mM dimethylglutaric acid buffer (DMGA buffer, pH 4.0,
0.006M DMGA, 0.0039M NaOH, 150mM NaCl). DMGA buffer was utilized to mimic
the conditions to which the NPs would be exposed during the process of vesicular
endocytosis, specifically the pH in endo-lysosomal compartments (Chapman 2002;
Panyam, Sahoo et al. 2003). For these studies, a known mass of DOX-loaded NPs was
suspended in the appropriate buffer with sonication in centrifuge tubes and maintained in
a water bath at 37oC. At specific times the samples were centrifuged for 10 minutes at
48k g and an aliquot of the supernatant was removed, collected for analysis, and replaced
with a known volume of fresh buffer. Absorbance at 480 nm of the supernatants was
used to determine the amount of DOX released based on a standard curves (r2 > 0.99) in
each buffer.
3.2.6 In Vitro Therapeutic Efficacy
The therapeutic properties of the DOX NPs were evaluated in MDA-MB-231
human mammary gland epithelial adenocarcinoma cells (Generous gift from Dr.
Dharmawardhane, previously from the Section of Molecular, Cell and Developmental
Biology at The University of Texas at Austin). Cells were maintained in Dulbecco’s
Modified Eagle Medium supplemented with 10% fetal bovine serum (Tissue Culture
Biologicals, Tulare, CA), 1% HEPES buffer, 1% L-glutamine (Mediatech Cellgro,
Herndon, VA), and 1% sodium pyruvate at 37oC in a humidified CO2 incubator. All cell
culture products were purchased from Invitrogen (Carlsbad, CA) unless otherwise
specified.
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For the studies, cells were seeded on 48-well plates at a cell density of 15,000
cells per well and incubated under normal growth conditions. After 24 hours of
incubation, the cell media was replaced with suspensions of DOX-loaded or blank NPs,
or solutions of free DOX in Dulbecco’s phosphate buffered saline with CaCl2 and MgCl2
(DPBS, BioWhittakerTM, Cambrex Bio Science Walkersville Inc., Walkersville, MD) in 4
different concentrations equivalent to 1.0, 10.0, 50.0 or 100.0 μg/ml of DOX for a 5.0%
drug loading in the NPs. Fresh DPBS was used as a control. Each condition was
repeated in three separate wells. Cells were then incubated for 2 hours, after which the
DOX/NP-containing media was removed and the cells were washed three times with
DPBS. An exposure time of 2 hours was chosen in order to try to isolate the therapeutic
effect of the DOX NPs from that caused by DOX released from the NPs after longer
exposure times in aqueous media. As will be described in the results section, after 2
hours of exposure significant amounts of DOX NPs had interacted with the cells. The
cells were subsequently incubated for 2 days in complete growth medium before cell
viability was assessed with the MTT Assay (Toxicolology Assay Kit TOX-1, Sigma).
Lower cell viability represents a higher therapeutic efficacy.
3.2.7 Microscopy Studies of Cell-NP Interaction
The fluorescence of DOX was utilized to study the interaction of DOX NPs with
MDA-MB-231 breast cancer cells through fluorescence confocal microscopy (Leica SP2
AOBS). Cells were seeded in 6-well plates containing a pre-sterilized coverslip in
complete cell media at a density of 100,000 cells per well. After 48 hours of incubation,
the media was replaced DPBS, with CaCl2 and MgCl2, including suspended DOX NPs,
free DOX, or blank NPs at concentrations equivalent to 1.0 or 10.0 μg/ml of free DOX
for a theoretical loading of 6.0 wt.%. DPBS was used as a control. The Cells were
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incubated under normal conditions and at specific time points (1 or 2 hours) the media
was removed and the cells were washed 3 times in ice cold DPBS to remove NPs that had
not entered or adhered to the cells. Cells were then fixed with -20oC methanol for 5
minutes and mounted onto microscopy slides utilizing Fluoromount-G mounting medium
(Southern Biotech, Birmingham, AL).
Confocal microscopy images of representative cell groups were obtained at the
plane of maximal fluorescence intensity or at consecutive z-planes with a 63x water
objective. Image acquisition variables such as gain, offset, and zoom were adjusted in to
obtain readable fluorescent signal from all concentration levels –which required some of
the highest concentration samples to be saturated— and maintained constant during the
study for all samples.
Separate studies were performed to determine if the fixation protocol had affected
the results obtained. In one study, cells were fixed with 3.7% formalin for 15 minutes,
washed three times with DPBS and mounted onto microscope slides as described above.
In a separate study, cells were seeded onto Lab-TekTM chambered coverslips and imaged
while live after exposure to 0.1 mg/ml of doxorubicin-loaded nanoparticles. Samples
were imaged as described above.
3.2.8 Statistical Analysis
Statistical significance of differences between data sets was determined by





Blank and DOX-loaded PLGA NPs were prepared through a nanoprecipitation
technique. Table 3.1 summarizes size and zeta potential results. The percent recovery, or
yield, for each batch of NPs ranged from 60 to 90 percent. This percent recovery was
calculated from comparison of the mass of NP powder recovered and the initial mass of
polymer and drug used for preparation of the NPs. The mass of BSA that remained
adsorbed to the surface of the NPs was not taken into account for determination of the
percent recovery. Although this oversight could lead to slightly elevated calculated
yields, we belive that the amount and variability of the yield was mainly affected by the
process of purification and recovery which involved repeated centrifugation and
resuspension, as well as the retrieval of NP powder from freeze drying tubes which was
hindered by static.
NPs are roughly spherical, as seen in the SEM image in Figure 3.1A. The average
diameter of the NPs resuspended in de-ionized water after lyophilization was determined
to be about 230 nm and was found to be independent of DOX loading. The average
polydispersity of the NP size as determined by a Coulter NanoSizer was 3 in a range from
0 to 9. The size and internal structural features of the NPs were also studied by TEM, as
shown in Figure 3.1B. The perturbations on the surface of the NPs can be attributed to
drying effects. Because of the uniformity of the uranyl acetate stain across the NPs, this
image suggests a matrix type drug delivery system in which the drug is uniformly
dispersed within the polymer matrix that forms the NP, as expected from a particulate
formulation in which the drug is co-dissolved with the polymer prior to the formation of
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the NP. The average size of the NPs measured from TEM images was determined to be
174 nm with a standard deviation of 76 nm, consistent with the SEM findings.
The average zeta potential of the NPs was determined to be -45 mV and to be
independent of the amount of DOX loaded. The zeta potential of PLGA NPs depends on
the end groups of the PLGA, the type of drug encapsulated and the type of stabilizing
agent utilized during their preparation. The zeta potential of uncoated PLGA NPs has
been reported to be -40.3 mV and to increase toward neutrality after coating with
poloxamines (Stolnik, Dunn et al. 1994). PLGA NPs prepared with poly(vinyl alcohol)
as a stabilizer have been reported to have a zeta potential in the range of -10.0 to -20.0
mV. The zeta potential of the NPs is key for their stability. Highly charged NPs are
better able to remain stable as colloidal suspensions since the Coloumbic repulsion forces
arising from their surface charge can overcome the Van der Waals attractive forces
between them (Heurtault, Saulnier et al. 2003).
3.3.2 DOX Encapsulation
Several batches of DOX-loaded NPs with three different drug loadings were
prepared for this study. Table 3.2 summarizes the results of DOX encapsulation
efficiency and loading within PLGA NPs obtained from quantification of (1) non-
encapsulated drug found in supernatants from NP washes, and (2) drug found from
dissolved freeze-dried NPs. As can be seen from this table, the maximum DOX loading
achieved was close to 5 mg of DOX per 100 mg of NPs (5 wt. %) with an average of 4.7
wt%, and the average encapsulation efficiency was 80%. The difference in drug loading
calculated from both analyses is not significantly different (p > 0.25).
Previous accounts of encapsulation of DOX in particle-based drug delivery
systems have reported DOX loadings in the order of less than 0.1 wt.% in cholesterol-
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bearing pullulan hydrogel NPs (Akiyoshi, Taniguchi et al. 1996), 3.45 wt. % in PLGA
NPs in which DOX was chemically conjugated to PLGA (Yoo, Oh et al. 1999), 2.2 wt. %
in micelles composed of DOX conjugated to PLGA-PEG block copolymers (Yoo and
Park 2001), 4.23 wt. % in micelles formulated with a copolymer of cholesterol and
poly(2-methacryloyloxyethyl phosphorylcholine) (Xu, Ji et al. 2005), and 4.0 wt. % in
chitosan NPs prepared by a ionotropic gelation with sodium tripolyphosphate (Janes,
Fresneau et al. 2001).
3.3.3 In Vitro Drug Release
Drug release studies were performed in buffered saline pH 7.4 and 4.0 to observe
the effect of pH on the release rates in the conditions that would most closely mimic
those that the NPs would encounter in vivo. Figure 3.2 displays the observed release
profiles. The release rate of DOX from PLGA NPs at pH 4.0 is significantly higher than
at pH 7.4 (p < 0.05). In fact, at the acidic pH more than 50% of the drug had been
released during the first hour, and more than 90% after 12 hours. On the other hand, the
release at pH 7.4 indicates that the formulation is able to deliver the drug in a controlled
manner over an extended period of time. Only 20 to 30% of the drug was released within
the first hour depending on the loading of the formulation, while only about 65 to 75%
was released within the first day. Drug continued to be released from this formulation at
a slower rate for over 3 days, after which the rate of release was minimal. Drug loading
did not appear to result in significantly different release profiles for a threshold of
statistical difference of p < 0.025. However, if a threshold for statistically significant
difference of p < 0.05 was used, NPs with lower loading appeared to result in
significantly higher cumulative release at various time points at pH 7.4.
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It is hypothesized that the difference in release rates at the different pH conditions
is influenced by two phenomena. First, the degradation of PLGA is accelerated in acidic
conditions and is further auto-catalyzed as the local concentration of lactic and glycolic
acids increases. Since the degradation of PLGA NPs is known to occur through bulk
erosion (Brannon-Peppas 1995; Brannon-Peppas 1997), the accelerated degradation
results in faster decrease in polymer molecular weight and NP mass loss, easier access of
physiological fluids into the NPs, quicker dissolution of the drug in physiological fluids
and consequent enhanced release of the drug.
The second phenomenon that could be involved in the enhanced release of DOX
at endo-lysosomal pH is related to the ionic interaction of the weakly basic DOX with the
carboxylic acid groups of acid-capped PLGA, lactic acid and glycolic acid. As can be
appreciated from Figure 3.3, DOX exists mostly as a single cation at the pH range of
interest up to 7.0 (Sturgeon and Schulman 1977). Above pH 7.0, DOX can become a
zwitterion or neutral compound by losing a proton from a phenolic hydroxyl group or
from the sugar amino group, respectively (Sturgeon and Schulman 1977). Utilizing its
pKA of 8.15 which accounts for dissociation from the single cationic state (C) to the
zwitterion and the neutral species (here combined into the term N) (Sturgeon and
Schulman 1977), one can determine the ratio of cationic DOX to the neutral or switterion






















Thus, at pH 7.4 nearly 85% of the DOX molecules will be in the cationic state, as
compared to 100% of the molecules at pH 4.0.
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At a pH of 7.4 almost 100% of the acid groups in PLGA and the degradation
products will be in the deprotonated (anionic) configuration, while at a pH of 4.0 almost
50% of the acid groups are in the protonated neutral form. As a result, at a pH of 7.4,
DOX present mostly in its cationic state interacts favorably with the anionic PLGA. As
the pH is reduced closer to the pKa of the acid groups in PLGA and the degradation
products, it is thus possible that the ionic interaction with the cationic DOX is lost and
results in faster release of the drug.
Scanning electron microscopy images of the NPs after the end of the release of
the drug show that although degradation of the polymer has occurred, much of the
morphology of the NPs remains, thus suggesting that most of the release of the drug
occurs through diffusion across the polymeric matrix. Figure 3.4 shows SEM images of
DOX-loaded PLGA NPs after release. Larger particle sizes and significant inter-particle
fusing can be observed in the SEM of particles exposed to the more acidic conditions,
thus confirming the contribution of the degradation of the NPs to the overall faster release
rate observed at pH 4.0.
The polymer degradation characteristics at pH 7.4 for NPs prepared with the same
PLGA type as that used in the present study have been previously reported by our group
(Birnbaum and Brannon-Peppas 2003). The molecular weight of these NPs is known to
decrease rapidly during the first week of degradation, followed by a slower rate of
molecular weight loss. After 18 days under release conditions, the weight-average
molecular weight was found to decrease from over 30K Da to about 2700 Da in previous
studies (Birnbaum and Brannon-Peppas 2003). Such reduction in molecular weight
would allow high water and drug diffusion rates, while still maintaining enough of the
polymer in cohesive semi-spherical form.
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3.3.4 In Vitro Therapeutic Efficacy
The in vitro anti-tumor efficacy of DOX-loaded NPs was evaluated with the
cytotoxicity MTT assay in MDA-M-231 breast cancer cells. Cell viability data, as a
fraction of control, are summarized in Figure 3.5. Lower cell viability represents a higher
anti-tumor therapeutic effect.
Free DOX and DOX-loaded NPs significantly reduced viability compared to
control and to blank NPs at concentrations equivalent to or higher than 10 μg/ml of DOX
(p < 0.05). Blank NPs did not show reduced cell viability compared to control at the
concentrations tested. Cytotoxicity induced by DOX encapsulated within NPs was not
significantly different than that caused by the free drug in solution within the
concentration range tested. However, it is important to note that since the drug and NP-
containing media was removed after 2 hours of exposure, the cytotoxicity caused by the
NPs had to be mainly associated with endocytosed particles or drug that was released
from the particles and that entered the cells during these two hours. According to the
data obtained from in vitro release studies in buffered media, the amount of drug that
would have been released during this time is between 25 and 35%. These data indicate
that despite the lack of significant increase in cytotoxicity by the NPs, this formulation
(1) maintains the activity of DOX, (2) readily interacts with the cells despite the
macromolecular size, and (3) is at least as effective as the free drug.
3.3.5 Microscopy Studies of NP/Cell Interaction
Figure 3.6 displays the fluorescence signal at the plane of maximum intensity for
representative groups of fixed cells. High fluorescence intensity was observed even after
1 hour of cell incubation with NPs or free drug. An increase in fluorescence intensity
was observed with increased concentration of DOX NPs or free DOX, and with increased
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time of exposure, as expected. For all times of incubation, the fluorescence intensity of
cells exposed to DOX NPs was significantly higher than that of cells exposed to free
DOX. The low but detectable level of fluorescence observed in cells exposed to blank
NPs did not appear to differ from that of the control samples, and is a result of cellular
auto-fluorescence.
Figure 3.7A and B show differential interference contrast and the corresponding
confocal fluorescence plane for cells exposed to DOX NPs or free DOX, respectively, in
solution for 2 hours. High fluorescence intensity corresponding to high concentration of
the nuclear drug DOX is observed at the nuclei of the cells. Since NPs are not able to
enter the nuclei because of their large size, it is probable that upon particle endocytosis,
the release rate from DOX NPs was accelerated in the acidic conditions of late
endosomes and endo-lysosomal compartments. Once in solution at high concentrations
within the cells, DOX was free to enter the nuclei. Figure 3.7C shows the fluorescence
signal of a cell exposed to the same concentration of DOX NPs for 2 hours along the x-y
plane and the z cross-section. Similar results were obtained when cells were fixed with
formalin instead of methanol (data not shown) and with live cells, as can be observed in
Figure 3.8.
3.4 DISCUSSION
Encapsulation of chemotherapeutic agents, and specifically of DOX, into
injectable drug delivery systems has been reported in several instances. Encapsulation of
hydrophilic molecules such as DOX in PLGA NPs is most commonly carried out through
water-in-oil-in-water procedures in which the drug is first dissolved in the inner aqueous
medium. However, the loading and encapsulation efficiency permissible are less than
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acceptable because (1) the volume of the inner aqueous phase and consequently the mass
of the active agent that can be used in the preparation must be small in order to prepare a
stable initial water-in-oil emulsion and (2) the drug will have the tendency to diffuse into
the outer aqueous phase during the preparation process because of concentration gradient.
Here an oil-in-water nanoprecipitation process was utilized for the preparation of
DOX-loaded NPs. The use of an oil-in-water process, nanoprecipitation, and an acid-
capped polymer resulted in higher drug loadings than those reported for other systems in
the past (Akiyoshi, Taniguchi et al. 1996; Yoo, Oh et al. 1999; Janes, Fresneau et al.
2001; Yoo and Park 2001; Xu, Ji et al. 2005). Incorporation of DOX hydrochloride in
the organic phase of the oil-in-water system together with the polymer was achieved by
first dissolving it in the polar protic solvent methanol which is fully miscible with
acetone. Co-dissolving the drug with the polymer permits the incorporation of higher
mass than would otherwise be possible with a water-in-oil-in-water process.
Nanoprecipitation offers various benefits compared to more commonly-used
emulsion processes. First and most importantly, NPs are formed spontaneously as the
solvents of the polymer and drug diffuse into the water phase causing the precipitation of
the water-insoluble polymer. The speed for NP solidification enables the drug to be
rapidly entrapped, thus preventing its diffusion into the outer aqueous phase. Second, the
nanoprecipitation process is simple and highly reproducible, and results in the formation
of NPs or nanocapsules –depending on the protocol-- of about 200 nm in size with little
influence from stirring or sonication (Couvreur, Dubernet et al. 1995; Legrand, Barratt et
al. 1999). Such NP size is optimal for the ability of the NPs to be used for intravenous
administration and passive targeting to tumors taking advantage of the EPR effect. NPs
larger than about 250-300 nm would be at higher risk of being seized by the filtration in
the spleen (Brannon-Peppas 1995). Finally, the use of acid-capped PLGA in the present
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formulation is also believed to improve the encapsulation of the mildly basic DOX
because, as described earlier, DOX is present as a single cation within the pH range at
which is exposed during the preparation of the NPs while the carboxylic acid at the end
of the PLGA chains is deprotonated, thus resulting in a moderate favorable ionic
interaction between these two compounds. As observed from the in vitro release data,
this interaction is lost when the loaded particles are exposed to acidic conditions and
results in rapid release of the drug.
For the preparation of stable NPs with the nanoprecipitation method, a surfactant
is normally required in the aqueous phase. Albumin has been previously utilized as a
surface agent for the preparation of NPs (Bazile, Ropert et al. 1992; Verrecchia, Huve et
al. 1993; Verrecchia, Spenlehauer et al. 1995). Albumin acts as a tensioactive agent by
exposing its hydrophilic and hydrophobic regions toward the aqueous and organic phases
during the process of NP formation, respectively. Once the organic solvent is removed,
albumin remains associated with the hydrophobic NP surface, and in fact, part of the
albumin is permanently bound (Bazile, Ropert et al. 1992; Verrecchia, Huve et al. 1993;
Verrecchia, Spenlehauer et al. 1995). Utilization of BSA as a stabilizing agent in the
present formulation was found to prevent aggregation of the NPs during the repeated
centrifugation-resuspension cycles utilized to wash un-encapsulated drug, and to
eliminate the need for a separate cryoprotectant. In addition to BSA, our group has
worked on the preparation of NPs with other stabilizers such as poly(vinyl alcohol) and
sodium cholate.
BSA adsorbed on the surface of the NPs was not taken into account in the
determination of the yield percent for the present formulation. Previous studies by
Verrecchia and colleages have shown that poly(lactic acid) (PLA) NPs prepared by an
emulsion and solvent evaporation method in the presence of radiolabeled human serum
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albumin have shown that the amount of albumin bound to the NP surface was inversely
proportional to the NP diameter and that, for their formulation, approximately 5.7 µg of
albumin remain bound per square meter of NP surface area (Verrecchia, Huve et al.
1993). According to this surface concentration, our NPs could contain around 125 µg of
albumin per mg of polymer, or about 10mg of albumin for an 80mg batch. However, this
comparison could be misleading because the cited study used different polymer, solvent,
and albumin type, did not encapsulate a drug, and used different preparation and recovery
procedures. In fact, the sizes of the particles in that study were markedly different when
prepared with the same albumin concentration in the aqueous phase compared to those
here reported. In addition, it is not clear whether the NPs in the cited study were freeze
dried or whether freeze drying would have changed their results. Further studies will be
necessary to determine the albumin fraction that remains adsorbed to the surface of the
present NPs.
The in vitro interaction of DOX-loaded PLGA NPs with MDA-MB-231 breast
cancer cells presented promising results. Cell exposure to DOX-loaded NPs or free DOX
in solution resulted in comparable cancer cell viability. Studies demonstrated higher
uptake and nuclear localization of DOX in the cells when presented in the form of NPs.
Although it was expected that the negatively-charged surface of the NPs would hamper
their interaction with negatively-charged cell membranes, the results suggest that the NP-
cell interaction is modulated by phenomena more complex than just charge effects and
must be further investigated. In addition, it is possible that the high cellular uptake could
be a result of the high DOX payload in the NPs (each NP could contain more than 400
DOX molecules as calculated from the drug loading, particle size and polymer density)
which would result in substantial intracellular delivery even if only small number of NPs
were able to enter the cells. Further studies will need to be performed to investigate why
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the increased DOX nuclear localization did not result in higher therapeutic efficacy in
vitro. Nonetheless, the data suggests that the encapsulated drug is active and that the
formulation could possibly lead to significantly higher therapeutic effect in vivo as result
of the improved biodistribution of the NPs and the pH-dependent release of the drug from
these particles.
The biodistribution of polymeric NPs in vivo is known to be distinctly different
from that of low-molecular weight drugs. NPs are known to undergo rapid opsonization
and be quickly sequestered by the macrophage phagocytic system. Bazile, et al. studied
the distribution and pharmacokinetics of albumin-coated PLA NPs and found that despite
longer circulation times compared to uncoated particles, the NPs were still captured by
liver, bone marrow, lymph nodes, spleen and peritoeal macrophages (Bazile, Ropert et al.
1992). Although this disctinct localization can be exploited for targeting of drugs to
these organs, its use for the delivery of chemotherapeutic agents to tumors could lead to
undesired toxicity. For this reason, further studies are underway in our laboratory to
modify the surface of the NPs in order to delay opsonization and provide specific
targeting capabilities.
3. 5 CONCLUSION
The use of an oil-in-water nanoprecipitiation technique for the encapsulation of
the chemotherapeutic drug DOX into acid-capped PLGA NPs was proven in this work to
be a satisfactory method. By co-dissolving the drug with the polymer, high entrapment
efficiency was achieved as the polymer precipitated into solid particles. In vitro studies
revealed a pH-dependent release profile that would result in slow drug release at
physiological pH and fast release within the more acidic endolysosomal compartments
after endocytosis. Increased degradation of the polymer at acidic pH as well an ionic
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interaction between the polymer and the mildly basic DOX are hypothesized to influence
its release from the NPs. DOX NPs were found to result in a therapeutic efficacy
comparable to the free drug, while blank NPs did not reduce cell viability. Confocal
microscopy studies revealed that exposure of MDA-MB-231 breast cancer cells to DOX
NPs resulted in higher intracellular drug concentrations than exposure to free DOX, and
that the level of intracellular accumulation increased in a time- and dose-dependent
manner as expected for both DOX NPs and free DOX.
Having satisfactorily prepared nanoparticles loaded with a chemotherapeutic
agent that could be used for therapeutic purposes, the following chapter describes the
preparation of nanoparticles loaded with imaging agents for in vitro and in vivo
monitoring of the biological distribution and activity of the nanoparticles.
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Table 3.1 Size and zeta potential of blank and doxorubicin-loaded nanoparticles.
Values represent the average ± standard deviation for n batches of
equivalent targeted drug loading. DOX: Doxorubicin; NP: Nanoparticle;
















Blank NPs 0 4 225 ± 49 3 ± 1.3 -44.7 ± 1.7
DOX NPs 1 2.1 1 249 3 -46.5 ± 1.5
DOX NPs 2 3.9 1 173 3 -46.4 ± 1.5
DOX NPs 3 5.3 ± 0.1 6 239 ± 27 3 ± 0.7 -44.9 ± 1.4
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Table 3.2 Doxorubicin encapsulation efficiency and loading within PLGA
nanoparticles. Results represent the average ± standard deviation for n
























2.1 1 80.9 95.4 1.7 2.0 114.5
3.9 1 75.6 72.7 2.9 2.9 97.1
5.3 ± 0.1 3 79.5 ±6.9 65.4 ±4.6 4.3 ±0.4 4.7 ±1.1 85.8 ±10.7
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Figure 3.1 (A) Scanning electron microscopy image of doxorubicin-loaded
poly(lactic-co-glycolic acid) nanoparticles prepared by a nanoprecipitation
method. (B) Transmission electron microscopy image of doxorubicin-



























2.9% loading at pH 7.4
5.0% loading at pH 7.4
2.9% loading at pH 4.0
5.0% loading at pH 4.0
Figure 3.2 In vitro release of doxorubicin from poly(lactide-co-glycolide)
nanoparticles in buffered saline, pH 7.4 and 4.0. Values represent release
data for 2 batches of nanoparticles with different loadings, each batch in
triplicate. Error bars represent the standard deviation in the release for
each batch.
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Figure 3.3 Possible ionic configurations of doxorubicin within the pH range of 4.0 to
9.0. Data obtained from Sturgeon et al. (1977).
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Figure 3.4 Scanning electron microscopy (SEM) image of PLGA nanoparticles after
a 16-day in vitro release study in 10mM phosphate buffered saline pH 7.4
(left) and after 4 days of release in 10mM dimethyl glutaric acid/NaOH
buffer pH 4.0 (right) at 37C. Nanoparticles were recovered from release
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Figure 3.5 Viability of MDA-MB-231 mammary gland epithelial adenocarcinoma
cells after exposure to doxorubicin-loaded nanoparticles (white bars), free
doxorubicin in solution (dark gray bars), or blank nanoparticles (light gray
bars) at concentrations equivalent to 1.0, 10.0 and 100.0 μg/ml of
doxorubicin. Control data (black bar) is for cells maintained in DPBS.
Data presented as a percentage of control average. Error bars represent
the standard deviation of the data. Abbreviations: NPs = nanoparticles,
DOX = doxorubicin.
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Figure 3.6 Confocal microscopy images of MDA-MB-231 breast cancer cells
exposed to doxorubicin-loaded PLGA nanoparticles (DOX NPs), free
doxorubicin (free DOX), or blank PLGA nanoparticles (Blank NPs) at
concentrations equivalent to 10.0 and 1.0 μg/ml of DOX for 1 or 2 hours.
Cells in control samples were incubated in DPBS for the same time
periods. Cells were fixed with -20oC methanol.
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Figure 3.7 Differential interference contrast (DIC) images (left) and corresponding
confocal fluorescence images (right) of MDA-MB-231 cells after
exposure to doxorubicin-loaded nanoparticles (A) or free doxorubicin in
solution (B) at a concentration equivalent to 1.0 μg/ml of doxorubicin for
2 hours. (C) Cross-sectional view of cell exposed to doxorubicin-loaded
nanoparticles for 2 hours at the same concentration along its depth. Cells
were fixed with ice-cold methanol. Doxorubicin preferentially localizes at
the nucleus of the cells when administered in nanoparticles or in solution.
73
Figure 3.8 Differential interference contrast images (left), corresponding confocal
fluorescence images along the x-y-z axes (right) and overlay of these images
(bottom) of live MDA-MB-231 cells after exposure to doxorubicin-loaded
nanoparticles at a concentration of 0.1 mg/ml of nanoparticles (5 g/ml
doxorubicin) for 4 hours. As observed in fixed cells, doxorubicin
preferentially localizes at the nucleus of the cells after entering the cells.
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CHAPTER 4
FORMULATION, CHARACTERIZATION AND EVALUATION OF
IMAGING NANOPARTICLES
4.1 BACKGROUND
As mentioned in Chapter 2, imaging methods are currently utilized for clinical
detection of tumors, although to date biopsies are the gold standard for final diagnosis
and staging. Contrast agents are invaluable for the detection of tumors as they provide
the means for distinguishing them from surrounding normal tissue by taking advantage of
various physiologic, metabolic or molecular differences. Contrast agents can also be
used for studying and monitoring the distribution and interaction of drug delivery systems
with cancer cells in vitro and with tumor tissue in vivo.
In this chapter, the formulation of biodegradable nanoparticles loaded with
imaging agents is described. Fluorescent or electron-dense agents were investigated with
the purpose creating formulations that could be used for study the interactions of the
nanoparticles with target cells through fluorescence microscopy or electron microscopy,
respectively. The hypothesis here was that these nanoparticles could be used to elucidate
the behavior of the formulations containing chemotherapeutic agents both in vitro and in
vivo through imaging methods. For this to be true, these nanoparticles must have
properties equivalent to the nanoparticles loaded with chemotherapeutic agents, i.e.
similar size, morphology, and surface chemistry.
Rhodamine 6G and Indocyanine Green were used as fluorescent agents while
gadopentetic acid (Gd-DTPA) was used as an electron dense agent. While the use of
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rhodamine-loaded nanoparticles would be limited to in vitro studies, use of indocyanine
green and Gd-DTPA as fluorescent and electron dense agents was motivated by the
desire to create formulations that, in addition, could be potentially used for clinical
detection and monitoring of tumors in vivo through photoacoustic computer tomography
and magnetic resonance imaging (MRI), respectively. Table 4.1 and the following
sections describe some of the characteristics of these agents. Figure 4.1 displays the
chemical structure of each of these imaging agents.
4.1.1 Rhodamine 6G
Rhodamine 6G (RHO) is a fluorescent dye that is commonly used as a label for
detection and monitoring of molecules in fluorescence microscopy, flow cytometry,
immunohistochemistry and spectroscopy. RHO has a molecular weight of 479 g/mol. Its
structure is depicted in Figure 4.1A. RHO is highly soluble in water, ethanol, methanol,
acetone and dimethyl sulfoxide, among other agents. It presents absorption and
fluorescence peaks at about 530nm and 550nm, respectively. RHO has been previously
used as a dye for mitochondrial staining and as an inhibitor of mitochondrial function in
cells (Gear 1974; Hu, Zhao et al. 2007), for general cellular staining (Tang, Yang et al.
2007) and also as a dye for imaging of nanoparticles for gene delivery in vivo (Vila, Gill
et al. 2004; Vila, Sanchez et al. 2004; Bejiani, BenEzra et al. 2005). In the present work,
RHO was used a means for monitoring the interactions of poly(lactic-co-glycolic acid)




Indocyanine green (ICG) is a fluorophore that exhibits high absorbance and
fluorescence in the near-infrared region. It has a molecular weight of 775 g/mol and is
highly soluble in aqueous solutions and polar solvents. Its chemical structure is shown in
Figure 4.1B. ICG presents absorbance and emission maxima at about 790 and 820 nm,
respectively. ICG and other near-infrared fluorophores have been widely accepted for
diagnostic applications because these molecules offer low background interference since
almost no biological molecules absorb or emit in the near-infrared region and because
infrared light offers the highest penetration depth in biological tissue. The absorption and
emission peaks of ICG are in the range of the isobestic point of 800nm, where
oxygenated and de-oxygenated hemoglobin have the same extinction coefficient, and
consequently permit imaging of tissues independently of oxygenation status (Kalliokoski,
Scheede-Bergdahl et al. 2006).
ICG has been widely used for imaging-based characterization of blood volume,
cardiac output, hepatic function, retinal blood flow, and pharmacokinetic behavior. The
main problems associated with the use of indocyanine green as an imaging agent have to
do with its small circulation half life, instability in aqueous solutions and its
photosensitivity. The circulation half life of ICG is only between 2 and 4 minutes
(Desmettre, Devoisselle et al. 2000). ICG has been reported to form aggregates and
undergo irreversible degradation in aqueous media (Saxena, Sadoqi et al. 2003). These
transformations result in decreased absorption and fluorescence, discoloration, and shifts
in the wavelength of maximum absorption. Some of the factors that influence the optical
behavior of ICG are: concentration, light exposure, temperature, and pH. The
fluorescence of ICG in aqueous solutions has been observed to decrease with
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concentration above 2g/ml, phenomenon that has been attributed to the formation of
aggregates, self quenching, and overlap of the absorption/emission spectra at higher
concentrations (Saxena, Sadoqi et al. 2003).
The effect of light exposure on the photostability of ICG has been reported to be
dependent on the type and intensity of the light. The half life of ICG was reported to be
2.3 hours when continuously exposed to light from a 786 nm laser, compared to a half
life of 14 hours when exposed to normal room lighting (Saxena, Sadoqi et al. 2003). The
mechanism of ICG degradation with light has been proposed to be associated with the
creation of a photoexcited molecule that is easily transformed into reactive radicals,
which can then react with ions and other radicals present in the solvent to form
leucoforms (Holzer, Mauerer et al. 1998).
When protected from light, the temperature of storage also has an effect on the
half life of ICG, with higher temperatures reducing its half life (Saxena, Sadoqi et al.
2003). The mechanism of degradation as a function of temperature has also been
proposed to be associated with the formation of radicals through vibrational, librational,
and translational agitation processes (Holzer, Mauerer et al. 1998). Finally, degradation
of ICG was reported to occur faster when stored at lower initial concentrations (Holzer,
Mauerer et al. 1998; Saxena, Sadoqi et al. 2003).
Depending on the solvent, ICG may be found in the monomeric form or as a
dimer or oligomer with absorption maxima at 780, 680 and 890 nm respectively (Holzer,
Mauerer et al. 1998). Dimerization occurs at very low concentrations in water. In water
and deuterated water at concentrations above 1.15 mg/ml ICG self-organizes into
aggregates that lead to a red-shifted narrow absorption band that is the result of
delocalized excitation by light (Holzer, Mauerer et al. 1998). This state is normally
referred to as J-aggregation, and is characteristic of relatively high stability compared to
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monomeric ICG. In organic solvents such as methanol or dimethyl sulfoxide, on the
other hand, the critical concentration for dimerization is very high (Holzer, Mauerer et al.
1998). In human plasma dimerization occurs at about 387 g/ml, although ICG
normally exists as a conjugate with plasma proteins (Holzer, Mauerer et al. 1998).
Encapsulation of ICG within nanoparticles can protect ICG from rapid clearance
and degradation, while at the same time modifying its biodistribution according to that of
the nanoparticles. As will be discussed in this chapter, the instability of ICG greatly
complicates characterization of nanoparticles loaded with this agent as it makes its
quantification difficult. However, by choosing appropriate solvents and being
meticulously careful with readings, it is possible to quantify ICG encapsulation efficiency
and weight percentage within nanoparticles.
4.1.3 Gd-DTPA
Diethylenetriaminepentaacetic acid Gd (III) dihydrogen salt hydrate or
gadopentetic acid (Gd-DTPA) is a gadolinium chelate approved for clinical use as a
positive MRI contrast agent. It is currently marketed under the brand name of
Magnevist® (Schering, Germany). Magnevist® distributes in the intravascular and
extracellular fluid spaces, does not cross the blood brain barrier, and is excreted rapidly
by glomerular filtration via the kidneys.
Gd-DTPA has a molecular weight of 548 g/mol. Its structure can be seen in
Figure 4.1C. Gd-DTPA is a hydrophilic agent that is not soluble in alcohols. As such,
encapsulation of this agent within the hydrophobic core of polymeric nanoparticles is a
challenge. A water-in-oil-in-water method was investigated for its incorporation of this
agent within nanoparticles, as described in the materials and methods section. This
method is based on the modification of a microparticle formulation that was previously
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reported (Faranesh, Nastley et al. 2004). Gd-DTPA provides the ability to visualize the
interaction of nanoparticles with cells and tissue with electron microscopy and MRI.
4.2 MATERIALS AND METHODS
4.2.1 Materials
Rhodamine-6G was obtained from ACROS Organics. Indocyanine green, bovine
serum albumin, sodium cholate hydrate and gadopentetic acid (Gd-DTPA) were obtained
from Sigma-Aldrich (Saint Louis, MO, USA). Acetone, methanol and ethyl acetate were
obtained from Fisher Scientific (Waltham, MA, USA) and were of HPLC grade.
Poly(lactic-co-glycolic acid) (formerly PLGA 50:50 DL 2A, now 5050 DLGA 2A, 50/50
D,L-lactide to glycolide ratio, molecular weight 11,000, carboxylic acid and hydroxyl
end groups) was obtained from LakeShore Biomaterials (Birmingham, AL, USA).
4.2.2 Preparation of Nanoparticles Loaded With Imaging Agents
The preparation methods described in Table 4.1 were utilized for encapsulation of
imaging agents. The specific method of nanoparticle preparation depended mainly on the
solubility properties of each of the imaging agents. Nanoparticles with rhodamine 6G or
indocyanine green were prepared with oil-in-water nanoprecipitation or emulsification
methods, while encapsulation of Gd-DTPA was carried out with the water-in-oil-in-water
method. Figure 4.2 displays the general steps that were taken for the preparation of
imaging agent-loaded particles.
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4.2.2.1 Rhodamine Loaded Nanoparticles
RHO was first dissolved in acetone at concentrations ranging from 0.017 to 0.1
mg/ml. A volume of 3 to 4.35ml of this solution was then used to dissolve 100 mg of
PLGA. This organic solution was then added to 10 ml of an aqueous solution containing
10 mg/ml of bovine serum albumin, vortexed and sonicated for 30 seconds to form a
nanoparticle suspension. Organic solvents were evaporated by stirring under vacuum for
45 minutes. Nanoparticles were recovered by centrifugation for 10 minutes at 48,000xg
with a refrigerated Beckman J2-21 centrifuge. The particles were washed three times by
resuspending in surfactant solution through sonication and/or vortexing, followed by
centrifugation. Supernatants from each centrifugation were collected for determination
of the amount of the imaging agent that had not been encapsulated within nanoparticles.
Small samples of the nanoparticle suspension were taken throughout the preparation
procedure in order to identify and troubleshoot any step at which the particles aggregated.
After 3 washes, the nanoparticle pellet was frozen at -20°C, freeze dried in a Labconco
Freeze Dryer 4.5 for 2 days and stored at -20oC.
4.2.2.2 Indocyanine Green Nanoparticles
ICG loaded nanoparticles were prepared similarly to RHO nanoparticles, except
for the fact that ICG was first dissolved in methanol at a concentration of 2.5 to 10 mg/ml
depending on the desired loading and then mixed with a solution of 100 mg of PLGA in 3
ml of acetone to form the organic phase. In addition, sodium cholate (SC) was used as
the surfactant instead of bovine serum albumin. Sodium cholate has been widely used as
a surfactant for nanoparticle preparation and has been observed to result in the
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preparation of particles with smaller and more homogeneous size distributions
(Lamprecht, Ubrich et al. 2001; Arica and Lamprecht 2005; Leo, Contado et al. 2006).
4.2.2.3 Gd-DTPA Nanoparticles
Nanoparticles loaded with Gd-DTPA were prepared by a water-in-oil-in-water
process. Gd-DTPA was first dissolved in DI water at a concentration of 14 mg/ml. A
volume of 100 to 500 l of this solution was then added to a solution of 100 mg of PLGA
in 3 ml of acetone or ethyl acetate, vortexed and sonicated for 1 minute to form a stable
water-in-oil emulsion. This emulsion was then added to 10 ml of an aqueous solution of
10 mg/ml bovine serum albumin or sodium cholate, vortexed and sonicated until a
homogeneous water-in-oil-in-water suspension was formed. The solvent was then
removed by evaporation and the nanoparticles washed as described for RHO
nanoparticles.
4.2.3 Nanoparticle Size
Particle size was determined using a Coulter Nanosizer or a dynamic light
scattering (DLLS) based instrument (Brookhaven Instruments Corporation) from
suspensions of nanoparticles in water. Particle sizes were determined during the
preparation process by diluting samples of nanoparticle suspensions in DI water and after




Nanoparticle morphology was studied through scanning electron microscopy
(SEM). A small amount of freeze dried nanoparticles was suspended in DI water with
sonication and vortexing and dried at room temperature on top of a carbon conductive tab
held on top of a aluminum sample disk. SEM samples were sputter coated with metal
plasma and imaged with a Hitachi 4500 electron microscopy.
4.2.5 Agent Encapsulation Efficiency
Encapsulation efficiency (EE), or the percentage of the total amount of imaging
agent used in the preparation that was actually encapsulated, was determined by
quantifying the amount of agent found in supernatants collected during the cycles of
nanoparticle washes (MAGENT-Supernatants) and comparing it to the mass of agent used for














The mass of the RHO or ICG lost in the supernatants was determined by
absorption spectroscopy using standard curves (r2 > 0.99) of known concentrations of the
agent in the respective surfactant solution (bovine serum albumin or sodium cholate
solutions) used for nanoparticle suspension and washing. A Shimadzu UV-1201 UV/Vis
spectrophotometer is with an optical range from 200 to 1100nm was used for this
purpose. RHO absorbance was measured at the peak wavelength of 530 nm in bovine
serum albumin solution, while ICG absorbance was read at 795 nm in sodium cholate and
800 nm in bovine serum albumin.
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The mass of Gd-DTPA in supernatants was determined by elemental analysis
using inductively-coupled mass spectroscopy (ICP-MS). A GBC Optimass 8000 ICP-
MS instrument from the group of Dr. James Holcombe in the Department of Chemistry
of The University of Texas at Austin was used for this purpose. ICP-MS is a highly-
sensitive technique, being able to detect concentrations of Gd-DPTA in the range of 102
to 106 ppt, or 0.1 to 1000 ng/ml. Supernatants from nanoparticle purification steps were
diluted from 100 to 10,000 times with deionized water and analyzed by introducing
directly into the ICP-MS. Concentrations were determined by comparing the average
intensity of the most commonly-occurring gadolinium isotopes –molecular weight of
152, 154, 155, 156, 157, 158, and 160 (Leland 1950) -- to a calibration curve based on
known Gd-DTPA concentrations. The mass of Gd-DTPA in the supernatants was
determined by multiplying the concentration by the total volume of each supernatant and
the dilution factor. The encapsulation efficiency was determined by comparing the mass
of Gd-DTPA found in the supernatants to that used for preparation of the nanoparticles.
4.2.6 Agent Loading
Loading, or the weight percent of the agent in the final formulation, was
determined by dissolving a known mass of nanoparticles in an organic solvent and
comparing the absorbance of these solutions to a standard curve (r2 > 0.99) of known
concentrations of the agent in the same organic solvent. Loading was calculated as
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RHO nanoparticles were dissolved in dichloromethane while ICG nanoparticles
were dissolved in dimethylsulfoxide.
Determination of the loading of Gd-DTPA nanoparticles by ICP-MS by direct
injection, as was done with supernatants, was not assessed as the presence of the polymer
and surfactant was expected to cause problems with quantification. However, at the end
of this part of the project, this was determined to not be a problem. Data for direct
injection of nanoparticle suspensions is not presented here.
A Jeol 2010F transmission electron microscope with energy dispersive
spectroscopy (EDS) capability was used as an alternative for elemental detection of
gadolinium within solid Gd-DTPA nanoparticles. A single nanoparticle was focused ,
scanned and analyzed for its elemental composition.
4.2.7 In Vitro Agent Release Experiments
The release of rhodamine and ICG under simulated physiological conditions from
nanoparticles was studied. A known mass of nanoparticles was suspended in a specific
volume of 0.01M phosphate buffered saline, pH 7.4, and incubated in poly(carbonate)
centrifuge tubes in a 37°C water bath. At specific time points, the samples were
centrifuged for 15 minutes at 48,000xg and a portion of the supernatant was removed for
analysis and replaced with fresh buffer. Absorption spectroscopy was used to determine
the mass of agent released with time. Each set of data was run in independent triplicates.
The average and standard deviation between repetitions was determined.
At the end of the release study, the nanoparticle suspension was centrifuged and
all the supernatant was removed. The nanoparticle pellet was resuspended in water and
centrifuged to remove excess buffer salts. The supernatant was again removed and the
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pellet was freeze dried for determination of remaining dry weight and agent content by
spectrophotometry.
4.2.8 Studies of Nanoparticle Interaction with Model Cancer Cells In Vitro
Human mammary gland adenocarcinoma cell line MDA-MB-231 was generously
provided by Dr. Dharamawhardane, formerly from the Section of Molecular, Cell and
Developmental Biology of The University of Texas at Austin. Cells were incubated at
37°C under a 5% CO2 atmosphere and maintained with Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum, 1% HEPES buffer, 1% L-
glutamine and 1% sodium pyruvate.
For microscopy studies, cells were seeded in four 6-well plates that contained a
pre-sterilized coverslip at a concentration of 300,000 cells per well. A day after seeding,
the cells were pre-treated with endocytosis inhibitors including 10mM ammonium
chloride or 450mM sucrose for 1 hour, or 30M cytochalasin D, 33M nocodazole, or
1g/ml filipin for 30 minutes. A separate plate of cells was placed incubated at 4C for 1
hour to study the effect of cell metabolism on the uptake or rhodamine or rhodamine-
loaded nanoparticles. After the specific pre-treatment time, the cell media was replaced
with media containing the appropriate inhibitor at the pre-treatment concentration and
100 g/ml of rhodamine-loaded nanoparticles or the equivalent rhodamine concentration
in solution (0.28 g/ml – based on the loading for the batch used). After a 2 hour
exposure to the rhodamine-containing formulations, the media was removed and cells
were washed three times with Dulbecco’s phosphate buffered saline (DPBS), fixed for 15
minutes in 3.7% formalin and again washed. Coverslips were then mounted onto
microscopy slides using Fluoromount-G (Southern Biotech, Birmingham, AL, USA) to
protect the samples. Microscopy slides were observed with a Leica SP2 AOBS confocal
90
microscope using laser sources at 476, 488 and 496 nm to excite rhodamine and detecting
the fluorescence signal in the 550-650 nm range. All microscopy gain and offset settings
were maintained constants throughout the study.
For flow cytometry studies, cells were seeded at a concentration of 500,000 cells
per well in 6-well plates. Growth media was replaced with rhodamine-containing
formulations 24 hours after seeding. The tested formulations included rhodamine-loaded
nanoparticles, rhodamine in solution, blank nanoparticles and DPBS as a control. The
concentrations used were 5, 50 and 500 g/ml in DPBS for nanoparticles. Equivalent
rhodamine solution concentrations of 0.014, 0.14 and 1.4 g/ml were used based on a
nanoparticle loading of 0.28 wt%. After exposure to these formulations for 2, 4 or 8
hours, cells were washed three times with DPBS and a cell suspension was created using
trypsin/EDTA. Cells suspensions were diluted in growth media, centrifuged and washed
three times with DPBS. Cells were finally resuspended in 1 ml of DPBS without Ca/Mg
and immediately analyzed with a FACS Calibur flow cytometer (Beckton & Dickinson,
Franklin Lakes, NJ, USA) using a 488nm laser for excitation of rhodamine and a band
centered at 585 nm for detection of fluorescence. Flow cytometer channel voltage and
gain were maintained constant throughout the analysis.
Flow cytometry data were processed to remove the events associated to free
nanoparticles according to their light scattering properties. From the filtered data, the
arithmetic mean of the fluorescence intensity of cells exposed to the various formulations
was determined.
4.2.9 In Vivo Imaging Study with Indocyanine Green Nanoparticles
A preliminary study of in vivo fluorescence imaging was performed with ICG-
loaded nanoparticles to determine if their ICG content was sufficiently high for in vivo
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detection and to observe their biodistribution. These studies were done in collaboration
with Dr. Keith Stantz from Purdue University, School of Health Sciences. ICG
nanoparticles with a loading of 967 ng/mg were suspended in water at 2.5 mg/ml by
sonication. Approximately 0.7 ml of this suspension was injected intravenously into
mice. The mouse model had two xenographs of MCF-7 human breast adenocarcinoma
cells, one originated with wild type (WT) cells and another of cells transfected with
vascular endothelial growth factor (VEGF). Fluorescence images were obtained by
photoacoustic computer tomography spectroscopy. Initial readings were done after
injection of known concentrations of free ICG in solution to establish the concentration
required for detection.
4.2.10 Statistical Analysis
Significant difference between the means of sample groups was determined using
Sudent’s t-test based on a confidence level of 95% (p < 0.05). Statistical analysis was
performed for sizing, zeta potential, yield, encapsulation efficiency and loading data.
4.3 RESULTS AND DISCUSSION
4.3.1 Rhodamine Loaded Nanoparticles
Rhodamine nanoparticles were successfully prepared using nanoprecipitation by
co-dissolving rhodamine and PLGA in acetone and precipitating the polymer into
nanoparticles in an aqueous phase having bovine serum albumin as a stabilizer. Table 4.2
summarizes the results of RHO nanoparticle characterization. Batch mass recovery, or
yield, ranged from the 70 to 90% and was not dependent on the loading of rhodamine.
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The average nanoparticle size was of 290 nm before freeze drying and of 317 nm after
freeze drying. No significant difference was observed in the size of the particles loaded
with 0.15 or 0.30 wt% RHO compared to blank nanoparticles, or between samples of a
given targeted loading before or after freeze drying (p >> 0.05). Approximately 86%
encapsulation efficiencies were achieved. No statistically significant difference was
observed between the encapsulation efficiency for the desired loading levels of 0.075,
0.15 or 0.30 wt% RHO. The actual weight percent of RHO that was found to be loaded
within dissolved PLGA nanoparticles was very close to the targeted loading. Figure 4.3
is a scanning electron microscopy image of RHO loaded PLGA nanoparticles. As
displayed, the nanoparticles have a spherical morphology and range in size between 150
and 300 nm, thus agreeing with the results described above.
In vitro release studies demonstrated that RHO-loaded nanoparticles were an
optimal formulation for imaging studies because the hydrophobic RHO was released very
slowly, as shown on Figure 4.4. Specifically, within 12 hours less than 15% of the agent
had been released when incubated at 37°C at pH 7.4. On the other hand, and as described
for doxorubicin-loaded nanoparticles in Chapter 3, at pH 4.0 the nanoparticles rapidly
released the agent, with 75% being released within the same 12 hours. Importantly,
controlled release of this fluorescent agent over a time period of 12 hours is sufficient for
studying the interaction and uptake of nanoparticles by cells in vitro.
4.3.1.1 Cellular Studies with Rhodamine-Loaded Nanoparticles
Microscopy and flow cytometry studies of the interaction of rhodamine-loaded
nanoparticles and breast cancer cells were conducted. Microscopy studies, as seen in
Figure 4.5 and 4.6, show that the cells are able to uptake rhodamine both when presented
in the form of nanoparticles or as a solution. Studies performed at 4°C showed that
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rhodamine uptake was not an active process as the reduced metabolism of the cells under
this condition did not seem to significantly decrease the level of rhodamine observed in
the cells (Figure 4.6). This observation had also been reported for retinal pigment
epithelial cells upon exposure to rhodamine-loaded poly(lactic acid) nanoparticles
prepared by precipitation from dimethylsulfoxide (Bejjani, BenEzra et al. 2005). It is
possible, then, that nanoparticle binding and uptake was mediated by interaction of
residual albumin on the surface of the particles and albumin receptors on the cells. These
receptors are normally involved in albumin transcytosis across endothelial tissue as have
been recently suggested to be participants in the delivery of paclitaxel-albumin bound
nanoparticles marketed under the name of Abraxane® (Green, Manikhas et al. 2006).
As can be seen in Figures 4.5 and 4.6, high level of nanoparticle adhesion to cells
and culture substrate was observed. This made objective comparison of fluorescence
intensities between the formulations more challenging, although there appeared to be
higher fluorescence from the cells exposed to rhodamine-loaded nanoparticles. It is also
important to note that rhodamine distributed throughout the cytoplasm of the cells,
contrary to the nuclear localization observed with the chemotherapeutic agent
doxorubicin as described in Chapter 3.
Flow cytometry was used in separate experiments to try to filter out the
fluorescence associated with nanoparticles that were adhered to the cell culture substrate
as opposed to being associated with the cells. For flow cytometry, suspensions of blank
or rhodamine-loaded nanoparticles and cells were analyzed after exposure of adhered
cells to nanoparticle suspensions or free rhodamine for specific periods of time. In these
studies, laser light of a wavelength of 488 nm was focused on a narrow stream of the
flowing suspension. Upon interaction of the light with a particle, which could be a
polymeric nanoparticle or a cell, the light scattered in line with the laser source (forward
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scattering) or perpendicular to it (side scattering), and the fluorescence produced by the
sample were detected. As expected, nanoparticles resulted in significantly greater side
scattering as a result of their high opacity while cells are able to scatter light in the
forward direction in a much greater amount as a result of their low index of refractivity.
This difference was used to separate the data of independent nanoparticles that had
remained in the samples of cells exposed to nanoparticles as the purpose of the
experiment was to obtain a quantitative measure of rhodamine (whether entrapped in
attached or endocytosed nanoparticles or free) directly associated with the cells. Figure
4.7 shows the side and forward scattering of rhodamine-loaded and blank nanoparticles,
and of control and nanoparticle-exposed cells.
After removal of the data of independent nanoparticles, the fluorescence
associated which each cell after exposure to rhodamine in solution or in nanoparticles
was determined. Figure 4.8A is a histogram that summarizes the number of events or
cells recorded (counts) and the fluorescence intensity of each event after exposure of the
cells for 4 hours with all the formulations. Figure 4.8B shows the arithmetic mean of the
fluorescence intensity recorded in the cells exposed to each dosage. As can be seen in
both of these figures, the fluorescence associated with cells exposed to rhodamine-loaded
nanoparticles was significantly higher than that of cells exposed to rhodamine in solution
for all concentrations and exposure times tested. No fluorescence was detected on cells
exposed to blank nanoparticles or to DPBS (control). As can be seen in figure 4.8B, the
fluorescence of cells exposed to rhodamine in solution appeared to decrease with
exposure time. The fluorescence intensity of cells exposed to rhodamine-loaded
nanoparticles increased from 2 to 4 hours but appeared to decrease after 8 hours of cell
exposure. This observation could be a result of cellular efflux mechanisms since
rhodamine molecules have been reported to be substrates for the P-glycoprotein (P-gP)
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transmembrane receptor associated with multidrug resistance (Yoshimura, Shudo et al.
1990; Sarver, Klis et al. 2002). P-gP is overexpressed in cell lines that are resistant to
chemotherapeutic agents, but could be expressed in normal levels by the MDA-MB-231
breast cancer cell line. This cell line is known to be sensitive to chemotherapeutic agents
unless specifically adapted to grow under constant chemotherapeutic agent exposure
(Schneider, Fuqua et al. 1990; de la Torre, Hao et al. 1993; Betancourt, Brown et al.
2007).
4.3.2 Indocyanine-Green Loaded Nanoparticles
Quantification of ICG for determination of encapsulation efficiency and loading
was a difficult task as a result of the severe instability of ICG when dissolved in various
media. An initial attempt to quantify the weight percent of ICG within nanoparticles was
made by dissolving the particles in a mixture of 60:40 v/v% dichloromethane/methanol
and utilizing absorbance spectroscopy for quantification. Interestingly, when running
samples of ICG in this medium to create a standard curve, a rapid and linear decrease in
absorbance was observed when an ICG solution sample was maintained under continuous
illumination within the spectrophotometer, as shown in Figure 4.9A. The absorbance of a
0.977 g/ml ICG solution in 60:40 v/v% dichloromethane/methanol decreased to about
1.5% of the original absorbance within 50 minutes. After 50 minutes of continuous
illumination no further changes in absorbance were observed, although by then the
absorbance was so low that any changes may not have been detectable by the instrument.
Although continuous illumination of the sample was not necessary for quantification of
ICG, the changes in absorbance occurred fast enough to be significant for the time of a
single absorbance scan (about 2 minutes).
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A second experiment was performed to determine if the rapid decrease in
absorbance of ICG could be minimized by protecting the samples from both
environmental and spectrophotometer light. The absorbance at 795 nm of a number of
ICG solutions in 60:40 v/v% dichloromethane/methanol was obtained. No spectrum
scans were done so that the time of light exposure was reduced to a few seconds. Figure
4.9A shows the effect of storage time on the absorbance of ICG solutions in this solvent
mixture. It was found that a decrease in absorbance was also observed even when light
exposure had been minimized. Interestingly, the rate of absorbance decrease was only
slightly lower than that of the samples continuously illuminated in the spectrophotometer.
For the 0.977 g/ml sample stored in the dark, the absorbance decreased to about 4% the
initial reading after 1 hour. These experiments pointed out the need to be extremely
consistent and careful when utilizing absorbance spectroscopy for quantification of ICG.
As described earlier in this chapter, time and intensity of illumination, pH,
solvent, concentration, temperature and other factors significantly affect the optical
stability of ICG (Gathje, Steuer et al. 1970; Holzer, Mauerer et al. 1998; Saxena, Sadoqi
et al. 2003; Saxena, Sadoqi et al. 2004). Since the type of solvent is one of the main
factors determining the stability of ICG, the absorbance of this agent was probed in other
solvents to determine if its stability could be improved compared to that in
dichloromethane/methanol mixtures. Standard curves of ICG were procured in dimethyl
sulfoxide (DMSO) as an alternative solvent for quantification of ICG within solid
nanoparticles. The absorbance of ICG was observed to be stable and behave linearly
DMSO for up to 17 hours when stored at 4°C and protected from light. Figure 4.10
shows the data for ICG solutions in DMSO at three concentrations and 2 different time
points.
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Table 4.3 displays the properties of the various formulations of ICG-loaded
nanoparticles that were prepared. Yields ranged from 50 to 65% for all batches and did
not depend on the amount of ICG used in the preparation. The average size of ICG-
loaded particles ranged from 140 to 170 nm before freeze drying and increased to about
200 nm after freeze drying. Size was not found to be significantly different between the
particles of different targeted loadings neither before nor after freeze drying (p > 0.1), as
expected for the low loading of a small molecular weight agent. The size of these
nanoparticles, which were prepared with sodium cholate as the surfactant, was smaller
than that of blank or rhodamine-loaded nanoparticles prepared with bovine serum
albumin as the surfactant (see Table 4.2). Nanoparticle size reduction and a more
homogenous size distribution has been observed in the past with the use of sodium
cholate as a surfactant compared to particles prepared with poly(vinyl alcohol)
(Lamprecht, Ubrich et al. 2001; Arica and Lamprecht 2005; Leo, Contado et al. 2006).
Accurate determination of ICG encapsulation efficiency was not achieved as a
result of ICG instability in aqueous solutions and the presence of small nanoparticles in
the supernatants which could not be successfully centrifuged or filtered as a result of their
small size. The presence of nanoparticles in the samples resulted in light scattering and
higher absorbance values during spectrophotometric analysis. For these particles only
determination of ICG loading from dissolved nanoparticles was deemed accurate.
The loading of ICG achieved was about two orders of magnitude lower than the
targeted loading, but it was clearly dependent on the amount of ICG used for preparation
of the particles (p < 0.05). Specifically, the loadings of ICG achieved ranged from 85 to
1028 ng of ICG per milligram of nanoparticles. It is possible that the maximum
encapsulation of ICG within PLGA nanoparticles is controlled by the partitioning of ICG
between the hydrophobic core of the particles and the outer aqueous phase. It is
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expected, consequently, that if a lower amount of ICG were used to make the
nanoparticles, even lower loadings would have been achieved. Alternative preparation
methods that utilize specific affinities between ICG and nanoparticle contents or that
prevent ICG diffusion into the outer emulsifying phase will need to be studied to achieve
better loadings.
Results of in vitro release studies can be seen in Figure 4.11. An initial burst
release of 15% of the ICG was observed within the first hour. By one day, 25% of the
ICG had been released. After this, ICG release was controlled at constant rate over a
period of 12 days. The initial burst release is most likely a result of rapid solubilization
of ICG that had been adsorbed to the surface of the nanoparticles instead of encapsulated
within their core. Once all adsorbed ICG has been dissociated, ICG within the particles
is released through a combination of diffusion and degradation of the polymeric matrix.
4.3.2.1 In Vivo Imaging Study with ICG Nanoparticles
A preliminary study in mice was performed to determine if the ICG content that
was achieved in the PLGA nanoparticles was adequate for its use as an image contrast
agent. From initial readings with free ICG solution, it was determined that a
concentration of 0.3g/ml of ICG was required to detect a decent fluorescent signal
within VEGF-transfected tumors. This concentration also resulted in enhanced signal in
the liver and heart, while only a small enhancement was observed in the wild type tumor
and muscle. Imaging after nanoparticle injection revealed that ICG-loaded nanoparticles
were able to clearly highlight with the wild type tumor vasculature a high level of
contrast. In the VEGF-transfected tumor, slight and non-uniform enhancement was
observed shortly after injection but disappeared after 20 minutes. Figure 4.12 display the
fluorescent image of a mouse after exposure to ICG nanoparticles and the relative levels
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of fluorescence intensity in tissues compared to background, respectively. Similar
images were obtained at 50, 200 and 500 ms. These results demonstrate that the ICG
nanoparticles could be successfully imaged in vivo despite the low encapsulation
efficiency and loading achieved.
Preferential distribution of ICG-loaded nanoparticles on wild-type tumor as
opposed to VEGF-transfected tumor is possibly a result of tumor characteristics. The
VEGF-transfected tumors were observed to have high blood flow and vascular blood
volume in comparison to the wild type with dynamic contrast enhanced computer
tomography. It is possible that high blood flow rates, and consequent low residence time,
prevented nanoparticles from extravasating from the tumor vasculature of VEGF-
transfected tumors.
4.3.3 Gd-DTPA Loaded Nanoparticles
Preparation of Gd-DTPA loaded nanoparticles was performed by a water-in-oil-
in-water technique. A volume of 100 to 500 l of Gd-DTPA solution was added to an
organic solution of the polymer. This first mixture was then added to an outer aqueous
phase containing a surfactant. Table 4.4 displays the various combinations of solvent,
inner aqueous phase volume, outer aqueous phase surfactant and Gd-DTPA loading that
were attempted. This table also displays the resulting nanoparticle sizes before and after
freeze drying, and the percent recovery. For a given solvent/surfactant combination, the
volume of the inner aqueous phase was increased with the purpose of achieving higher
Gd-DTPA loading until the size of the particles became too large as a result of
aggregation or un-controlled polymer precipitation.
As can be seen in Table 4.4, the best results were obtained using a combination of
acetone and bovine serum albumin as this was the only method in which 500 l of the
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inner aqueous phase and a enough Gd-DTPA for a maximum loading of 6.4wt.% were
incorporated without increasing the size of the particles above 1 m. The size of these
particles ranged from 218 to 340 nm before freeze drying and from 230 to 570nm after
freeze drying. A scanning electron microscopy image of these particles is shown in
Figure 4.13. Acceptable results were also obtained using a combination of ethyl acetate
and sodium cholate, although the size of the particles increased significantly and even
above 1 um after freeze drying, depending on the volume of the inner aqueous phase that
was used. The remaining combinations, which included ethyl acetate with bovine serum
albumin and acetone with sodium cholate, only allowed addition of 100-200 l of Gd-
DTPA solution before their size escalated. Figure 4.14 shows a scanning electron
microscopy image of particles made with 500 l of Gd-DTPA solution, ethyl acetate and
bovine serum albumin. As can be seen, particles are visible but are surrounded by large
polymer precipitates.
The yield of the formulations ranged from 50 to 80% for nanoparticles made with
bovine serum albumin as a surfactant and from 30-60% for nanoparticles made with
sodium cholate. As described for ICG nanoparticles previously, sodium cholate
commonly results in smaller particle sizes and lower polydispersity. Lower nanoparticle
sizes prior to freeze drying result in lower recovery as a result of the centrifugation
process.
Quantification of Gd-DTPA in aqueous supernatants collected during nanoparticle
preparation by ICP-MS led to inconclusive results. Numerous variables resulted in
highly inconsistent encapsulation efficiency values, including the need for dilution of
samples to up to 10,000 times their initial concentration, the need for creating standard
curves of concentrations in the parts-per-trillion concentration range, possible
contamination of samples with low levels of gadolinium in the laboratory, and instrument
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instability during readings. For a single control sample containing 10,000 ppt Gd-DTPA,
the concentration between runs varied by up to 30% as a result of instrument stability
issues. When the supernatants of a single batch were run on two different occasions, the
encapsulation efficiency was determined to be 40.1% the first time and 12.5% the second
time. In any case, the need for substantial dilution of supernatants demonstrated the low
encapsulation efficiency of Gd-DTPA within PLGA nanoparticles.
Energy dispersive spectroscopy analysis of Gd-DTPA loaded nanoparticles via
transmission electron microscopy was able to identify the presence of gadolinium within
a single nanoparticle, as shown on Figure 4.15, although the signal is very close to the
noise level. Elemental analysis of that sample revealed that Gd was approximately
0.07% of the weight of the nanoparticle.
4.4 CONCLUSIONS
Emulsification and nanoprecipitation methods were utilized for preparation of
poly(lactic-co-glycolic acid) nanoparticles loaded with the imaging agents RHO, ICG and
Gd-DTPA. Various modifications to the preparation protocols were investigated to try to
achieve nanoparticles of properties similar to those of drug-loaded particles that were
described in Chapter 3, but with sufficient imaging agent loading to be used for imaging
studies.
RHO particles were prepared through nanoprecipitation of a solution of PLGA,
rhodamine and acetone after addition to an aqueous phase containing bovine serum
albumin as a stabilizer. In vitro studies with RHO nanoparticles revealed that MDA-MB-
231 breast cancer cells were better able to intake this agent when presented in the form of
a nanoparticle suspension rather than as a rhodamine solution, result that agrees with
what was observed with doxorubicin-loaded nanoparticles in Chapter 3.
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Indocyanine green particles were best prepared by first dissolving it in methanol,
mixing the solution with a polymer-acetone solution and then precipitating the polymer
upon addition to an aqueous phase containing sodium cholate. Although the loading
achieved was much lower than desired, an in vivo study revealed that ICG content was
sufficient for detection through photoacoustic computer tomography spectroscopy.
Gd-DTPA-loaded nanoparticles were obtained by oil-in-water-in-oil methods
using acetone or ethyl acetate as the solvent and bovine serum albumin or sodium cholate
as the surfactant in the outer aqueous phase. Determination of actual Gd-DTPA loading
within nanoparticles was unsuccessful although EDS analysis was able to identify its
presence on a single nanoparticle even if at low levels.
Although use of alternative methods of nanoparticle preparation could have
resulted in higher loading of ICG and Gd-DTPA, this would also have resulted in
nanoparticles with properties different from those of the chemotherapeutic agent-loaded
particles described in Chapter 3. Dissimilar physiochemical characteristics between the
therapeutic and imaging nanoparticles would surely result in different interactions with
biological systems, and consequently would not be representative of one another.
Up to this point, research efforts resulted in the preparation of biodegradable
nanoparticles which could deliver a high payload of the chemotherapeutic agent
doxorubicin in a pH-dependent manner, and at least two similar formulations containing
imaging agents for in vitro cellular studies. The following chapter describes the
modification of these preparations for incorporation of poly(ethylene glycol) on the
surface of the nanoparticles in order to improve the fate of the particles in vivo and to













































Table 4.1 Properties of imaging agents and methods used for their encapsulation and
quantification
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Table 4.2 Properties of rhodamine-loaded poly(lactic-co-glycolic acid) nanoparticles.

























0 4 74.1 ± 3.9 293 ± 32 332 ± 104 --- ---
0.075 2 81.5 ± 2.8 376 ± 109 310 ± 153 90 ± 0.4 0.08 ± 0.002
0.15 4 82.8 ± 3.6 258 ± 54 333 ± 219 83 ± 8 0.15 ± 0.03
0.3 4 79.1 ± 7.6 282 ± 63 291 ± 51 90 ± 8 0.29 ± 0.01
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Table 4.3 Properties of Indocyanine Green (ICG)-loaded poly(lactic-co-glycolic acid)
nanoparticles. Values displayed are averages ± standard deviation for





















1.22 4 55.6 ± 2.1 142 ± 10 205 ± 46 0.009 ± 0.004 85.0 ± 36
2.41 8 53.3 ± 5.3 166 ± 26 194 ± 28 0.014 ± 0.005 139.5 ± 49
4.71 8 51.2 ± 8.6 172 ± 32 207 ± 19 0.028 ± 0.151 284.1 ± 151
9.07 2 64.6 ± 2.0 152 ± 10 157 ± 1.2 0.103 ± 0.009 1028.5 ± 86
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100 1.4 5 234 ± 60 228 ± 43 66 ± 11
500 3.6 4 218 ± 13 226 ± 12 79 ± 2
500 6.4 8 343 ± 69 570 ± 513 72 ± 4
100 1.4 1 168 354 53
200 2.7 1 189 236 47
300 4 1 > 3,000 --- ---
400 5.2 2 > 3,000 --- ---
500 3.6 4 > 3,000 --- ---
500 6.5 2 > 3,000 --- ---
100 1.4 1 188 144 56
200 2.7 1 > 3,000 --- ---
300 4.0 1 > 3,000 --- ---
200 2.7 1 247 749 27
300 4 1 251 214 28
400 5.3 1 896 896 34






























































Figure 4.3 Scanning electron microscopy image of rhodamine-loaded poly(lactic-co-














f 0.14 wt% loading - pH 7.4
0.08 wt% loading - pH 7.4
0.14 wt% loading - pH 4.0
Figure 4.4 In vitro release of rhodamine from poly(lactic-co-glycolic acid)
nanoparticles as a function of rhodamine loading and pH. The y axis,
Mt/Minf, corresponds to the cumulative fraction of rhodamine mass released
(Mt) over time compared to the total mass of rhodamine that was released or
found in the remaining nanoparticles (Minf). Y bars represent the standard
deviation between 3 independent samples for each condition.
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Figure 4.5 Confocal microscopy images at the plain of maximum cellular fluorescence
of MDA-MB-231 breast cancer cells after exposure to (A) rhodamine
loaded nanoparticles, (B) rhodamine in solution or (C) growth media as a
control for 2 hours at 37°C. Cells were exposed to 280 ng/ml of rhodamine
or to equivalent nanoparticle concentrations based on rhodamine loading.
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Figure 4.6 Confocal microscopy images at the plain of maximum cellular fluorescence
of MDA-MB-231 breast cancer cells after exposure to (A) rhodamine
loaded nanoparticles, (B) rhodamine in solution or (C) growth media as a
control for 2 hours at 4°C. Cells were exposed to 280 ng/ml of rhodamine
or to equivalent nanoparticle concentrations based on rhodamine loading.
C
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Figure 4.7 Plot of forward versus side scattering (x and y axis, respectively) of
nanoparticle or cell suspensions obtained after flow cytometry analysis.
Scattering profile of (A) rhodamine-loaded nanoparticles, (B) blank
nanoparticles, (C) MDA-MB-231 breast cancer cells and (D) cells exposed
to rhodamine-loaded nanoparticles. Red- and green-lined regions on each
plot represent the gates used for separating the data associated with
nanoparticles or cells, respectively.
Control 2 8hr.012
FSC-H
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Figure 4.8 Fluorescence intensity of cells exposed to rhodamine (RHO)-loaded
nanoparticles or free RHO in solution obtained by flow cytometry.
Fluorescence associated with independent nanoparticles has been removed.
(A) Histogram of fluorescence intensity of cells exposed to blank
nanoparticles, RHO in solution or RHO-loaded nanoparticles for 4 hours at
nanoparticle concentrations of 5, 50 and 500 g/ml. (B) Arithmetic average
of the fluorescence intensity of cells exposed to the same formulations for 2
or 4 hours. RHO solution concentrations for cell exposure were determined























































Figure 4.9 (A) Effect of illumination and storage time on indocyanine green (ICG)
absorbance. A 0.977 g/ml sample of ICG in a 60/40 v/v%
dichloromethane/methanol was continuously illuminated in a Shimadzu
UV-1201 spectrophotometer. Absorbance readings at the peak wavelength
of 794 nm were taken at specific time points. (B) Time-dependence of
absorbance of ICG at 795 nm in 60/40 v/v% dichloromethane/methanol
after storage at room temperature for specific time periods in the dark.
































Figure 4.10 Concentration and time dependence of absorbance of indocyanine green
(ICG) dissolved in dimethyl sulfoxide initially and after 17 hours of storage






















Figure 4.11 In vitro release of ICG from poly(lactic-co-glycolic acid) nanoparticles.
Nanoparticles with a loading of 967 ngICG/mg were suspended in 0.01M
phosphate buffered saline, pH 7.4, and at 37°C.
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Figure 4.12 Results of in vivo imaging study with ICG nanoparticles. ICG nanoparticles
were intravenously injected into mice that had a xenografts of wild-type
(WT) and vascular endothelial growth factor (VEGF)-transfected human
MCF-7 breast cancer cells. Photoacoustic computer tomography
spectroscopy was used to detect the fluorescent signal from ICG. (A)
Fluorescent image obtained with and ICG filter displays biodistribution of
ICG nanoparticles and enhancement of tumor tissue. (B) Fluorescence
intensity in sternum, tumors, and heart, relative to background at 50, 200,
500 and 5000 ms after injection.
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Figure 4.13 Scanning electron microscopy image of Gd-DTPA loaded particles prepared
with acetone as the organic solvent, 500 l of 7.6 mg/ml Gd-DTPA solution
as the inner aqueous phase and bovine serum albumin solution as the outer
aqueous phase. Particles are roughly spherical and are 200-300 nm.
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Figure 4.14 Scanning electron microscopy image of Gd-DTPA loaded particles prepared
with ethyl acetate as the organic solvent, 500 l of 14 mg/ml Gd-DTPA
solution as the inner aqueous phase and bovine serum albumin solution as
the outer aqueous phase. Particles in the size range of 500 nm are visible
but are surrounded by a much larger polymeric precipitate. The morphology
of the particles is corrugated. Bar represents 5 m and 2 m on the top and
bottom images, respectively.
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Figure 4.15 Transmission electron microscopy image and corresponding energy
dispersive spectra (EDS) of poly(lactic-co-glycolic acid) nanoparticle
loaded with Gd-DTPA . This batch of particles was prepared with acetone
as the organic solvent, 500 l of 7.8 mg/ml Gd-DTPA solution as the inner
aqueous phase and bovine serum albumin solution as the outer aqueous
phase. Gadolinium is identified in a single nanoparticle although most
peaks are very close to the noise level.
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STRATEGIES FOR PEGYLATION OF NANOPARTICLES
5.1 INTRODUCTION
As mentioned in Chapter 2, nanoparticle-based drug delivery systems are rapidly
removed from the circulation upon intravenous injection by the reticuloendothelial
system (Fawaz, Bonini et al. 1993; Brannon-Peppas and Blanchette 2004). Removal is
dictated by the rapid absorption of plasma proteins, or opsonins, on the surface of the
particles, which leads to recognition and sequestration by the Kupffer cells in the liver
and macrophages in the spleen, both of which are part of the macrophage phagocytic
system (Avgoustakis 2004). The short residence time of particulate drug delivery
systems in the circulation limits their ability to reach the targeted disease tissue and,
consequently, their effectiveness.
Incorporation of poly(ethylene glycol) (PEG) on the surface of nanoparticles, or
PEGylation, confers them with stealth properties by creating a hydrophilic steric barrier
that delays opsonization and rapid recognition by the macrophage phagocytic system
(Stolnik, Dunn et al. 1994; Gref, Luck et al. 2000; Mehvar 2000; Hu, zhai et al. 2002;
Otsuka, Nagasaki et al. 2003; Avgoustakis 2004). For example, a study of the
biodistribution of liposomes in vivo in New Zealand White rabbits found that their
circulation half life increased from 10-15 minutes to more than 1000 minutes as a result
of PEGylation (Torchilin, Narula et al. 1996). PEGylation of nanoparticles also provides
stability to the colloidal suspension through inter-particle steric repulsion (Avgoustakis
2004). The mechanism of protection offered by PEG has been associated with the high
flexibility of the polymer chain which allows free rotation of the polymer units and the
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high hydrophilicity that creates a shield around the particle, both of which prevent
interaction of the particle with macromolecules in the body (Torchilin 1995).
Incorporation of PEG on the surface of particles has been attempted in the past
through adsorption or covalent conjugation. However, it has been shown that the
adsorption of surfactants containing PEG segments such as poloxamers and poloxamines
does not confer permanent protection to the particles (Neal, Stolnik et al. 1998).
Specifically, these surfactants have been shown to be displaced from PLGA nanoparticles
by rat serum proteins in vitro. Such temporal surface protection limits the potential
circulation time of the colloidal carriers. Covalent attachment of PEG to the nanoparticle
polymer has been shown to be more effective than adsorbed PEG at reducing
complement activation (Vittaz, Bazile et al. 1996), reducing interaction of the particles
with the macrophage phagocytic system in vitro (Bazile, Prud'Homme et al. 1995; Barratt
2003), and reducing the uptake of the particles by the macrophage phagocytic system in
vivo (Bazile, Prud'Homme et al. 1995).
Incorporation of PEG on the polymeric nanoparticles developed in the present
research was carried out not only to increase the stability of the formulation and to
provide the particles with improved circulation time once utilized in vivo, but also with
the objective of utilizing surface PEG chains for attachment of targeting molecules such
as antibodies, which could be utilized to direct the nanoparticles to the target cancerous
tissue. Because of this, incorporation of PEG chains that included functional terminal
groups was of outmost importance. The preparation of PEGylated nanoparticles has been
widely investigated previously (Gref, Minamitake et al. 1994; Beletsi, Leontiadis et al.
1999; Zambaux, Bonneaux et al. 1999; Li, Pei et al. 2001; Avgoustakis, Beletsi et al.
2003). However, few reports have been made of the preparation of targeted nanoparticles
that include functional PEG chains.
126
The use of the highly specific biotin-avidin interaction has been proposed as a
means for the preparation of targeted drug delivery systems containing PEG.
Specifically, the preparation of poly(lactic-acid)-PEG copolymers with biotinylated end
gropus, which could be used for the preparation of targeted nanoparticles, has been
reported (Cannizzaro, Padera et al. 1998; Salem, Cannizzaro et al. 2001). Also,
nanoparticles of poly(ɛ-caprolactone)-PEG-biotin, which can be used for binding avidin-
modified targeting agents, have been described in the literature (Gref, Couvreur et al.
2003). These systems, however, require that the targeting agent be chemically bound to
avidin, a bulky glycoprotein that could interfere with the interaction of the targeting agent
and its target receptor. One other interesting system involves the use of PLA-PEG-
maleimide copolymers to create nanoparticles that can be bound to thiol-containing
targeting agents (Gao, Tao et al. 2006). This technique is useful for site-specific
conjugation to targeting agents because of the relatively low percentage of thiol-
containing cysteine residues in most targeting agents –commonly antibodies, antibody
fragments, peptides. However, most times it is necessary to add cysteines to these agents,
thus increasing the possibility of altering their structure and reducing their activity.
In the present research, conjugation of targeting agents to functional PEG termini
was performed with the use of electrophilic N-hydroxysuccinimide (NHS) esters of PEG
carboxylic acids, as will be described in more detail in Chapter 6. Reaction between
lysines or terminal amine groups of targeting agents and NHS-PEGs results in the
formation of physiologically-stable amide bonds. The strategies for PEGylation of
nanoparticles described in this chapter are focused on the use of PEG molecules
containing NHS terminal groups, as shown on Figure 5.1, or others containing hydroxyl
or carboxylic acid end groups which could be easily modified to include the NHS end
group.
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Four main strategies were studied in the present research for the incorporation of
functional poly(ethylene glycol) (PEG) chains onto the surface of the nanoparticles. Two
strategies were based on the use of blends of poly(lactic-co-glycolic acid) (PLGA) with
PEG-containing polymers. The other strategies were based on covalently binding PLGA
to heterofunctional PEG. For the latter strategy, synthesis of the copolymers was
performed by polymerization of lactide and glycolide onto pre-made heterofunctional
PEG or conjugation of pre-made poly(lactic-co-glycolic acid) to heterofunctional PEG.
5.1.1 Ring-Opening Polymerization of Lactide and Glycolide
Copolymers containing lactide and glycolide, including poly(lactic-co-glycolic
acid) and poly(lactic acid) have traditionally been prepared by polycondensation from
glycolic and/or lactic acids (Wang, Zhao et al. 2005) as shown on Figure 5.2, or more
commonly by the ring-opening polymerization of the cyclic dimers of glycolide and
lactide, shown on Figure 5.3. Polycondensation cannot normally produce polymers of
acceptable molecular weight because this step polymerization reaches equilibrium
prematurely when the water byproduct is not satisfactorily removed, i.e if the reaction is
not continuously driven toward the polymer side (Dechy-Cabaret, Martin-Vaca et al.
2004). This equilibrium results in the formation of low molecular weight product. The
ring-opening polymerization of lactide and glycolide is currently the preferred method for
preparation of biodegradable polymers of these monomers as it can be easily controlled
and can produce polymers with a wide range of molecular weights (Kiremitci-
Gumusderelioglu and Deniz 1999; Jeong, Lim et al. 2000; Huh, Cho et al. 2003; Dechy-
Cabaret, Martin-Vaca et al. 2004; Porjazoska, Karal-Yilmaz et al. 2004).
Lactide and glycolide cyclic dimers are among the few six-membered ring
structures that can be polymerized. Thermodynamically, polymerization of all except six
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membered rings is favored. Normally the stability of six-membered rings is too great to
be overcome by the polymerization driving force. It is believed that the presence of two
ester moieties in the dimers of lactide and glycolide causes sufficient strain to permit their
polymerization (van Hummel, Harkema et al. 1982; Duda and Penczek 1990). The
polymerization enthalpy of lactide, for example, was determined to be -22.9 kJ/mol
(Duda and Penczek 1990), which is less favorable than that of 3-, 4- and 8-membered
rings but similar to that of 5- and 7-membered cycloalkane rings (Odian 2004).
Ring opening polymerization of lactide and glycolide is normally carried out
using stannous octoate as catalyst. Stannous octoate, also known as tin(II) bis(2-
ethylhexanoate) or tin(II)octoate, is very effective, commercially available, easy to
handle and is amenable to use in biomedical applications since it has been approved by
the FDA for use as a food additive, although toxicity may still be an issue (Avgoustakis
2004; Dechy-Cabaret, Martin-Vaca et al. 2004). Stannous octoate is soluble in numerous
organic solvents and in the melted monomers. Reaction times in the presence of stannous
octoate at temperatures of 140 to 180°C are in the range of minutes to hours.
The mechanism of the catalyzed polymerization is believed to be of coordination-
insertion (Dittrich and Schulz 1971; Du, Lemstra et al. 1995). The kinetics of
polymerization have been reported to be first order with respect to the concentration of
monomer (Dittrich and Schulz 1971). The reactivity of glycolide compared to that of
lactide to polymerization has been reported to be about 10 times larger for the former
versus the latter monomer (Gilding and Reed 1979). This fact played an important role in
the results obtained in the present research, as will be discussed in later sections. The
polymerization reaction can occur in a more controlled manner and at a faster speed in
the presence of a protic agent such as an alcohol (Dechy-Cabaret, Martin-Vaca et al.
2004). This concept was also important for the use of ring-opening in the preparation of
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functionalized copolymers in the present research. Importantly, impurities in the feed
such as alcohols, lactic or glycolic acid and water can act as co-initiators. This is
especially significant when the reaction is carried out without additional protic initiators.
The ring opening polymerization of lactide in the presence of alcohol-containing
agents, including poly(ethylene glycol) and methyl ether terminated poly(ethylene
glycol), has been utilized and studied previously (Kricheldrof and Meier-Haack 1993;
Stolnik, Dunn et al. 1994; Bazile, Prud'Homme et al. 1995; Du, Lemstra et al. 1995;
Tobio, Gref et al. 1998; Perez, Sanchez et al. 2001; Vila, Gill et al. 2004; Venkatraman,
Jie et al. 2005; Vila, Sanchez et al. 2005). The polymerization is believed to begin with
the activation of lactide by stannous octoate followed by the initiation of this active
species with a hydroxyl group. Further lactide units coordinate at the end of the growing
chain where the stannous octoate complex is located, and continue chain growth or chain
transfer through either intra- or intermolecular attack. Intermolecular propagation
commonly occurs with highly reactive initiators (Dechy-Cabaret, Martin-Vaca et al.
2004). When the initiator is a primary alcohol, such as PEG end groups, intermolecular
attack is favored (Du, Lemstra et al. 1995). Importantly, when a high monomer-to-
initiator ratio is used in the feed, the initiator is consumed rapidly (Du, Lemstra et al.
1995). The end groups of the polymer formed through this reaction are hydroxyls
(Kricheldrof and Meier-Haack 1993). Initiation of the polymerization by secondary and
tertiary alcohols occurs at slower rates than primary alcohols, as determined by
comparing the reactions initiated by PEG and triethylene glycol as primary alcohols,
methyl lactate and 2,3-butanediol as secondary alcohols, and pinacol and tertbutyl
alcohol as tertiary alcohols (Du, Lemstra et al. 1995).
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5.2 MATERIALS AND METHODS
5.2.1 Materials
Fluroescein-PEG-N-hydroxysuccinimide (FITC-PEG-NHS, molecular weight
5,000 g/mol) was purchased from Nektar Therapeutics (Huntsville, AL, USA).
Heterofunctional PEGs including OH-PEG-COOH (molecular weight 3,400 g/mol) and
HCl.NH2-PEG-COOH (molecular weight 3400) were purchased from Nektar
Therapeutics (Huntsville, AL, USA) and later from Laysan Bio, Inc. (Arab, AL, USA).
Pluronic® F-127 (Poloxamer 407, molecular weight of 12,600 g/mol, hydrophilic-to-
lipophilic balance 22, 101 ethylene oxide repeat units on each side of 56 central
propylene oxide repeat units), stannous octoate (Tin(II) 2-ethylhexanoate), 2-(N-
morpholino)ethanesulfonic acid (MES), N,N-dicyclohexylcarbodiimide (DCC), N-
hydroxysuccinimide, poly(ethylene glycol) methyl ether (mPEG2000, molecular weight of
2,000 g/mol) and poly(ethylene glycol) (molecular weight of 3,350 g/mol) were obtained
from Sigma-Aldrich (Saint Louis, MO, USA).
Cyclic d,l-lactide (molecular weight 144.1) and glycolide (molecular weight
116.1) monomers were obtained from PolySciences, Inc. (Warrington, PA, USA).
Poly(lactic-co-glycolic acid) (formerly PLGA 50:50 DL 2A, now 5050 DLGA 2A, 50/50
D,L-lactide to glycolide ratio, molecular weight 12,000 g/mol, carboxylic acid and
hydroxyl end groups) was obtained from LakeShore Biomaterials (Birmingham, AL,
USA).
The reagent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDC) was obtained from Fluka. Anhydrous toluene and N,N-diisopropylethylamine
were obtained from Acros Organics. Ethyl ether, acetone, ethyl acetate,
dimethylformamide and methanol were obtained from Fisher Scientific.
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5.2.2 Preparation of Nanoparticles with Blends of PLGA and PEG-Containing
Polymers
Incorporation of PEG on nanoparticles through the use of polymer blends was
pursued because it represented a rapid, simple and inexpensive method that could be
translated rapidly into a clinical product. The hypothesis was that PEG or PEG-
containing polymers could be incorporated into nanoparticles through hydrophobic
interactions between the polymers. Specifically, PEG being a polymer that readily
dissolves in numerous organic solvents such as acetone, dichloromethane, chloroform,
acetonitrile, dimethylformamide, and methanol, as well as in water, it could be co-
dissolved with PLGA in an organic solvent or mixture of solvents prior to precipitation or
emulsification of the PLGA in an aqueous phase. Despite the fact that PEG would then
partition between the organic and aqueous phases according to its solubility, it was
expected that a significant amount would be incorporated within or on the surface of the
nanoparticles.
Figure 5.4 shows the types of PEG-containing polymers that were investigated for
incorporation within PLGA nanoparticles. Fluorescein-PEG-NHS (FITC-PEG-NHS)
was used for easy monitoring and quantification of PEG incorporation as it offers similar
properties and reactivity as unlabeled PEG derivatives containing the NHS group on one
end such as methoxy-PEG-succinimidyl propionate (NektarTherapeutics 2005).
Pluronic® F127 (PF127) is a tri-block copolymer of ethylene oxide and propylene oxide.
The external ethylene oxide units are chemically identical to poly(ethylene glycol) and
surround a more hydrophobic central domain of propylene oxide units. PF127 was used
as opposed to other more commonly used poloxamers as it provides a relatively large
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hydrophobic section (molecular weight ~ 3700 Da) compared to its hydrophilic ethylene
oxide portions (molecular weight ~ 4400 Da on each side) while, at the same time having
long-enough hydrophilic ends to provide protection to the particles. It was hypothesized
that the higher hydrophobicity of poloxamers would enhance their incorporation within
and on the surface of nanoparticles compared to simpler PEG derivatives because of
improved hydrophobic interactions with the hydrophobic PLGA.
Preparation of polymeric nanoparticles including poloxamer blends have been
reported previously (Moghimi, Muir et al. 1993; Li, Caldwell et al. 1994; Storm, Belliot
et al. 1995; Moghimi and Hunter 2000; Csaba, Gonzalez et al. 2004; Csaba, Caamano et
al. 2005; Csaba, Sanchez et al. 2006; Santander-Ortega, Jodar-Reyes et al. 2006);
however, per our knowledge, no one has proposed the use of poloxamers for covalent
attachment of targeting agents onto drug delivery nanoparticles.
For preparation of nanoparticles with FITC-PEG-NHS, 10 or 20 mg of PEG were
dissolved in 1 ml of methanol and 100 mg of PLGA were dissolved in acetone. These
two solutions were mixed to form the organic phase, which was then added to 10 ml of an
aqueous solution containing bovine serum albumin (BSA), sodium cholate (SC) or
poly(vinyl alcohol) (PVA) as surfactants. The mixture was sonicated and stirred at 500
rpm for 45 minutes under vacuum to evaporate the solvents. The nanoparticle suspension
was then centrifuged with a Beckman J2-21 refrigerated centrifuge (Beckman
Instruments, Palo Alto, CA, USA) for 10 minutes at 48,000 x g, and the supernatant
collected for analysis of PEG-polymer incorporation. The nanoparticle pellet was then
resuspended in the surfactant solution and centrifuged three more times to remove
adsorbed PEG. Nanoparticle pellets were frozen at -20°C and freeze dried using a
Labconco Freeze Dryer 4.5 (Kansas City, MO, USA).
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Nanoparticles with poloxamer F-127 were prepared similarly, except that the
poloxamers were not dissolved in methanol but directly co-dissolved in 6 ml of acetone
with PLGA. For these nanoparticles, the ratio of poloxamer to PLGA used in the
preparation was 50:50 (50 mg of PF127 and 50 mg of PLGA) or 25:75 (25 mg of PF127
and 75 mg of PLGA). No surfactant was used in the aqueous phase used to precipitate
the polymer because its inclusion resulted in the formation of small micelles and a
significant reduction in the yield to less than 4% according to initial studies.
Nanoparticles were resuspended in 1ml of 50 mg/ml of glucose prior to freezing and
freeze drying to try to minimize lyophilization-induced aggregation which led to batches
that were impossible to resuspend in preliminary studies.
5.2.2.1 Physiochemical Characterization of PLGA/PEG-polymer Nanoparticles
Freeze dried nanoparticles were weighted to determine the yield or percent
recovery compared to the mass of polymers that was used in the preparation of the
particles. For determination of sizing, dried nanoparticles were resuspended in deionized
water with sonication and sized using a Coulter® NanoSizerTM (Coulter Electronics LTD.,
Harpenden Herts, UK).
5.2.2.2 Determination of PEG-polymer Content on Nanoparticles
Incorporation of FITC-PEG-NHS was determined from spectrophotometric
quantification of the FITC on supernatants from all wash/centrifugation cycles.
Supernatants were collected and their volume and absorbance at 500 nm were measured.
The concentration of FITC-PEG-NHS was determined based on a calibration curve (r2 >
0.99) generated with solutions of known FITC-PEG-NHS concentration in the surfactant
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solution used for each batch. The efficiency of incorporation was determined by
comparing the mass of the polymer found in the supernatant to that which was used for
preparation of the particles.
For determination of poloxamer content in nanoparticle batches, supernatants
from all wash/centrifugation cycles were collected for analysis with a spectrophotometric
assay based on the molar proportion of ions that coordinate around PEG chains (Skoog
1979). Specifically, 0.75 ml of 100 mM barium chloride solution was mixed with 0.375
ml of a solution that is 5 mM in Iodine and 15 mM in potassium chloride. To this, 3 ml
of supernatant was added. The absorbance of the solution at 500 nm was used to
determine the concentration of PEG or poloxamer in the supernatants based on a standard
curve (r2 > 0.99) generated with solutions of known poloxamer concentrations. PEG
incorporation efficiency and PEG weight percent within nanoparticles was determined by
comparing the amount of PEG in the supernatants to that used for preparation of the
particles.
5.2.3 Preparation of PLGA-PEG Copolymers
The second main strategy used for incorporation of PEG on the nanoparticle
formulation was based on covalently binding PEG to the nanoparticle core polymer. This
strategy was expected to be superior as it assures incorporation of PEG and prevents
premature loss of the PEG protective layer in vivo, which would result in rapid
nanoparticle opsonization, sequestration by the macrophage phagocytic system and
consequent undesired pharmacokinetics. As described next, the preparation of these
copolymers was performed by conjugation of pre-made PEG and PLGA polymers
(section 5.2.3.1) or by polymerization of lactide and glycolide monomers onto a different
pre-made heterofunctional PEG (section 5.2.3.2).
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5.2.3.1 Preparation of PLGA-NH-PEG-COOH Copolymers by Conjugation
Pre-made PLGA terminated in carboxylic acid and hydroxyl groups was
conjugated to a heterofunctional PEG terminated on amine and carboxylic acid groups
(NH2-PEG-COOH) utilizing standard carbodiimide/NHS-mediated chemistry (Staros
1982; Hermanson 1996) using a method similar to that reported by Farokhzad and
colleagues (Farokhzad, Cheng et al. 2006). Figure 5.5 is a schematic of the conjugation
chemistry used in this protocol. PLGA was reacted with DCC and NHS in an organic
solvent at room temperature and in the dark to activate the carboxylic acids to the semi-
stable amine-reactive activated NHS-ester of PLGA (PLGA-NHS). After a specific
reaction time, the polymer mixture was filtered with a 0.45 m syringe filter to remove
insoluble dicyclohexyl urea byproduct. The solution was then concentrated under
vacuum while submerged in a water bath at 30°C. The solution was transferred to two
45-ml Teflon centrifuge tubes (less than 4ml of polymer solution per tube) and the
polymer was precipitated by filling the rest of the tube with ethyl ether or -20°C methanol
and mixing well. The precipitated polymer was pelleted by centrifugation for 10 minutes
at 48,000 x g and the supernatant was removed. The pellet was dissolved in a small
volume of dichloromethane (less than 1ml), precipitated and centrifuged once more. The
purpose of the precipitation and centrifugation cycles is to remove excess DCC, NHS and
remaining water-insoluble dicyclohexyl urea byproduct (Hermanson 1996).
If storage of the activated PLGA was required, the final pellet of activated PLGA
was transferred to a Teflon beaker, dried in a vacuum dessicator, frozen at -20°C and
freeze dried. Else, the pellet of activated PLGA was conjugated immediately. Activated
PLGA was reacted with NH2-PEG-COOH in an organic solvent in the presence of N,N-
diisopropylethylamine to desalt the terminal PEG amine group. After a specific reaction
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time the solution was concentrated under vacuum and the polymer was recovered and
purified by three cycles of precipitation and centrifugation as described above. The
purified copolymer pellet was transferred to a Teflon beaker, placed on a vacuum
dessicator for 2 hours, frozen and freeze dried. The dried copolymer was stored under a
nitrogen atmosphere and at -20°C. The conditions that were varied in the conjugation
reaction included the molar ratio of PLGA to DCC/NHS (1:10, 1:50), the molar ratio of
activated PLGA to PEG and to N,N-diisopropylethylamine, the solvent
(dichloromethane, chloroform, or dimethylformamide) and the reaction time (2, 4 or 24
hours).
5.2.3.2 Conjugation of PEG After Nanoparticle Preparation
The method described for the preparation of copolymers by conjugation in the
previous section also permitted conjugation of PEG to PLGA after nanoparticle
preparation by utilizing protocols similar to those reported by Kasturi et al. for the
preparation of polyethyleneimine-conjugated PLGA microspheres (Kasturi,
Sachaphibulkij et al. 2005). Figure 5.6 shows the synthetic route used for activation
PLGA in solid nanoparticles and conjugation of heterofunctional PEG on the particle
surface.
Nanoparticles were first prepared by dissolving 100 mg of PLGA in 3 ml of
acetone, adding this organic solution to 10 ml of 10 mg/ml aqueous poly(vinyl alcohol)
solution, vortexing and sonicating for less than 1 minute. Solvent was removed by
stirring under vacuum for 45 minutes. The nanoparticle suspension was centrifuged and
washed three times with water to remove excess surfactant. Carboxylic acid groups on
the surface of the nanoparticles were activated by resuspending the nanoparticles by
sonication in isotonic 0.1M 2-[morpholino]ethylsulfonic acid (MES) buffer saline (1 or
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10 ml), pH 5.5, and reacting for a specific time with EDC and NHS. A low-pH buffer
was used to reduce the rate of hydrolysis of the NHS esters of PLGA that are formed in
this step. The optimal reaction pH range is between 4.7 and 6 (Hermanson 1996).
Importantly, this buffer was selected because the reaction medium must not contain
amine or carboxylic acid groups which could compete in the reaction and which are
found on other more commonly used buffers. Nanoparticles were then centrifuged and
washed to remove excess EDC/NHS and the water-soluble isourea byproduct.
Activated nanoparticles were then resuspended in PBS buffer (1 or 10 ml) and
reacted with NH2-PEG-COOH for a specific period of time. Nanoparticles were
centrifuged and washed to remove unbound PEG. The nanoparticles were resuspended
in 1 ml of 50 mg/ml glucose or 8 ml of water with 400 mg of trehalose, frozen and freeze
dried. The variables that were adjusted in the activation and conjugation steps were the
reaction time and the molar ratio of PLGA to EDC/NHS or PEG, respectively, which
assumes that 100% of the carboxylic acid end groups of PLGA are available on the
surface of the nanoparticles.
The size and zeta potential of dry particles was determined after resuspending
them in deionized water or 1mM KCl solution, respectively. Both sizing and zeta
potential were obtained with a ZetaPlus® instrument (Brookhaven Instrument
Corporation, Holtsville, NY, USA). The composition of these nanoparticles was
determined by nuclear magnetic resonance, as described in more detail on Section 5.2.5.
In addition, X-ray photoelectron spectroscopy (XPS) was used to analyze the surface
composition of the nanoparticles. A dispersion of dry nanoparticles was analyzed with a
PHI 5700 XPS instrument. The atomic composition of surface components was obtained.
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5.2.3.3 Preparation of PLA-PEG-COOH Copolymers by Polymerization
Ring-opening polymerization of cyclic glycolide and/or lactide dimers initiated by
the hydroxyl groups of PEG was carried out either as a melt of the reagents or in solution.
Three types of PEG reagents were used: methyl ether PEG with hydroxyl groups on one
end of the chain and a molecular weight of 2,000 g/mol (mPEG2000), poly(ethylene
glycol) with hydroxyl end groups on both sides of the molecule and a molecular weight
of 3,350 g/mol (PEG3350), and a heterofunctional PEG containing hydroxyl and
carboxylic acid end groups and of a molecular weight of 3,400 g/mol (OH-PEG3400-
COOH). The first two types of PEG were used for all initial batches until the protocol
had been optimized as they are significantly less expensive than the heterofunctional
reagent. However, for preparation of targeted nanoparticles, the copolymer of the
heterofunctional PEG was desired since it permits conjugation of targeting agents on the
free carboxyl end group. Polymerization using this heterofunctional PEG has been
reported previously (Farokhzad, Jon et al. 2004). Figure 5.7 is a schematic of the
polymerization of lactide and glycolide initiated by the hydroxyl group of
heterofunctional OH-PEG3400-COOH.
Dimers of lactide and glycolide were first purified by recrystallization from ethyl
acetate. Specifically, dimers were dissolved in 70°C ethyl acetate near their solubility and
hot-filtered if needed. The dimer solutions were then allowed to cool down undisturbed
to room temperature to permit formation of dimer crystals. After reaching room
temperature, the samples were placed on an ice bath to try to maximize the formation of
crystals. The crystals were recovered by vacuum filtration and dried in a vacuum
desiccator for a few hours prior to freezing and freeze drying for more than 24 hours.
Immediately after removing from the freeze drier, the dimers were polymerized as
follows.
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For preparation of the copolymers, the appropriate PEG and the dimers were
added to a three-necked glass reaction flask that contained a magnetic stir bar. The mass
of each reagent to be added was calculated based on the desired molecular weight and the
assumption that each hydroxyl end group on each molecule of PEG polymer would
initiate the polymerization of a single chain of PLGA or PLA. The reaction flask was
closed with stopcocks and connected to a nitrogen line and a vacuum pump. The system
was dried by cycles of vacuum and nitrogen for about 1 hour prior to starting the
reaction. If the polymerization was to be carried out in solution, the solvent was then
added while purging with nitrogen to prevent inflow of atmospheric gases.
Polymerizations in solution were carried out in dimethylformamide at 140°C or in
anhydrous toluene at 110°C.
The reaction flask was then immersed in a preheated silicon oil bath to allow the
polymer and dimers to melt and/or go into solution. Once all reagents were liquid,
stannous octoate was added while purging with nitrogen. The amount of stannous
octoate was varied between 0.05 % of the total reagent mass, to a 1-to-1 molar ratio with
respect to the hydroxyl groups of the PEG used, based on the amounts used in previous
reports (Quellec, Gref et al. 1998; Kiremitci-Gumusderelioglu and Deniz 1999; Gref,
Luck et al. 2000; Yoo and Park 2001). The reaction flask was then pressurized with 20
psi of nitrogen and sealed, and the reaction was allowed to occur for a specific period of
time. At the end of the reaction time, or once the polymer had solidified, the reaction
flask was removed from the heated bath and rapidly cooled in iced water. The polymer
was then transferred to four Teflon centrifuge tubes if liquid, or mixed with
dichloromethane if solid to try to dissolve it. The liquid polymer was precipitated by
filling each centrifuge tube with ethyl ether, and centrifuged at 48,000 x g for 15 minutes
to separate it from the supernatant. The pellets were dissolved in 1-2 ml of
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dichloromethane per tube and again precipitated. This procedure was repeated once more
so that the polymer was precipitated a total of 3 times. The pellets were then dried in a
vacuum desiccator overnight, frozen at -20°C and freeze dried for 2 days.
If the polymer had solidified in the reaction flask or was unable to be dissolved
after precipitation regardless of the volume of solvent used, the mixture of dissolved and
solid polymer was filtered to remove the insoluble fraction. The polymer solution was
then precipitated and purified as detailed above.
5.2.4 Characterization of Copolymers
Copolymers were characterized by proton nuclear magnetic resonance and gel
permeation chromatography to determine their composition and molecular weight,
respectively. Proton NMR was performed with a Varian INOVA-500 instrument (500
MHz, Palo Alto, CA, USA) after dissolving the polymers in deuterated chloroform or
dimethyl sulfoxide at a concentration of 1 mg/ml and filtering the solution through a 0.2
m syringe filter. Proton intensities corresponding to lactide methine quartets at 5.2
ppm, lactide methyl doublets at 1.6 ppm, glycolide protons at 4.8 ppm and PEG
methylene protons at 3.6 ppm were used for determination of the composition of the
copolymers, as described previously (Du, Lemstra et al. 1995; Hrkach, Peracchia et al.
1997; Heald, Stolnik et al. 2002; Garcia-Fuentes, Torres et al. 2004). Based on the area
of PEG methylene proton peaks and the known number of protons associated with this
area based on the starting molecular weight of PEG, a value of proton peak area per
number of protons was determined. From this value, a molecular weight for the
copolymer was estimated based on the peak areas for the lactide and glycolide protons.
This calculation permitted the determination of PLGA-to-PEG ratios in the final
copolymer.
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The GPC system consisted of a two Polymer Labs columns in series designed for
use with polymers of molecular weight between 200 and 2,000,000 g/mol, a Waters 515
HPLC pump, a multi-angle laser light scattering (MALLS) detector (DAWN EOS, Wyatt
Techonology) that measures the light scattered by the polymers as they elute from the
columns and permits determination of absolute weight-average molecular weight, and a
refractometer (Optilab DSP, Wyatt Techonology) that measures changes in the refractive
index with concentration. For analysis, polymers were dissolved in either tetahydrofuran
or dimethylformamide depending on their solubility, and filtered through a 0.2 m
syringe filter prior to injection into the GPC system. Number average molecular weight
(Mn) and polydispersity index are reported. The polydispersity index is the ratio of
weight average to number average molecular weights and provides an indication of the
width of the distribution of molecular weights of the chains that make up the polymer.
5.2.5 Preparation of Nanoparticles with PLGA-PEG or PLA-PEG Copolymers
Nanoparticles of PLA-PEG or PLGA-PEG copolymers were prepared by a
nanoprecipitation solvent evaporation method (Fessi, Devissaguet et al. 1986; Barichello,
Morishita et al. 1999; Betancourt, Brown et al. 2007). The copolymers were dissolved in
3 ml of acetone to form the organic phase. This organic phase was added to 10 ml of an
aqueous solution with or without poly(vinyl alcohol) as a surfactant. After brief
sonication, the solvent was removed by stirring the suspension under vacuum for 45
minutes. Nanoparticles were recovered through centrifugation, washed, and lyophilized
with or without cryoprotectant. Glucose or trehalose were used as cryoprotectants. The
composition of the nanoparticles was determined by nuclear magnetic resonance as
described above for the characterization of copolymers.
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Liquid state NMR of nanoparticles in suspension was also performed. For this, a
batch of nanoparticles was prepared as above but not mixed with a cryoprotectant or
freeze dried. Instead, the particles were centrifuged, resuspended in deuterated water and
centrifuged again to try to remove as much water as possible without having to dry them.
The pellet was then resuspended in deuterated water, filtered through a 0.45 m syringe
filter and analyzed. This method detects the resonance signal of nanoparticle components
in intimate contact with the deuterated solvent but not that of solid components.
5.3 RESULTS AND DISCUSSION
5.3.1 Nanoparticles with Blends of PLGA and FITC-PEG-NHS
Table 5.1 summarizes the results of the preparation of nanoparticles with blends
of PLGA and FITC-PEG-NHS. The yield of the formulations was approximately 60%
for all batches prepared with PVA as a surfactant in the outer aqueous phase and was not
dependent on the amount of PEG added during preparation (p > 0.6). Batches prepared
with BSA as surfactant had an average yield of 68%, which is statistically different from
that of particles with the same targeted PEG incorporation prepared with PVA (p < 0.05).
Particles prepared with sodium cholate had a yield that was not significantly different
from that of particles prepared with PVA with the same targeted PEG incorporation (p >
0.2).
The size of the nanoparticles before freeze drying was between 190 and 220 nm
for batches made with PVA as surfactant and was also not influenced by the mass of PEG
included in the formulation. Particles made with BSA had a significantly larger size in
the range of 230 nm (p < 0.05), consistent with previous results of blank and
doxorubicin-loaded nanoparticles described in Chapter 3 (Betancourt, Brown et al. 2007).
143
Batches prepared with SC had a significantly smaller size (p < 0.05) in the range of 180
nm, consistent with the results previously described for nanoparticles loaded with
indocyanine green in Chapter 4. The size of the nanoparticles after freeze drying
significantly increased for all formulations compared to that of the particles before freeze
drying, but the type of surfactant continued being the major factor determining size. The
size of nanoparticles made with BSA after freeze drying was not significantly different
from that of those made with PVA. Because of the high variation in the size of the
particles made with PVA and 9.2 wt.% PEG targeted incorporation, the size of particles
made with SC after freeze drying was not statistically different; however, it was different
from that of particles made with PVA without PEG.
Incorporation of FITC-PEG-NHS was significantly lower than desired, as can be
seen in Table 5.1. Most of the PEG was removed in the first supernatant. The second
supernatants contained at least one order of magnitude less PEG than the first. For the
particles prepared with BSA, the average incorporation efficiency was negative possibly
as a result in errors in the calibration curve, presence of particles in the supernatants, or
errors in the measurement of supernatant volumes. These errors could also affect the data
for all other formulations. The calculated PEG content in the nanoparticles was 0.1 or
0.8% by weight for particles made with PVA with a targeted wt% of 9.2 and 16.8%
respectively, -0.2% for particles made with BSA and 1.1% for particles made with SC.
In all cases, however, the incorporation efficiency achieved is less than desirable for the
modification of the surface of the nanoparticles since PEG was expected to act as a shield
preventing rapid opsonization and sequestration of the nanoparticles by the
reticuloendothelial system in vivo and provide a conjugation site for targeting agents. In
addition, the fact that PEG incorporated with this method is only physically entrapped
within or adsorbed on the particles could be problematic when utilized in vivo as it could
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diffuse out of the particles or be rapidly displaced as the particles interact with serum
proteins. Finally, FITC-PEG-NHS, which was used because it facilitated quantification
of PEG, is more hydrophobic than unlabeled PEG and, consequently, it is expected that
preparation of particles with unlabeled PEG would result in even lower incorporation.
5.3.2 Nanoparticles with Blends of PLGA and Poloxamers
Table 5.2 summarizes the properties of nanoparticles prepared with blends of
PLGA and PF127. Statistically significant differences were observed in the yield, size
before and after freeze drying, incorporation efficiency and final PEG content between
the two types of formulation with different PF127/PLGA ratios prepared (p < 0.05). The
yield of the formulations was highly dependent on the ratio of the polymers blended,
although it could be approximated to be about 60% of the PLGA mass used. However,
this comparison can be misleading since, according to the measured incorporation
efficiency, PF127 is in fact a significant part of the final nanoparticle composition. The
lower yield and size of the particles prepared with higher PF127 content (PF127/PLGA
ratio of 50:50) could be a result of the surfactant properties of the amphiphilic poloxamer
which would lower the surface tension as the organic polymer-containing solution mixes
with the aqueous solution, and would permit the formation of smaller particles. In
addition, excess poloxamer not intimately associated with PLGA particles can form
micelles of smaller sizes which would significantly decrease the percent recovery.
The large increase in particle size after freeze drying could be a result of the
presence of the poloxamer on the surface of the particles. Poly(ethylene glycol), and
consequently poly(ethylene oxide) chains, are known to crystallize upon freezing, thus
causing major mechanical stresses on the particles and resulting in their aggregation (de
Jaeghere, Allemann et al. 2000; Abdelwahed, Degobert et al. 2006). Batches that were
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freeze dried without a cryoprotectant were impossible to resuspend after drying. The
sizes shown in Table 5.2 are for batches that were frozen and freeze dried after addition
of 50 mg of glucose to the nanoparticle suspension. Even in the presence of this
cryoprotectant, particle aggregation to about four times the pre-dried sized occurred.
The incorporation efficiency of PF127, as determined by a colorimetric method,
was higher in particles that were prepared with higher PF127/PLGA feed ratio. Increased
poloxamer concentration, which led to the formation of smaller particles, could result in
higher degree of association of the poloxamer with the particles as a result of increased
nanoparticle surface area and the need for better stabilization of the thermodynamically
unstable colloidal system. The final poloxamer content of the nanoparticles was of 12 or
43 wt.%, for the nanoparticles prepared with 25:75 or 50:50 PF127/PLGA mass ratios,
respectively.
The zeta potential of the formulations was found not to be statistically different
regardless of the amount of poloxamer used during preparation. However, the zeta
potential of these formulations compared to that of other PLGA nanoparticles prepared
with bovine serum albumin, sodium cholate or poly(vinyl alcohol) as surfactants is
significantly different. Per our own data, the zeta potential of particles prepared with
BSA, SC and PVA is of about -45mV, -50mV and -10mV, respectively. The difference
in the zeta potential compared to these other formulations confirms the fact that the
nanoparticles formulated with blends of PLGA and PF127 do in fact have a modified
surface chemistry as a result of the presence of PF127.
5.3.3 Preparation of PLGA-NH-PEG-COOH Copolymers by Conjugation
Carbodiimide-mediated conjugation of PLGA to NH2-PEG-COOH in solution, as
shown on Figure 5.5, was used because of the extremely high efficiency of activation
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achievable with DCC in anhydrous media since no hydrolysis of the active ester occurs as
it does in bioconjugaiton methods that are carried out in aqueous suspensions using EDC
(Hermanson 1996). Conjugation of PLGA to NH2-PEG-COOH could have been
performed using DCC without the presence of NHS. However, the O-acylurea
intermediate formed upon reaction of the PLGA carboxyl with DCC can spontaneously
rearrange to the inactive N-acylurea form, thus reducing the efficiency of the reaction
(Hermanson 1996). This problem is specially important when the reaction is carried out
in aprotic organic solvents such as dimethylformamide (Hermanson 1996). In addition, if
no amine-containing molecule is available in the reaction medium to bind to the O-
acylurea intermediate, it can react with other carboxyl groups in the system to form
anhydrides (Hermanson 1996). NHS results in the formation of a more stable
intermediate that can be subsequently reacted with the heterofunctional PEG, thus
increasing the efficiency of conjugation. The half life of the intermediate created in the
presence of NHS is of a few hours, as opposed to minutes or even seconds for the direct
carbodiimide intermediate (Hermanson 1996).
A two step activation/conjugation method was used because direct reaction of
heterofunctional PEG with NHS and EDC would have also resulted in activation of the
carboxylic acid end groups of PEG, and very likely in the undesirable formation of PEG-
PEG conjugates in addition to PLGA-PEG.
Proof-of-concept conjugations were performed to show that this method could be
performed and that the resulting polymer composition could be regulated by varying the
preparation variables. Nuclear magnetic resonance (NMR) and gel permeation
chromatography were used to determine the resulting copolymer composition and
molecular weight, respectively. Figure 5.8 displays the NMR spectra for various batches
of copolymers. NMR confirmed the presence of both PLGA and PEG in all batches, and
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allowed determination of the PLGA-to-PEG molar ratio of the resulting copolymer based
on the areas of the proton peaks associated with each of the polymers. NMR spectra
were run in deuterated chloroform, except for the copolymer in Figure 5.8C which was
run in deuterated DMSO. Increasing peak size (area) of PEG protons at 3.6 ppm (d)
relative to those of lactide at 5.2 ppm (a) and 1.6 ppm (b) and of glycolide at 4.8 ppm (c)
was observed with increasing conjugation efficacy, as seen in the progression of
copolymers from Figure 5.8 B through E.
Table 5.3 summarizes the results of these conjugations. For all conjugations, the
desired PLGA to PEG end molar ratio based on the feed mass of each polymer was of 1
to 1. In Table 5.3 results are organized according to increasing actual molar ratio of
PLGA-to-PEG as determined by NMR, and consequently of decreasing conjugation
efficiency. Since conjugations were carried out with pre-made polymers, a molar ratio of
PLGA to PEG greater than 1 means that there are PLGA chains that have not conjugated
to PEG. Increased reaction time appeared to make a significant difference in the
resulting copolymer composition. Decreasing reaction time resulted in decreasing
conjugation efficiency. For equivalent reactions performed in chloroform, for example, a
reaction time of 24 hours resulted in a copolymer that had 58% PLGA and 42% PEG
(PLGA/PEG ratio of 1.4), while a reaction time of 2 hours resulted in a polymer that had
90% PLGA and only 10% PEG (PLGA/PEG ratio of 8.9). The solvent used in the
reaction also appeared to make a difference in the resulting conjugation efficiency. For
conjugations run for 4 hours, the use of dichloromethane or dimethylformamide as the
solvent did not appear to make a difference. On the contrary, for reactions carried out for
2 hours, using chloroform as the reaction solvent led to significantly better results than
using dichloromethane.
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It was observed that the molar ratio of DCC and NHS to PLGA used for
activation of carboxylic acids did not make a significant difference in the conjugation
results at least within the ratios used (10:10:1 and 50:50:1). The same observation
applies for the amount of N,N-diisopropylethylamine added for desalting the amine group
of the PEG at least within the molar ratios used (PLGA/PEG/amine of 1:1:2 and 1:1:10).
Addition of excess PEG to the reaction could have resulted in better conjugation
efficiencies, but this was not feasible as a result of the high cost of the heterofunctional
reagent.
According to gel permeation chromatography, the number average molecular
weight of the starting polymers was of 5,395 with a polydispersity index (PI) of 1.13 for
PEG and 11,160 with a PI of 1.26 for PLGA, although the PEG had a molecular weight
of 3,400 according to the manufacturer. GPC analysis of the copolymers revealed that
the number average molecular weight was very close to that of PLGA. One reason for
this is that the resulting polymer may contain not only the co-polymer but also free
PLGA and PEG chains which would skew the resulting average molecular weight toward
that of the lower molecular weight components. Copolymers were purified by
precipitation with cold methanol only or with ethyl ether and cold methanol. Methanol
was used to try to remove unbound PEG since it is more soluble in this solvent than in
ether; however, it is possible that some of the unbound PEG remained. Also, the fact that
not all PLGA chains were conjugated to PEG would result in average molecular weights
close to that of PLGA alone, depending on the extent of modification. Another reason
why a definite difference between the number average molecular weight of PLGA and
that of the copolymers was not seen could be related to the challenges of utilizing gel
permeation chromatography with polymers of such small molecular weight. In all runs of
these copolymers, the refractive index signal of the polymers was low and highly affected
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by background noise. Also, the gel permeation chromatography columns used were
designed for separating polymers of molecular weight in the wide range of 200 to
2,000,000 g/mol and were possibly not sufficiently sensitive to separate polymers that
had only a 3,400 g/mol molecular weight difference. Finally, the multi-angle laser light
scattering technique that was used to determine the molecular weight of the polymers
assumes that the rate of change of the refractive index of the polymers with concentration
is a constant, which is a good assumption for polymers of molecular weight above 10,000
g/mol but may result in more significant errors with polymers close to or below this size.
It is worth noting that polymer recovery ranged between 20 and 45% for most
batches. The remaining polymer was lost during purification as a result of challenges
with precipitating amphiphilic copolymers of relatively similar hydrophobic-to-
hydrophilic chain sizes. These copolymers could easily remain in solution with less-
than-ideal solvent amounts or solvent-to-precipitant ratios.
5.3.4 PEGylation of NPs by Surface Conjugation of PEG
Carbodiimide chemistry similar to that used in the previous method was utilized
for conjugation of heterofunctional PEG directly to the surface of pre-made nanoparticles
suspended in an aqueous medium. EDC was used for conjugation of NH2-PEG-COOH to
carboxyl groups on the surface of nanoparticles because it is widely used in
bioconjugation strategies. The conjugation route is displayed in Figure 5.6. Table 5.4
summarizes the size and zeta potential of the resulting nanoparticles.
The size of PEGylated nanoparticles prepared with poly(vinyl alcohol) as the
surfactant was of 245 nm in average and was not significantly different from that of non-
PEGylated particles prior to freeze drying. The size of particles prepared without
surfactant was significantly larger (324 nm, p < 0.05). These particles were prepared
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with the hope of determining if surfactant adsorbed on the surface of the nanoparticles
would be detrimental for the conjugation of PEG to terminal carboxylic acid groups of
PLGA. Freeze drying of nanoparticles in the absence of a cryoprotectant was found to
result in aggregation of particles which prevented their resuspension. This could be an
indication of the presence of PEG in the formulation, but further studies will need to
confirm this because aggregation of PLGA nanoparticles with the use of PVA has
sometimes been observed in previous data from our laboratory. Glucose and trehalose,
when used at the concentrations specified in the methods section, successfully prevented
aggregation of the nanoparticles upon freeze drying (p > 0.05). The size of freeze dried
PEGylated particles with cryoprotectant was not significantly different than that of non-
PEGylated particles, regardless of the type of croprotectant used. Figure 5.9 shows a
scanning electron microscopy image of nanoparticles to which PEG was conjugated in
suspension after preparation.
The zeta potential of the PEGylated nanoparticles that were freeze dried with
either glucose or trehalose was not significantly different than that of non-PEGylated
nanoparticles. Zeta potential is commonly used to show the presence of PEG in
formulation of nanoparticles prepared with copolymers of PLGA-PEG or PLA-PEG as it
shifts it towards low but negative values according to the methyl ether or hydroxyl groups
at the free end of PEG (Quellec, Gref et al. 1998; Gref, Luck et al. 2000; Li, Pei et al.
2001; Avgoustakis, Beletsi et al. 2003; Vila, Gill et al. 2004). However, in the present
research, the free end group of the PEG is a carboxylic acid which confers the surface of
the particles with a negative charge at neutral pH, similarly to that of a non-PEGylated
PLGA nanoparticles. In addition, the use of poly(vinyl alcohol) as a surfactant also
masks the surface of the nanoparticles and lowers the zeta potential to low negative
values regardless of the presence of PEG in the formulation.
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Proton NMR analysis of the dried particles after dissolution in either deuterated
chloroform (for particles prepared without a surfactant) or dimethyl sulfoxide revealed
that the PEG content of the formulations was low. For a conjugation that was carried out
in dilute conditions (10 ml suspensions) with a 2-fold excess of NHS and EDC per PLGA
chain and 20% excess PEG, the resulting molar ratio of PLGA to PEG according to NMR
was of 1,732. For a conjugation that was carried out in concentrated conditions (1 ml
suspensions) with 140% molar excess of PEG, the copolymer prepared had 787 PLGA
chains for every PEG present. Figure 5.10 displays the NMR spectra of these two
copolymers. Note the small peak near 3.6 ppm (d) associated with PEG.
It is worth noting that one batch of particles was prepared with bovine serum
albumin as a surfactant instead of PVA to study whether it would make a positive impact
on the conjugation. It was hypothesized that the presence of carboxylic acid groups on
the protein would provide additional binding sites since it is known that a fraction of the
albumin used as a surfactant in the preparation of the nanoparticles remains permanently
bound on the surface of the particles (Bazile, Ropert et al. 1992; Verrecchia, Huve et al.
1993; Verrecchia, Spenlehauer et al. 1995). In addition, since albumin acts as a
surfactant by exposing its hydrophilic, hydrogen-bonding domains toward the outer
aqueous phase, it was expected that at least some of its carboxylic acids would be found
at accessible locations on the surface for binding. Unfortunately, NMR analysis of this
batch revealed no improvement in the conjugation efficacy.
Results for XPS analysis of control, activated and PEGylated nanoparticles are
shown on Table 5.5. Theoretical atomic compositions of PLGA and PEG are also shown
in this table. A decrease in the carbon and an increase in the oxygen content of the
samples was expected upon PEGylation based on the carbon-to-oxygen ratio of PLGA
and PEG. No significant differences were seen between the carbon and oxygen
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compositions of the three nanoparticle samples, suggesting that the PEG amount on the
surface of the sample, if any, is too small to make a significant difference. However, a
difference was observed in the nitrogen content of both activated and PEGylated
nanoparticles in comparison to control. The nitrogen content increased 10 times upon
activation, suggesting the successful activation of the carboxylic acid end groups of
PLGA with N-hydroxysuccinimide (NHS). Upon conjugation, the nitrogen content
decreased, possibly as a result of surface masking of remaining NHS groups or amide
linkages by any PEG that bound to the activated carboxylic acid groups. These results,
similarly to NMR characterization, suggest that the surface of the nanoparticles is only
being modified to a small extent.
PEGylation of PLGA nanoparticles by direct conjugation on their surface has a
number of benefits and drawbacks. It permits preparation of PLGA nanoparticles
without modification of protocols and so it may be used for encapsulation of agents
through well-established methods that lead to acceptable drug loadings. PEGylation
would occur after the agent has been encapsulated within the solid polymeric matrix so
that key affinity of the drug to the polymer, such as hydrophobic or charge interactions,
would not be disturbed. This is important because the loading of certain agents within
particles of pre-made copolymers may be negatively affected as a result of poor
interactions of the drug with the copolymer. Although the nanoparticles need to be
exposed to an aqueous environment during conjugation, extensive loss of drug is not
expected for moderately or hydrophobic drugs because the pH of the reaction can be
adjusted within a relatively wide range without significantly affecting the rate of reaction
and because the reaction is carried out at room temperature. Additionally, and in contrast
to the preparation of copolymers by conjugation with carbodiimide chemistry that was
discussed in the previous section, excess reagent and soluble byproducts can be easily
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washed off since the particles and any associated PEG can be separated from the reaction
medium by centrifugation.
On the other hand, the maximum possible surface PEG density that can be
achieved is dependent on the number of PLGA carboxylic acid end groups that are
available for reaction on the surface of the nanoparticles. This key factor could be
possibly optimized by the use of various surfactants and nanoparticle preparation
techniques that favor the presentation of these groups on the interface. Also, this type of
conjugation technique is prone loss of efficiency to a number of competitive reactions of
the O-acylisourea intermediate, such as that with sulfhydryl groups to form unstable thiol
linkages, with oxygen atoms, and with water to regenerate the carboxylic acid group
(Hermanson 1996). Although NMR analysis confirms the presence of PEG on the
nanoparticles, the extent of PEGylation achieved with the experimental protocols used in
the present research would not be sufficient for effective conjugation of targeting agents
or for shielding of the particles in an in vivo setting.
5.3.5 Preparation of PLGA-PEG-COOH Copolymers by Polymerization
The ring-opening polymerization of lactide and glycolide using the hydroxyl
group of the heterofunctional OH-PEG-COOH as an initiator was used to prepare PLGA-
PEG-COOH copolymers, as shown on Figure 5.7. The reactions were catalyzed by
stannous octoate, and run either as a melt of the monomer and PEG, or in the presence of
a solvent. The two solvents that were utilized were dimethylformamide and toluene. The
main requirement of the solvents was a high boiling point so that the reaction could be
carried out at an elevated temperature, thus providing the necessary energy to favor the
polymerization of these cyclic monomers. Dimethylformamide is a polar non-protic
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solvent and has a boiling temperature of 153°C. Toluene is a non-polar solvent with a
boiling temperature of 110.6°C.
Initially, a number of batches were prepared using unfunctionalized PEG of
molecular weight 3,350 g/mol (PEG3350) or monofunctional methyl ether PEG of
molecular weight 2,000 g/mol (mPEG2000) as these reagents are significantly less
expensive than the heterofunctional PEG that was used to make the polymers to be used
in the preparation of targeted nanoparticles (Chapter 6). Additionally, initial batches
were designed to prepare copolymers with a 1-to-1 molar ratio of lactide to glycolide and
a molecular weight of 11,000 to 15,000 g/mol with the purpose of recreating the PLGA
polymer that had been used for all experiments of encapsulation of chemotherapeutic
drugs and imaging agents described in Chapter 3 and 4. The theoretical molecular weight
was controlled based on the number of moles of hydroxyl groups of PEG added to the
reaction (two per chain for PEG3350 and one per chain for mPEG2000), and assuming that
each hydroxyl group on each chain of PEG would initiate the growth of a single chain of
PLGA. Accordingly, PEG3350 would produce a triblock copolymer of the form PLGA-
PEG-PLGA while mPEG2000 produced a diblock copolymer of the form mPEG-PLGA.
The size of these initial batches was limited to less than 2 grams, which is significantly
smaller than batch sizes reported in the literature (Du, Lemstra et al. 1995; Quellec, Gref
et al. 1998; Beletsi, Leontiadis et al. 1999; Kiremitci-Gumusderelioglu and Deniz 1999;
Yoo and Park 2001; Porjazoska, Karal-Yilmaz et al. 2004).
Table 5.6 displays the results of some of these initial batches. Specifically, this
table summarizes the results of batches carried out as a melt or in dimethylformamide.
The main variables that were adjusted between batches were the type of PEG used, the
temperature of reaction, the time of reaction and the amount of catalyst added. In all
cases, the production of copolymer was experimentally observed as an increase in the
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viscosity of the reagent medium with reaction time or, in some cases, with its
solidification prior to the desired reaction time. After the completion of the desired
reaction time, the reaction medium was cooled to room temperature. If possible, the
viscous polymer was immediately precipitated and centrifuged to obtain a solid product.
Dichloromethane was then added to the solid copolymer (either to the one
precipitated or to that which had solidified during reaction) to try to solubilize it for
further purification. However, in most instances only a small portion of the solid
dissolved regardless of the volume of solvent or the time allowed for solubilization.
Other solvents, including ethyl acetate, chloroform and dimethylformamide were also
used to see if these could better dissolve the solidified polymer but no significant
differences were observed. Since solubilization was required for further purification, the
portion that did not dissolve was removed by filtration, thus significantly reducing the
yield for the batch. The yield reported in Table 5.6 is associated with the mass of
polymer that was dissolved and precipitated at least 2 times. A few batches of of 50/50
PLGA-PEG were attempted in toluene (data not shown), but similar low yields of
purified polymer were obtained. Although the insoluble polymer could have been kept
without further purification since it probably did not contain significant amounts of
monomer, it would not have been useful for the preparation of nanoparticles.
The generation of insoluble polymer could have a number of causes. One reason
could be the presence of impurities in the feed reagents which would initiate side
reactions and could possibly result in the formation of a crosslinked polymer. Both
monomers were purified by recrystallization prior to use and the system was dried and
maintained under a nitrogen atmosphere or under vacuum at all times during the reaction.
Impurities, if any, could have come with the PEG. A second and more likely reason is
the effect of higher reactivity of glycolide compared to lactide. As described earlier in
156
this chapter, glycolide has been observed to be about 10 times more reactive than lactide
in this polymerization (Gilding and Reed 1979). It is possible, then, that long stretches of
poly(glycolide) were being produced as opposed to a more randomly distributed PLGA.
Since poly(glycolide) is insoluble in most organic solvents including ethyl acetate,
dichloromethane, chloroform, acetone, dimethylformamide and tetrahydrofuran because
of its high degree of crystallinity, it would not have been possible to dissolve it in the
solvents that were available (Middleton and Tipton 2000). In addition, the melting point
of poly(glycolide) is 225-230°C and that of 10:90 poly(lactic-co-glycolic acid) is 180-
200°C, which would account for the solidification of the reaction medium during
polymerization at temperatures as high as 180°C (Middleton and Tipton 2000; Huh, Cho
et al. 2003). To remedy the formation of poly(glycolide) domains, one solution may be
to add glycolide dimer either in a continuous manner or in portions so that the dimer
composition in the reagent mix is lower than 50% glycolide at any given time, thus
permitting the polymerization of lactide and the formation of a more random copolymer.
Proton NMR analysis of the soluble fraction of two of the 50/50 PLGA-PEG
copolymers prepared was done. Figure 5.11 shows the NMR spectra of these two
polymers, which were prepared in the melt at 140°C using PEG3350 and stannous octoate
at 0.05 wt.% of the feed. As observed, the peaks for polymerized lactide and glycolide as
well as for PEG are observed. From the area under the peaks for each of these agents, the
composition of the copolymers was determined to be of 46/54 and 59/41 lactide-to-
glycolide, which is close to the desired 50/50 copolymer. The molecular weight
calculated from the NMR data was of 18,000 g/mol for both copolymers, i.e. slightly
lower than the desired 25,000 g/mol. The low yield of these batches did not permit gel
permeation chromatography analysis.
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In contrast to the 50/50 PLGA-PEG copolymers, a number of batches of 75/25
PLGA-PEG and 100/0 PLA-PEG were successfully prepared in toluene at 110°C, as
shown on Table 5.7. During polymerization, these batches increased in viscosity but
never solidified as the polymerization continued. Also, after precipitation and
centrifugation, the polymer pellets easily dissolved in small volumes of dichloromethane
for purification. The yield of these batches was in the range of 65 to 81% for batches
made with mPEG2000 and of 52 to 87% for batches prepared with the heterofunctional
OH-PEG3400-COOH. The composition of these polymers was confirmed by NMR
analysis. For all 75/25 copolymers made with mPEG2000 the resulting copolymer
contained between 71 and 76% lactide. All 100/0 PLA-PEG copolymers showed only
the lactide and PEG protons, as expected. Figures 5.12, 5.13 and 5.14 show the NMR
spectra of 75/25 PLGA-mPEG2000, 100/0 PLA-mPEG2000 and 100/0 PLA-PEG3400-COOH
copolymers, respectively. Note the absence of the glycolide peak at 4.8 ppm on 100/0
PLA-PEG copolymers.
The molecular weight of the copolymers as calculated from NMR composition
data was in most cases very similar to the theoretical molecular weight which is based on
the reagents fed to the reaction. Only for one batch the calculated molecular weight was
close to two times the theoretical molecular weight. Gel permeation chromatography was
used to determine the molecular weight distribution of the copolymers. As shown on
Table 5.7, the number average molecular weight (Mn) was, in most instances, lower than
the theoretical or NMR-calculated value, but mostly showed increased Mn with increased
theoretical molecular weight, as expected. The polydispersity, or ratio of the weight
average to the number average molecular weights of the polymers was low, mostly
between 1.1 and 1.3. Only two batches had higher polydispersities. The increasing
molecular weight of the copolymers can be seen from the NMR spectra, as the size of the
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proton peaks associated with glycolide (4.8 ppm) and/or lactide (5.2 and 1.6 ppm) peaks
increase relative to the proton peak associated with PEG at 3.6 ppm. This can be
observed in Figures 5.12, 5.13 and 5.14 in which spectra are in order of increasing
molecular weight, unless noted, for the three groups of copolymers.
NMR analysis permits determination of the monomer content in the final
formulations. As the reagents are converted from monomers to polymers, the NMR
peaks of the monomer decreases while that of the polymer increases. For lactide, the
monomer doublets at 1.69 ppm and quartets at 5.03 ppm are replaced by broad polymer
peaks at 1.6 and 5.2 ppm (Du, Lemstra et al. 1995). Figure 5.15 shows the NMR spectra of
a PLA-mPEG copolymer that was precipitated only once without further purification.
The monomer peaks are readily visible, although very small compared to the polymer
peaks. It is important to note that all molecular weights calculated from NMR data were
specific to the polymer peaks, i.e. not affected by the presence of residual monomer, if
any.
Nanoparticles were prepared with the copolymers that were successfully prepared
by polymerization of glycolide and/or lactide dimers onto PEG. Since these copolymers
were chosen for preparation of targeted nanoparticles, detailed protocols and optimization
of nanoparticle preparation variables are described in Chapter 6. In the present chapter, it
is worth mentioning that nanoparticles prepared with these amphiphilic copolymers
presented significant differences compared to PLGA nanoparticles. The former had
significantly smaller sizes in the range of 150-180 before freeze drying as opposed to
200-300 nm for PLGA particles, were more stable in suspension and underwent severe
aggregation when freeze dried without a cryoprotectant. All of these characteristics are
consistent with the presence of PEG on their surface. Figure 5.16 shows a scanning
electron microscopy image of some of these nanoparticles.
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NMR analysis of the nanoparticles dissolved in deuterated dimethylsulfoxide after
freeze drying confirmed that the composition of the nanoparticles was very similar to that
of the copolymers used to make them. Figure 5.17 shows the NMR spectra for a batch of
nanoparticles and for the PLA-mPEG2000 copolymer with which they were prepared.
Using the NMR peak intensities, the calculated molecular weight of the polymers of four
identical nanoparticles batches to that in Figure 5.17C were found to be similar, although
slightly lower than that of the starting copolymer. Specifically, the nanoparticle polymer
molecular weights were calculated to be between 31,000 and 39,000 g/mol for all four
batches, while the molecular weight of the copolymer was first determined to be 27,501
g/mol. It is possible that lower molecular weight polymer molecules were lost during
preparation of the particles as a result of the formation of micelles, thus resulting in a
lower average molecular after nanoparticle preparation. Importantly, no residual
monomer is observed in the nanoparticles, as expected.
Nuclear magnetic resonance was also used to show the distribution of PEG within
or around the nanoparticles. Specifically, Figure 5.18 shows the NMR spectra of a
copolymer of PLA-PEG3400-COOH dissolved in deuterated chloroform (B), of the
nanoparticles prepared with this copolymer while suspended in deuterated water (C), and
of the dried nanoparticles after being dissolved in deuterated dimethylsulfoxide (D). In
the nanoparticles, PLA forms the hydrophobic core of the nanoparticle in which drugs or
imaging agent can be encapsulated. PEG is localized at the surface of the nanoparticles
and forms a hydrophilic shield that protects the nanoparticle from rapid recognition by
the immune system, thus prolonging its circulation time. When nanoparticles are
suspended in water, PLA remains solid and does not produce a resonance signal. PEG
present on the surface of the nanoparticles, on the other hand, remains solvated and
produces a signal in the NMR spectra, as shown in Figure 5.18C. Smaller peaks
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observed in this spectra are associated with the surfactant (poly(vinyl alcohol)) and
possibly with lactide protons that are in immediate proximity to PEG at the surfaced of
the nanoparticles. After dissolving the dry particles, the copolymer composition can be
once more confirmed.
Polymerization of lactide and glycolide onto PEG to form block copolymers is a
viable method the incorporation of PEG onto nanoparticles. Copolymers of 75/25
PLGA-PEG or 100/0 PLA-PEG were successfully prepared in good yields and with good
reproducibility. The polymerization method can be easily adjusted for the preparation of
copolymers of varied composition and molecular weight, both of which are key factors in
the resulting nanoparticle characteristics. In addition, and as will be confirmed in
Chapter 6, the use of heterofunctional PEG containing both carboxylic acid and hydroxyl
groups permits the preparation of copolymers that can be used for further derivatization.
5.4 CONCLUSION
This chapter describes various methods for the incorporation of poly(ethylene
glycol) on the surface of PLGA nanoparticles. The preparation of nanoparticles with
blends of PLGA and functionalized PEG did not prove to be effective as most of the
hydrophilic PEG partitioned to the aqueous phase during preparation and further during
nanoparticle washes. Blends of PLGA with Pluronic F127 did result in significant
modification of the nanoparticle composition and surface charge, with up to 43%
incorporation efficacy. However, this method does not provide permanent surface
particle coverage, especially if the Pluronic is only adsorbed to the surface of the
particles.
Three methods were used for covalent attachment of PEG to PLGA nanoparticles.
Direct conjugation of PEG to the carboxylic acid groups of PLGA that were present on
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the surface of the nanoparticles did not result in sufficient incorporation, possibly because
of inaccessibility of these groups. Conjugation of PEG to PLGA in solution resulted in
moderate copolymer conjugation efficiency depending on the specific conditions in
which the conjugations were carried out. However, the main difficulty with this method
was the purification of the copolymers by precipitation, which prevented the recovery of
high yields. Finally, preparation of copolymers by the ring-opening polymerization of
lactide and glycolide dimers onto PEG, methyl ether PEG, or OH-PEG-COOH was
achieved. This last method could be used for the preparation of copolymers of a wide
range of compositions and molecular weights. NMR analysis confirmed the composition
of all copolymers in which PEG was covalently attached to PLGA or PLA. NMR also
confirmed that the composition of the copolymers was maintained after preparation of
nanoparticles, proving that PEG was in fact attached to the hydrophobic PLGA or PEG as
opposed to simply associated to the polymer. Finally, NMR analysis of PLA-PEG
nanoparticles in suspension confirmed that PEG was in fact being presented on the
surface of the nanoparticles as a shielding layer that would protect them from rapid
opsonization and sequestration by the reticuloendothelial system.
Chapter 3 and 4 described the preparation of PLGA nanoparticles loaded with
chemotherapeutic and imaging agents, and their interaction with tumor cells in vitro. The
present chapter describes how to modify these particles to include poly(ethylene glycol)
on their surface so that targeting agents can be incorporated on their surface and so that
they have a better chance of reaching the target diseased tissue in vivo. The following
chapter describes the optimization of the parameters for the preparation of nanoparticles
with PLA-PEG copolymers including cryoprotection, the encapsulation of
chemotherapeutic and imaging agents within them, and the attachment of targeting agents
to their surface.
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Table 5.1 Summary of results for the incorporation of FITC-PEG-NHS in
poly(lactic-co-glycolic acid) nanoparticles by blending of polymers.
Abbreviations: poly(vinyl alcohol) (PVA), bovine serum albumin (BSA),
sodium cholate (SC), poly(ethylene glycol) (PEG). Data are the average ±





















0 PVA 60.9 ± 6 190 ± 3 263 ± 42 --- ---
9.2 BSA 68.4 ± 11 236 ± 18 305 ± 21 -1.7 ± 7.6 -0.2 ± 0.8
9.2 PVA 58.9 ± 7 201 ± 11 331 ± 153 1.2 ± 8.0 0.1 ± 0.8
9.2 SC 56.9 ± 7 137 ± 16 179 ± 14 11.6 ± 12 1.1 ± 1.3
16.8 PVA 57.8 ± 11 217 ± 30 271 ± 14 4.1 ± 6.4 0.8 ± 1.3
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Table 5.2 Incorporation of Pluronic F127 (PF127) in poly(lactic-co-glycolic acid)
(PLGA) nanoparticles by blending of polymers. Data are the average ±
























50 : 50 27.7 ± 3.7 130 ± 12 493 ± 49 -27.9 ± 3.4 76.5 ± 2.4 43.3 ± 0.8
25 : 75 46.7 ± 3.3 168 ± 31 765 ± 133 -32.0 ± 3.5 42.0 ± 6.0 12.3 ± 1.5
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Table 5.3 Preparation of PLGA-NH-PEG-COOH copolymers by conjugation of pre-
made poly(lactic-co-glycolic acid) (PLGA) with heterofunctional
poly(ethylene glycol) (PEG) mediated by carbodiimide chemistry. Results
include the molar ratio of PLGA to PEG as determined by nuclear magnetic
resonance (NMR) and the number average molecular weight (Mn) of the
resulting copolymers as determined by gel permeation chromatography
(GPC). Abbreviations: Chloroform (CHCl3), dichloromethane (DCM),









GPC Mn GPC PI
CHCl3 24 1.4
DCM 4 2.0 10,760 1.2
DCM 4 2.9 12,400 1.3






Table 5.4 Characteristics of nanoparticles PEGylated by conjugation of NH2-PEG-
COOH on their surface using carbodiimide chemistry in aqueous











PEGylated N/A none 324 ± 31 * *
PEGylated PVA none * *
PEGylated PVA glucose 261 ± 25 -9.7 ± 1.3
PEGylated PVA trehalose 235 ± 3 -15.4 ± 2.7
Not PEGylated PVA trehalose 229 ± 5 234 ± 2 -10.8 ± 2.0
245 ± 15
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Table 5.5 Molar composition based on XPS analysis of nanoparticles (NPs)
PEGylated after preparation by conjugation of NH2-PEG-COOH on their
surface using carbodiimide chemistry (EDC/NHS) in suspension. Values
for PLGA and PEG are theoretical compositions based on the chemical
structure of their repeating units.
Carbon Oxygen Nitrogen
PLGA (theoretical) 55.56 44.44 0
PEG (theoretical) 33.33 66.67 0
Control PLGA NPs



































Melt 50/50 mPEG2000 14,000 140 1 0.05 wt % 12.4
Melt 50/50 mPEG2000 14,000 140 2 0.05 wt % 23.2
Melt 50/50 mPEG2000 14,000 140 3 0.05 wt % 15.5
Melt 50/50 PEG3350 25,000 140 0.2 0.05 wt % 3.9
Melt 50/50 PEG3350 10,000 140 0.3 0.05 wt % 2.2
Melt 50/50 PEG3350 25,000 140 0.3 0.05 wt % 12.7
Melt 50/50 PEG3350 17,000 140 0.1 1:1 to PEG 25.3
Melt 50/50 PEG3350 35,000 140 0.4 1:1 to PEG 18.3
DMF 50/50 mPEG2000 14,000 140 24 1:1 to PEG 6.7
DMF 50/50 mPEG2000 14,000 140 28 1:1 to PEG 0.0
DMF 50/50 mPEG2000 14,000 140 48 1:1 to PEG 0.7
DMF 50/50 mPEG2000 14,000 140 72 1:1 to PEG 2.4
DMF 50/50 mPEG2000 14,000 140 90 1:2 to PEG 0.1
DMF 50/50 mPEG2000 14,000 140 90 1:1 to PEG 0.7
DMF 50/50 PEG3350 17,000 110 0.5 1:1 to PEG 7.4
DMF 50/50 PEG3350 17,000 140 0.3 1:1 to PEG 10.0
DMF 50/50 PEG3350 32,000 140 0.5 2:1 to PEG 3.6
DMF 50/50 PEG3350 32,000 140 2 2:1 to PEG 1.4
DMF 50/50 PEG3350 32,000 140 4 2:1 to PEG 6.2
DMF 50/50 PEG3350 32,000 140 5 2:1 to PEG 1.3
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Table 5.7 Characteristics of batches of PLGA-PEG or PLA-PEG copolymers prepared
by solution polymerization in toluene at 110°C using a 1:1 molar ratio of
PEG to stannous octoate catalyst. Abbreviations: Molecular weight (MW),
nuclear magnetic resonance (NMR), number average molecular weight





















75/25 1 mPEG2000 81.0 23,390 27,501 76 / 24 18,305 1.13
75/25 1 mPEG2000 67.2 34,128 29,005 71 / 29 14,520 1.12
75/25 1 mPEG2000 77.1 44,832 44,342 74 / 26 21,080 2.05
100/0 4 mPEG2000 72.4 24,502 24,251 -- 12,350 1.09
100/0 4 mPEG2000 76.9 35,738 36,794 -- 14,235 1.08
100/0 4 mPEG2000 75.9 46,908 88,081 -- 28,463 1.29
100/0 4 OH-PEG3400-COOH 52.7 28,358 19,483 -- 35,550 1.22
100/0 4 OH-PEG3400-COOH 85.3 53,414 61,965 --- 38,915 1.12
100/0 4 OH-PEG3400-COOH 87.4 53,428 55,592 --- 80,820 1.15
100/0 12 OH-PEG3400-COOH 76.0 53,401 59,519 -- 35,470 3.16
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Figure 5.1 N-hydroxysuccinimide ester of poly(ethylene glycol) (PEG-NHS). The
NHS functionality was a desired characteristic of the PEG-derivatives
utilized in the design of the targeted nanoparticles. The electrophilic NHS
functional group was used to form physiologically stable amide linkages









Figure 5.2 Polycondensation of lactic and glycolic acid to form poly(lactic co-glycolic
acid)
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Figure 5.4 Chemical structure of PEG derivatives incorporated into PLGA
nanoparticles through polymer blending. (A) Fluorescein-PEG-N-
hydroxysuccinimide (FITC-PEG-NHS), and (B) Poloxamer F127 (n = 101
and m = 56).
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Figure 5.5 Conjugation of poly(lactic-co-glycolic acid) (PLGA) to heterofunctional
poly(ethylene glycol) (PEG). Carboxyl groups of PLGA are activated
with DCC and N-hydroxysuccinimide (NHS) to form an NHS-ester that is
highly reactive to terminal amino groups on heterofunctional PEG. These




Figure 5.6 Conjugation of PEG to PLGA on the surface of pre-made nanoparticles.
Carboxylic acid groups of PLGA present on the surface of the
nanoparticles are activated with EDC and N-hydroxysuccinimide to form
an NHS ester. This reacts with the primary amino group of







Figure 5.7 Ring-opening polymerization of lactide and glycolide initiated by the








Figure 5.8 Nuclear magnetic resonance (NMR) spectra of PLGA-NH-PEG-COOH
copolymers prepared by conjugation of PLGA and heterofunctional PEG.
(A) Chemical structure of the copolymer and assignment of proton labels.
Conjugations were carried out for (B) 2 hr in dichloromethane, (C) 2 hr in
chloroform, (D) 4 hr in dichloromethane and (E) 24 hr in chloroform.
Spectra are arranged in order of increasing conjugation efficiency (B
through E). Note the increasing size of the PEG peak d at 3.6 ppm relative
to the peaks of PLGA at 1.6 (c), 5.2 (b) and 4.8 ppm (a) with increasing
conjugation efficiency. Spectrum in C was run in deuterated DMSO while
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Figure 5.9 Scanning electron microscopy images of PLGA nanoparticles that were
PEGylated in suspension after preparation using EDC and NHS. White bar
represents a distance of 667 nm. Nanoparticle sizes are in the range of 200
nm.
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Figure 5.10 1H-NMR spectra of dried nanoparticles PEGylated by conjugation of NH2-
PEG-COOH in suspension after nanoparticle preparation. (A) Structure of
copolymers and assignment of peak labels. (B) Particles prepared without
surfactant and freeze dried without a cryoprotectant. NMR spectra obtained
after dissolving the particles in deuterated chloroform. (C) Nanoparticles
prepared with poly(vinyl alcohol) as surfactant. This portion of the batch
was freeze dried without cryoprotectant to prevent spectra interference with






















Figure 5.11 Proton NMR spectra of soluble portion of 50/50 PLGA-PEG copolymers
prepared by melt polymerization (A) Chemical structure and peak
assignment for PLGA-PEG. Note that the actual structure is a triblock
copolymer (PLGA-PEG-PLGA) since PEG3350 has hydroxyl groups on both























Figure 5.12 Proton NMR spectra of 75/25 PLGA-mPEG2000 prepared in toluene in order
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Figure 5.13 Proton NMR spectra of 100/0 PLA-mPEG2000 prepared in toluene in order
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Figure 5.14 Proton NMR spectra of 100/0 PLA-PEG3400-COOH prepared in toluene in
order of increasing theoretical and NMR-determined molecular weight.
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Figure 5.15 Chemical structure and proton NMR peak assignment (italics) for (A) PLA-
mPEG2000 copolymer and (B) lactide monomer. (C) NMR spectra of PLA-
PEG copolymer prepared by ring-opening polymerization of lactide initiated
by the hydroxyl group of OH-PEG-COOH with stannous octoate as catalyst.
Reaction carried out in toluene for 4 hr at 110°C. This batch was
precipitated in ethyl ether once but not further purified. Spectra show the















Figure 5.16 Scanning electron microscopy image of nanoparticles prepared with 100/0
PLA-PEG-COOH copolymer prepared by polymerization in solution.
White bar represents 300 nm.
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Figure 5.17 (A) Chemical structure and proton NMR peak assignment for PLGA-PEG
copolymer. (B) 1H-NMR spectra of PLGA-mPEG2000 prepared by
polymerization and (C) nanoparticles prepared with this polymer.
Additional peaks in nanoparticles correspond to glucose used as a





















Figure 5.18 Nuclear magnetic resonance analysis of nanoparticles of PLA-PEG3400-
COOH. (A) Chemical structure and proton peak assignment. (B) NMR
spectra of PLA-PEG-COOH copolymer used for nanoparticle preparation.
(C) NMR spectra of nanoaparticles suspended in D2O. No lactide peaks are
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CHAPTER 6
FORMULATION AND CHARACTERIZATION OF TARGETED
NANOPARTICLES
6.1 INTRODUCTION
Chapter 3 and 4 described the methods for preparation of biodegradable
poly(lactic-co-glycolic acid) nanoparticles encapsulating the chemotherapeutic agent
doxorubicin and the imaging agents rhodamine 6G, indocyanine green and gadopentetic
acid. Chapter 5 presented various methods for the incorporation of poly(ethylene glycol)
(PEG) on these types of nanoparticles, including the formulation of particles with
polymer blends of PLGA and PEG-containing polymers, the covalent conjugation of
PEG on the surface of pre-made nanoparticles using carbodiimide-mediated chemistry,
and the preparation of covalently-bound block copolymers of poly(lactic-co-glycolic
acid) (PLGA) and PEG by conjugation and polymerization. Based on the results
described in Chapter 5, the polymerization of lactide and/or glycolide monomers initiated
by hydroxyl groups on heterofunctional OH-PEG-COOH provided the best method for
the synthesis of functional copolymers that could be used for preparation of nanoparticles
with a high PEG surface coverage. In this chapter, the preparation of nanoparticles with
these copolymers, the encapsulation of chemotherapeutic and imaging agents within
them, and the attachment of targeting antibodies to their surface is described.
6.1.1 Preparation and Characteristics of PEGylated Nanoparticles
Nanoparticles made with block copolymers of PLGA and PEG have been
investigated in the past because of their ability to circulate in the bloodstream for
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extended periods compared to their unmodified PLGA counterparts (Moghimi, Porter et
al. 1991; Gref, Minamitake et al. 1994; Stolnik, Dunn et al. 1994; Gref, Domb et al.
1995; Torchilin, Narula et al. 1996; Gref, Luck et al. 2000; Riley, Stolnik et al. 2001;
Avgoustakis 2004). PEGylated nanoparticles are also known to adsorb less plasma
protein with increased PEG content. Speficically, as much as 43% and 64% reduction in
protein adsorption was observed in PLA-PEG nanoparticles with a PLA-to-PEG
molecular weight ratio of 45,000/2,000 and 45,000/5,000, respectively (Gref, Luck et al.
2000). Surface PEG has also been observed to modify the biodistribution of
nanoparticles as a result of surface chemistry differences. In addition to prolonged
residence time in the blood pool, surface modification of PLGA nanoparticles with PEG
resulted in significantly lower accumulation in the liver and higher accumulation in the
spleen, intestines, and bones (Avgoustakis, Beletsi et al. 2003). A separate study
revealed increased accumulation of PLGA-PEG nanoparticles in the lungs and decreased
accumulation in the kidneys compared to unmodified PLGA nanoparticles (Li, Pei et al.
2001).
In addition to surface properties, the size of particles also has a great effect on
their in vivo activity. For intravenous administration, the size of solid nanoparticles has
to be significantly smaller than that of capillaries, i.e. less than 5 m (Avgoustakis
2004). Nanoparticles of less than 200 nm have been found to be better able to avoid
filtration by the spleen (Moghimi, Porter et al. 1991). Nanoparticles are also known to
accumulate in tumors when their size is less than 100 nm (Kim and Nie 2005).
A number of different methods have been used for the preparation of
nanoparticles with PLGA-PEG or PLA-PEG copolymers. Among these,
emulsification/solvent evaporation (Gref, Luck et al. 2000; Li, Pei et al. 2001) and
nanoprecipitation (Fessi, Devissaguet et al. 1986; Fessi, Puisieux et al. 1989;
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Avgoustakis, Beletsi et al. 2003) are the most commonly used. Nanoprecipitation is also
commonly described as solvent diffusion or solvent displacement method. In both
methods, the copolymer is first dissolved in an organic solvent together with the active
agent to be encapsulated. This organic phase is mixed with an aqueous solution to form
the nanoparticles. In the emulsification method, a water immiscible solvent, such as
ethyl acetate or dichloromethane, is used. Input of energy, in the form of sonication,
homogenization or vigorous vortexing is necessary to emulsify the organic solution
within the aqueous outer phase. The organic solvent must then be evaporated to solidify
the polymer droplets. In the nanoprecipitation method, on the other hand, a water
miscible solvent such as acetone or acetonitrile is used to dissolve the polymers and drug.
Upon mixing, the organic solvent diffuses into the added aqueous phase, thus lowering
the surface tension between the two phases and resulting in the spontaneous formation of
an oil-in-water nanometric emulsion. Surfactants are not necessary for the preparation of
PEGylated particles as PEG is able to stabilize the colloidal system through steric
interactions. However, surfactants do improve the resuspension of particles after
mechanically-induced sedimentation (Avgoustakis 2004).
The structure of nanoparticles made from amphiphilic copolymers such as PLGA-
PEG and PLA-PEG is known to be highly influenced by the overall molecular weight of
the polymer as well as the ratio of the molecular weights of the hydrophilic and
hydrophobic domains. With larger size ratio of the hydrophilic to the hydrophobic
domain, the structure of the nanoparticles becomes more dynamic or micelle-like
(Avgoustakis 2004). A molecular weight ratio of 45/5 for the hydrophobic domain
relative to the hydrophilic domain has been suggested for preparation of solid
nanoparticles of PLA-PEG. With lower ratios, particle formation is thought to occur
through self-assembly of the polymers into micelle-like structures, instead of by
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precipitation of the hydrophobic polymer regions when in contact with the outer
continuous aqueous phase.
6.1.2 Freeze Drying of PEGylated Nanoparticles
Freeze drying is a process that is commonly used in the pharmaceutical industry
for preservation of moisture-sensitive formulations including nanoparticles, liposomes
and nanoemulsions (Abdelwahed, Degobert et al. 2006). This process consists of three
steps: freezing of the formulation, removal of water by sublimation or primary drying,
and desorption of residual water. During freeze drying, however, the stability of colloidal
formulations can be compromised because of the various mechanical stresses that the
samples must be subjected. A number of formulation variables can be adjusted to
increase the ability of nanoparticles to undergo freeze drying and maintain their stability.
These variables include the type of surfactant used for stabilization of the nanoparticle
suspensions, the type of polymer making the nanoparticles, the presence of agents bound
to the surface of the particles, and the use of cryoprotectants (Abdelwahed, Degobert et
al. 2006).
The freezing step of the freeze drying process can be highly influential with
respect to the ability of the formulation to be reconstituted after drying. Freezing of
colloidal suspensions occurs through the formation of pure water crystals. This
separation of phases results in the segregation of nanoparticle into dehydrated domains
which ultimately solidify in amorphous form at their glass transition temperature
(Abdelwahed, Degobert et al. 2006). Aggregation of nanoparticles can occur at this step
since the particles are physically concentrated within these domains. In addition,
formation of water crystals around the nanoparticle domains can induce mechanical
stresses that result in particle destabilization. During the primary drying step, the sample
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is subjected to high vacuum. As the sample absorbs heat from the surrounding
environment, water crystals sublimate and the water travels in vapor form from the
sample to the freeze dryer condenser, where it solidifies. During this step, samples must
be maintained below a critical temperature above which the sample loses its macroscopic
porous network structure and collapses, thus preventing efficient sublimation of water.
This critical temperature is usually about 2°C higher than the glass transition temperature
of the amorphous domains (Abdelwahed, Degobert et al. 2006).
The use of excipients called cryoprotectants has been suggested for prevention of
particle aggregation as a result of freeze drying stresses. Some commonly used
cryoprotectants include sucrose, lactose, trehalose, glycerol, mannitol, sorbitol, glycine,
alanine, lysine, polyethylene glycol, dextran and poly(vinyl pyrrolidone) (Abdelwahed,
Degobert et al. 2006). These agents solidify in amorphous conformation below their
glass transition temperature, thus protecting the particles from mechanical stress caused
by the formation of water crystals. Trehalose has been suggested to be a preferred
cryoprotectant because it is less hydroscopic than other cryoprotectants, has a low
chemical reactivity, does not present internal hydrogen bonding, and has a higher glass
transition temperature (-30°C) than other sugars such as glucose (-41°C). This latter fact
is important because in order for the freezing and sublimation processes to proceed until
completion, these steps must be done under the glass transition temperature of the
cryoprotectant-nanoparticle domains (Abdelwahed, Degobert et al. 2006). In addition to
the type of cryoprotectant used, the concentration of this agent and that of the
nanoparticle suspension have been reported to be important for successful freeze drying
of nanoparticles (de Jaeghere, Allemann et al. 2000; Abdelwahed, Degobert et al. 2006).
Freeze drying of nanoparticles containing poly(ethylene glycol) is known to result
in particle aggregation (de Jaeghere, Allemann et al. 1999). In fact, previous studies have
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demonstrated a relationship between the amount and molecular weight of PEG and the
aggregation of the formulation (de Jaeghere, Allemann et al. 2000; Abdelwahed,
Degobert et al. 2006). This phenomenon has been attributed to the crystallization of PEG
during the freezing step (Izutsu, Yoshioka et al. 1996). Trehalose has been used to
protect PEGylated poly(lactic acid) nanoparticles during freeze drying successfully (de
Jaeghere, Allemann et al. 2000). Trehalose protects PEGylated nanoparticle suspensions
by preventing PEG crystallization with the formation of an amorphous matrix around the
nanoparticles and creating hydrogen bonds with PEG (Abdelwahed, Degobert et al.
2006).
6.1.3 Antibodies as Targeting Agents for Ovarian Cancer
Antibodies are immunoglobulins capable of recognizing a specific antigen.
Structurally, antibodies are Y-shaped molecules composed of two identical heavy chains
and two antigen-specific variable light chains. Commonly antibodies are produced by
immunizing a susceptible animal with an antigen and collecting the immunoglobulins
that are specific to the antigen from the animal’s blood. This mixture of
immunoglobulins will contain antibodies to various epitopes of the same antigen and,
consequently, constitutes a polyclonal antibody mixture (Greener 2005). Monoclonal
antibodies, on the other hand, contain only one type of antibody specific to a given
epitope of the antigen molecule. Monoclonal antibodies are normally produced in
hybridoma cell lines, which consist of fused B lymphocytes and immortal myeloma cells
(Greener 2005).
No monoclonal antibodies specific to the follicle stimulating hormone receptor
are commercially available to date. The group of Dr. James A. Dias from the Wadsworth
Center of the New York State Department of Health kindly provided a monoclonal
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antibody that his group developed for investigation of the binding site of follicle
stimulating hormone to FSHR. This antibody, labeled mAb106-105, is an
immunoglobulin of IgG2b isotype that is specific to the extracellular domain of human
FSHR (Lindau-Shepard, Brumberg et al. 2001). It was derived from mice immunized
with a recombinant protein expressed by insect cells representing the extra-cellular
domain of human FSHR, and produced by hybridoma cells. The epitope of this antibody
is located within amino acid residues 300-315 of FSHR, as determined by ELISA
Binding of mAb106-105 to the extracellular domain of FSHR was determined by ELISA
and SDS-PAGE/Western immunoblot (Lindau-Shepard, Brumberg et al. 2001). Binding
of the mAb106-105 antibody to FSHR-expressing cells was determined by flow
cytometry (Lindau-Shepard, Brumberg et al. 2001).
Binding of the mAb106-105 antibody to FSHR was shown to block binding of the
follicle stimulating hormone to the receptor and consequent cAMP production in a
concentration-dependent manner in Y1-R FSHR-expressing cells (Lindau-Shepard,
Brumberg et al. 2001). Specifically, a mass of 10 g of the monoclonal antibody was
shown to completely inhibit hormone binding (Lindau-Shepard, Brumberg et al. 2001).
Inhibition of hormone binding and function was observed to be reversed by increased
concentration of FSH. Binding of 10 g of antibody was determined to be disrupted by
addition of 30ng or more of the follicle stimulating hormone in a dose dependent manner
(Lindau-Shepard, Brumberg et al. 2001). It has also been shown that binding of this
antibody to the target receptor does not cause adenyl cyclase activation and subsequent
signaling events (Lindau-Shepard, Brumberg et al. 2001). The mAb106-105 monoclonal
antibody has been used by other groups for investigation of the role of FSHR in ovarian
cancer development (Choi, Choi et al. 2004).
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Development of monoclonal antibodies to FSHR has also been reported by
Vannier and colleagues (Vannier, Loosfelt et al. 1996). These antibodies were produced
by immunizing mice with a fusion protein containing the extracellular domain of FSHR.
All antibodies produced were shown to recognize the 172-358 amino acid fragment of the
receptor, although most had different epitopes and could bind simultaneously. These
antibodies were shown to cause little cAMP production (Vannier, Loosfelt et al. 1996).
Cell studies demonstrated that these antibodies recognized and bound to the cell
membrane of cells expressing FSHR but not to control cells (Vannier, Loosfelt et al.
1996). Antibodies labeled 323 and 156 resulted in the strongest immunohistochemical
labeling.
6.2 MATERIALS AND METHODS
6.2.1 Materials
Heterofunctional PEG containing hydroxyl and carboxylic acid end groups (OH-
PEG-COOH) of molecular weight 3,400 g/mol was purchased from Laysan Bio Inc.
(Arab, AL, USA). Stannous octoate (Tin(II) 2-ethylhexanoate), poly(vinyl alcohol) (87-
90% hydrolyzed, molecular weight average of 30,000 to 70,000), 2-(N-
morpholino)ethylsulfonic acid (MES), N-hydroxysuccinimide, 3,3’5,5’-
tretramethylbenzidine dihydrochloride (TMB) tablets, bovine serum albumin, phosphate
buffered saline packages pH 7.4 were purchased from Sigma-Aldrich (Saint Louis, MO,
USA). D-(+)-trehalose dihydrate was obtained from ACROS. The reagent 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) was obtained from Fluka.
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Cyclic d,l-lactide (molecular weight 144.1) and glycolide (molecular weight
116.1) monomers were obtained from PolySciences, Inc. (Warrington, PA, USA).
Poly(lactic-co-glycolic acid) (formerly PLGA 50:50 DL 2A, now 5050 DLGA 2A, 50/50
D,L-lactide to glycolide ratio, molecular weight 12,000 g/mol, carboxylic acid and
hydroxyl end groups) was obtained from LakeShore Biomaterials (Birmingham, AL,
USA). Doxorubicin hydrochloride, ethyl ether, acetone, dimethylsulfoxide, ethyl acetate,
dimethylformamide, methanol, and sulfuric acid were obtained from Fisher Scientific.
Sodium hydroxide was obtained from JT Baker.
Mouse purified IgG, used as a model antibody for protocol validation, was
purchased from Biomeda (Foster City, CA, USA). Monoclonal antibody mAb 106-105
specific to the extracellular domain of the follicle stimulating hormone receptor was
generously provided by Dr. James Dias from the Wadsworth Center (Albany, NY, USA).
Purified IgG2b isotype control from murine myeloma and goat anti-mouse IgG (whole
molecule) horseradish peroxidase conjugate were obtained from Sigma (Saint Louis, MO,
USA).
6.2.2 Preparation of Copolymers
PLA-PEG-COOH copolymers were prepared by the solution polymerization of
cyclic lactide initiated by the terminal hydroxyl group of heterofunctional PEG
containing hydroxyl and carboxylic acid end groups (OH-PEG-COOH) (Laysan Bio Inc.,
Arab, AL, USA), as described in Chaper 5. The polymerization was catalyzed by
stannous octoate (1:1 molar ratio to PEG) and carried out for four hours in anhydrous
toluene at 110°C. Copolymers were purified by three cycles of dissolution in
dichloromethane and precipitation in ethyl ether. Copolymers were then dried overnight
in a vacuum desiccator, frozen and freeze dried. Copolymers were prepared in a manner
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to give theoretical molecular weights between 24,500 and 53,000 g/mol. For all batches
of nanoparticles containing imaging agents, therapeutic agents or antibodies, the
copolymer used had a theoretical molecular weight of 53,000 g/mol, which was
confirmed by nuclear magnetic resonance analysis of the copolymer composition.
6.2.3 Preparation of Targeted Nanoparticles with PLA-PEG-COOH Copolymer
The preparation of targeted nanoparticles was carried out in three consecutive
steps, as displayed in Figure 6.1. First, nanoparticles of the PLA-PEG-COOH
copolymers were prepared by oil-in-water nanoprecipitation. Next, the terminal
carboxylic acid groups of PEG, which were expected to be exposed on the surface of the
nanoparticles, were activated using carbodiimide chemistry to create an amine-reactive
semi-stable N-hydroxysuccinimide ester. Finally, antibodies were reacted with the
activated carboxyls on the nanoparticles. Each of these steps is described in detail below.
6.2.3.1 Preparation of Nanoparticles with PLA-PEG-COOH Copolymer
Nanoparticles of the PLA-PEG-COOH copolymers were prepared by oil-in-water
nanoprecipitation. A mass of 100±0.2 mg of PLA-PEG-COOH copolymer was dissolved
in 3 ml of acetone. After the polymer was completely dissolved, 1 ml of methanol or a
solution of drug or imaging agent in methanol was added and the solution was briefly
mixed. Methanol, although not required for preparation of blank nanoparticles, was
added to simulate the preparation of nanoparticles loaded with methanol-soluble drugs or
imaging agents. The polymer solution was filtered through a 0.2 m nylon syringe filter
directly onto 10 ml of an aqueous solution of 10 mg/ml PVA. The purpose of the
filtering step was to remove any impurities that may have accumulated in the copolymers
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during their preparation and handling. The suspension was rapidly vortexed and
sonicated for 5 seconds each to form a homogeneous system. Organic solvent was
removed by stirring the suspension in a vacuum flask at 500 rpm for 45 minutes while at
room temperature and under 400 mmHg of vacuum. The nanoparticle suspension was
transferred to a 45 ml polycarbonate centrifuge tube. The vacuum flask was rinsed with
10 ml of water and the rinse was transferred to the same centrifuge tube. The
nanoparticle suspension was then centrifuged in a Beckman J2-21 refrigerated centrifuge
for 1 hour at 43,600 x g. The supernatant was removed, the pellet was again resuspended
in water by vortexing and sonication, and the sample was centrifuged again at 43,600 x g
for one more hour to remove excess surfactant from the surface of the nanoparticles.
Nanoparticles loaded with drug or imaging agents were prepared similarly, except
that the agent was included in the initial organic phase of the polymer in acetone and
methanol. Specifically, rhodamine 6G (RHO) nanoparticles were made by dissolving
rhodamine in acetone at a concentration of 0.3 mg/ml, using 3 ml of this solution to
dissolve the copolymer and then adding 1 ml of methanol to form the organic phase.
Indocyanine green (ICG) loaded nanoparticles were prepared by dissolving ICG in
methanol at a concentration of 10 mg/ml and adding 1 ml to a solution of the copolymer
in acetone. Finally, doxorubicin (DOX) loaded nanoparticles were prepared by first
dissolving doxorubicin at a concentration of 1.33 mg/ml in methanol and then adding a
volume in the range of 1.5 to 2.25 ml of this solution to 3ml of pre-dissolved copolymer
in acetone, depending on the loading desired. Nanoparticles loaded with active agents
were washed three times after solvent evaporation by cycles of centrifugation and
resuspension in water to remove unencapsulated agent.
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6.2.3.2 Activation of Surface Carboxylic Acid Groups
Immediately after preparation and removal of excess surfactant, the nanoparticle
pellet was resuspended in 0.99 ml of 0.01 M MES buffer (pH 5.5) using sonication and
vortexing. EDC and NHS were then added immediately after being dissolved in 50 l of
0.01 M MES buffer, each, at a 50:1 molar ratio compared to the moles of PLA-PEG-
COOH used to make the batch of nanoparticles. The reaction was allowed to occur for
15 minutes at room temperature while shaking, after which 19 ml of 0.01M MES buffer
were added and the suspension was centrifuged for 15 minutes to remove excess NHS,
EDC and isourea byproduct. The supernatant was removed and the nanoparticles were
immediately conjugated to targeting antibodies as described below.
6.2.3.3 Conjugation of Targeting Antibodies to Activated Nanoparticles
The pellet of activated nanoparticles was rapidly resuspended in 1 ml of 0.1 M
PBS buffer (pH 7.5) with sonication and vortexing. The appropriate amount of antibody
solution was added and the system was allowed to react for 3 hours at room temperature
while shaking. After reaction, 19 ml of PBS were added and the suspension was
centrifuged at 19,000 rpm for 1 hour. The nanoparticles were resuspended in 20 ml of
PBS buffer by pipetting with a Pasteur pipet and again centrifuged. It is important to
note that no sonication or vortexing were used after antibody conjugation to prevent loss
of antibody activity. The nanoparticles were then resuspended in 8 ml of water by
pipetting with a Pasteur pipette. One fourth of this suspension was frozen at -80°C and
freeze dried for 2 days in the absence of a cryoprotectant for determination of batch yield
and drug loading. A second fourth of the batch was used for determination of antibody
conjugation efficiency. The last one half of the batch was freeze dried in the presence of
a cryoprotectant, as described next, at stored at -20°C for further studies.
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6.2.3.4 Freeze Drying of Nanoparticles
Long term storage of nanoparticles requires that water be removed from the
formulation to prevent premature drug release and polymer degradation. The process
most commonly used for this purpose is lyophilization, or freeze drying. As the name
implies, the process consists of two main steps: freezing of the formulation and
subsequent drying by sublimation of ice. Unfortunately, formulations containing PEG
are known to undergo aggregation after this process as a result of PEG crystallization.
The use of cryoprotectants, and specifically of trehalose, has been suggested for
minimization of particle aggregation during freeze drying (de Jaeghere, Allemann et al.
2000).
An initial study was done to determine the optimal variables for freeze drying of
the nanoparticles to permit reconstitution after storage. The variables studied were the
concentration of nanoparticles in suspension, the mass of trehalose with respect to the
mass of nanoparticles, and the freezing temperature. The concentration of nanoparticles
in the suspension was varied between 7.5, 10, 12.5 and 15 mg/ml while the ratio of the
mass of D-(+)-trehalose dihydrate to that of nanoparticles was increased between 0 and
10 mg/ml. Particles were frozen in a -80°C freezer after being transferred to a
borosilicate glass vial, or in a liquid nitrogen tank (-196°C) after being transferred to a
polypropylene cryogenic vial. Suspension volumes were of about 1 ml total.
Nanoparticles were left freezing overnight for at least 3 hours if frozen at -80°C, or for 10
minutes if frozen in liquid nitrogen. Nanoparticles were then freeze dried for 2 days in a
Labconco Freeze Dryer 4.5 (Kansas City, MO, USA).
After determining the optimal conditions for freeze drying, as described in the
results section, all washed particles encapsulating active agents or with targeting
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antibodies were resuspended in 8 ml of water with sonication. A fraction of this
suspension was transferred to a vial that contained trehalose (200± 0.1 mg of trehalose
per 4 ml of nanoparticle suspension) as a cryoprotectant, and frozen at -80°C. The
remaining fraction was frozen without trehalose for determination of batch yield and drug
loading, when applicable. The frozen nanoparticle suspensions were freeze dried for 2
days and stored at -20°C. The volume of water used to resuspend each batch of
nanoparticles and the amount of trehalose used for cryoprotection were designed to create
a 12.5 mg/ml nanoparticle suspension (based on starting mass of polymer) that has 50
mg/ml trehalose, conditions that were found to be optimal for cryoprotection of these
PLA-PEG nanoparticles in the above study.
6.2.3.5 Preparation of Sterile Nanoparticles
For the preparation of nanoparticles that would be used for in vitro cellular
studies, as described in Chapter 7, nanoparticles were prepared under aseptic conditions
to prevent contamination, which occurred during preliminary studies. All vials, flask and
pipets used during nanoparticle preparation, lyophilization and storage were either
purchased in pre-sterilized form, autoclaved or subjected to ultraviolet light for > 12
hours. These included vacuum flasks, centrifuge tubes, and Pasteur pipets. All feed
solutions, including the polymer/drug organic solution, aqueous surfactant solution,
buffers, activation reagents, antibody solutions, and trehalose solutions were filtered
through 0.2 m sterile syringe filters. All filtered solutions or particle suspensions were
handled inside a laminar flow cell culture hood unless securely sealed inside a sterile
container such as a vial or centrifuge tube. Vacuum solvent removal was carried out with
the nanoparticle-containing flasks inside laminar flow hood, but connected to a vacuum
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pump located outside of the hood through vacuum tubing. No mechanical stirring was
used during this step.
For freeze drying of nanoparticle batches under aseptic conditions, frozen
nanoparticle suspensions were placed inside a freeze drying flask and connected to the
freeze dryer through two glass stopcocks, as displayed in Figure 6.2. These stopcocks
were closed at all times unless the particles were under vacuum in which case all flow
would be going from the samples through the freeze dryer and out from the vacuum
pump. After the freeze drying cycle, both stopcocks were closed and the sample was
removed from the freeze dryer while still under vacuum. Vacuum was released inside a
laminar flow hood. Sterile freeze-dried particles were handled inside the laminar flow
hood whenever needed, and stored in a well sealed flask at -20°C.
6.2.4 Physiochemical Characterization of Nanoparticles
Nanoparticles were characterized with respect to batch yield, size, zeta potential,
morphology, and agent loading when applicable. The yield of each batch was determined
from the dry weight of the fraction of the nanoparticle suspension that was frozen and
freeze dried without cryoprotectant. For determination of size and zeta potential, and for
preparation of samples for scanning electron microscopy, approximately 20mg of
nanoparticles originally freeze dried with cryoprotectant (nanoparticle/trehalose blends)
were resuspended in 10 ml of water and centrifuged to remove excess trehalose. The
pellets were then resuspended in 500 l of water and diluted in the respective solvent as
described below. For size determination, nanoparticles were further diluted in deionized
water and sized by dynamic light scattering with a ZetaPlus® instrument (Brookhaven
Instrument Coorporation, Holtsville, NY, USA). Each batch was sized for 2 minutes.
Zeta potential was determined with this same instrument after dilution of the concentrated
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nanoparticle suspension with 1mM potassium chloride solution to make a 1 mg/ml
nanoparticle suspension. For each batch at least 10 readings of zeta potential were
averaged.
A Hitachi S-4500 field emission scanning electron microscope (SEM) was used
for observation of nanoparticle morphology and confirmation of nanoparticle size. After
removal of trehalose from freeze dried nanoparticles as described above, nanoparticle
suspensions in water were placed on top of a SEM stub covered with a conductive carbon
tab (Electron Microscopy Sciences, Hatfield, PA, USA) and allowed to dry at room
temperature. Samples were then sputter coated with gold plasma prior to imaging.
Transmission electron microscopy was also used to image the nanoparticles. A
sample of pre-dried nanoparticles suspended in water was applied to a 300 mesh copper
TEM grid with a carbon film. The sample was stained with uranyl acetate and rinsed
once before allowing it to dry at room temperature.
6.2.4.1 Determination of Agent Loading
For determination of the doxorubicin, rhodamine and ICG content within
nanoparticles, a known mass of dry nanoparticles was dissolved in a known volume of
dimethylsulfoxide (DMSO) at a concentration equal or lower than 1mg of nanoparticles
per milliliter. When necessary, the solutions were diluted in DMSO until the absorbance
of doxorubicin, rhodamine or ICG was within the standard curve for the specific agent in
DMSO. Samples were placed in quartz cuvettes and a Shimadzu UV-1201
spectrophotometer was utilized for reading their absorbance. The mass of the agent in
the sample was determined based on a standard curve of known concentrations of the
agent in DMSO. The loading, or weight percent of the agent in the nanoparticle
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formulation was determined by dividing the mass of the agent found by the mass of
nanoparticles that were dissolved.
6.2.4.2 In Vitro Agent Release
The release of doxorubicin and rhodamine from PLA-PEG-COOH nanoparticles
that had been conjugated with model antibodies or without antibodies was investigated.
A known mass of nanoparticles was suspended in phosphate buffered saline of pH 7.4 or
pH 6.0. These suspensions were maintained in the dark in poly(carbonate) centrifuge
tubes in a 37°C water bath. At specific time points, the samples were centrifuged for 1
hour at 19,000 rpm while maintaining the centrifuge rotor temperature at 35°C, and a
sample of the supernatant was removed for analysis.
For doxorubicin-loaded nanoparticles, nanoparticles were first suspended in 4 ml
of buffer. Since the concentration of doxorubicin was very low, samples of 100 l were
taken and no fresh buffer was added during the course of the experiment. Doxorubicin
samples were analyzed by fluorescence spectroscopy for determination of drug content
based on a standard curve in the appropriate buffer. A BioTek FLX 800 microplate
fluorescence reader was used for this purpose. Samples were excited with light of 484
nm and emission was read at 645 nm. Rhodamine-loaded nanoparticles were suspended
in 4 ml of PBS buffer pH 6.0 or 10 ml of PBS buffer pH 7.4. These samples were
analyzed by absorbance spectrophotometry.
6.2.4.3 Determination of Antibody Conjugation Efficiency
Detection and quantification of antibodies bound to the surface of the targeted
nanoparticles were carried out with the tetramethylbenzidine (TMB)-horseradish
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peroxidase assay, as described previously for PEGylated silica/gold nanoshells
conjugated to anti-HER2 antibodies (Lowery, Gobin et al. 2006). This assay is based on
the time-dependent oxidation of TMB under the enzymatic action of horseradish
peroxidase, which results in the formation of a blue soluble product (Josephy, Thomas et
al. 1982; Menegazzi, Zabucchi et al. 1992). As such, this sensitive assay is dependent on
the presence of the secondary antibody conjugated to the peroxidase enzyme, which in
turn is specific to the primary antibody that is to be quantified. This method is superior to
more commonly-used protein quantification techniques which are commonly less
sensitive and influenced by the presence of surfactants, ions, carbohydrates, and protein
contamination (Bradford 1976). The TMB assay permited visual inspection of the
reaction, and was able to detect concentrations of antibody as low as 0.3 ng/ml.
First, 10 mg of bovine serum albumin were dissolved in 1 ml of a nanoparticle
suspension of 1/8th of each batch in water and allowed to interact for 1 hour to block non-
specific sites. After 1 hour, 9 ml of 0.01 M PBS were added and the nanoparticles were
centrifuged for 30 minutes at 19,000 rpm. The nanoparticle pellet was resuspended by
pipetting in 450 l of 0.01 M PBS and 49 l of 0.51 g/l goat anti-mouse IgG-
horseradish peroxidase conjugate were added and allowed to react for 1 hour at room
temperature while shaking. A volume of 19 ml of 0.01 M PBS was added and the
nanoparticle suspension was centrifuged for 30 minutes at 43,600 x g. The supernatant
was removed and the particles were washed again with 10 ml of 0.01 M PBS.
The TMB substrate solution was prepared as suggested by the manufacturer: one
tablet of TMB was dissolved in 10 ml of 0.05 M phosphate/citrate buffer pH 5.0 and 2 l
of 30% hydrogen peroxide were added immediately prior to use. The nanoparticle pellet
was resuspended in 2 ml of 0.05 M phosphate/citrate buffer (pH 5.0) by pipetting. A
volume of 1l of this nanoparticle suspension was diluted in 99 l of buffer in 96 well
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plates and reacted with 100 l of TMB substrate solution. After 15 min of reaction, 50 l
of 4 N sulfuric acid were added to stop the reaction. The absorbance of the solution was
read a 450 nm and the amount of antibody present was determined based on a calibration
curve generated with known concentrations of goat anti-mouse IgG – horseradish
peroxidase antibody ranging from 0.3 to 20 ng/ml.
6.3 RESULTS
6.3.1 Preparation of Nanoparticles with PLA-PEG-COOH Copolymers
Preparation of nanoparticles was carried out by emulsification or
nanoprecipitation methods, as described previously for nanoparticles of poly(lactic-co-
glycolic acid) (PLGA) in Chapters 3 and 4. Clear differences were observed in the
colloidal suspension characteristics, including the significant size decrease, as will be
described in more detail later in this section, and improved stability of the colloids. Two
main variables had to be optimized for the production of nanoparticles with reproducible
yields and sizes: recovery and lyophilization.
6.3.1.1 Nanoparticle Recovery
During initial experiments, the recovery of the nanoparticles by centrifugation
was very low as a result of the small size of the particles. The size of the nanoparticles
was in average 170 nm before freeze drying, which is at least 40% smaller than that of
PLGA nanoparticles prepared with bovine serum albumin or poly(vinyl alcohol) as
surfactants, as reported in Chapters 3 and 4 (See Tables 3.1 and 4.2 for example). Per
Stokes’ Law applied to dilute suspensions of spherical particles, as described in Equation
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6.1, the rate of sedimentation (V) is proportional to the square of the size of the particles
(d), the square of the angular velocity of centrifugation (ω), the density difference
between the particles (ρs) and the liquid medium in which they are suspended (ρl), and the
radius of rotation of the centrifugation system (r), while being inversely proportional to












Since the size of the PLA-PEG particles decreased by a factor of 0.6 compared to
PLGA nanoparticles, the velocity of sedimentation was effectively reduced to 36% of
that of PLGA nanoparticles under the same centrifugation conditions. Consequently, it
was necessary to increase the time of centrifugation by at least 3.8 fold, from 10 to 38
minutes, to achieve the same trajectory along the centrifugation tube. In addition, since
the poly(ethylene glycol) chains were expected to form a hydrophilic brush along the
surface of each particle, it was expected that the actual speed of sedimentation would be
even lower as a result of increased friction or interaction between the particle surface and
the liquid medium. A centrifugation time of 1 hour was finally selected to minimize loss
of mass during the repeated wash steps that the nanoparticles were subjected to. Size
analysis of the particles remaining in the supernatants even after 1 hour of centrifugation
suggests that particles of size in the range of or smaller than 110 nm were not
successfully recovered.
6.3.1.2 Effect of Copolymer Molecular Weight on Nanoparticle Size
The effect of copolymer molecular weight on the size of the particles and
recovery was also studied. Since PEG of constant molecular weight was used to initiate
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the polymerization of the copolymers, increased copolymer molecular weight was
dependent on larger poly(lactic acid) (PLA) domains and increased PLGA to PLA ratio.
As is displayed in Figure 6.3A, and although most of the data points are not statistically
significantly different, the size of the nanoparticles, both in the centrifuged pellet and
remaining in the supernatants after centrifugation, appeared to follow an almost-linear
increasing trend with increasing theoretical molecular weight. At the same time, the
mass of dried supernatants, which includes 100 mg of poly(vinyl alcohol), decreased with
increased copolymer theoretical molecular weight, suggesting that particles were more
efficiently sedimented as a result of their larger size. Figure 6.3B shows an image of the
nanoparticle suspension and the combined particle-laden supernatants for the same batch.
It is important to note that the theoretical molecular weight of the copolymers (24,500 to
53,400 g/mol) was, in all cases, larger than the number average molecular weight
measured by gel permeation chromatography (12,350 to 35,500 g/mol) although they
followed the same increasing trends.
6.3.1.3 Effect of Cryoprotectant on Nanoparticle Reconstitution
Trehalose was used for cryoprotection of the nanoparticles during freezing and
lyophilization (freeze drying). Studies were performed to determine the optimal
concentration of nanoparticles and trehalose, and the optimal freezing temperature that
would best protect the nanoparticles from aggregation. Table 6.1 summarizes the effect
of these variables on the ratio of the size of the particles before and after freeze drying.
As shown, particles dried without a cryoprotectant (trehalose/NP ratio of 0/1) aggregated
so significantly that the particles could not be sized regardless of the nanoparticle
concentration or freezing temperature. Qualitatively, particle aggregates of up to several
hundreds of microns were observed by visual inspection for most of these batches. With
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inclusion of trehalose at a ratio of 0.25/1 to nanoparticles, the size ratio decreased to
between 1.8 and 60 depending on the concentration of the particles and the freezing
temperature. As the ratio of the mass of trehalose to the mass of nanoparticles in the
formulation was increased from 0.25 to 2, the size of the dried particles decreased to
nearly that of the pre-lyophilized particles. No further improvement was observed with
trehalose concentrations greater than 2 or 4 times that of the nanoparticles, as is
graphically displayed in Figure 6.4.
The influence of the nanoparticle concentration on the final size of the particles
was determined to not be nearly as significant as the amount of trehalose, at least within
the concentration range tested. For the lowest nanoparticle concentrations tested (7.5 and
10 mg/ml), the size ratio was greater than 1.2 for all trehalose/nanoparticle. The best
nanoparticle reconstitution was achieved with a nanoparticle concentration of 12.5 mg/ml
for all nanoparticle/trehalose ratios.
The data in Table 6.1 also suggested that freezing the particles in a -80°C freezer
resulted in less particle aggregation at the lower trehalose concentrations, contrary to
what other authors have reported (de Jaeghere, Allemann et al. 2000). It is possible that
the containers on which the particles were frozen could have had an impact in the actual
rate of freezing regardless of the temperature. When being frozen in liquid nitrogen,
particle suspensions were put into polypropylene cryogenic tubes that are designed to be
used for cryopreservation of cells, while particles frozen at -80°C were put in borosilicate
glass containers. Glass has a higher coefficient of thermal conductivity than the polymer,
which could result in better heat transfer from the samples frozen in these the borosilicate
glass vials and consequently in a more favorable rate of freezing. Based on these data, a
nanoparticle concentration of 12.5 mg/ml with a trehalose-to-nanoparticle mass ratio of
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4/1 and a freezing temperature of -80°C was selected for safe freezing and drying of the
PLA-PEG nanoparticles.
6.3.2 Physiochemical Characteristics of PLA-PEG-COOH Nanoparticles
Table 6.2 summarizes some of the characteristics of PLA-PEG-COOH
nanoparticles that were prepared, including those without an agent (blank), and those
loaded with doxorubicin (DOX), rhodamine 6G (RHO), and indocyanine green (ICG).
Three types of antibodies were utilized in the preparation of some of these batches.
Mouse IgG was used as a model antibody for optimization of antibody binding protocols
and also as a control. A number of batches of nanoparticles were prepared by adsorbing
or conjugating this antibody. When adsorbing the antibody, nanoparticles were not
activated with EDC and NHS, but just incubated with the antibody under the same
conditions in which the antibody conjugations were carried out. The antibody mAb106-
105 was used as the targeting agent as it is specific to the extracellular domain of the
FSHR receptor. The IgG2b antibody was used as an isotype control for mAb106-105.
These two later antibodies were only conjugated to the nanoparticles, not adsorbed. It
should be noted that only two batches of blank and DOX-loaded nanoparticles with
mAb106-105, two batches of blank nanoparticles with IgG2b, and one batch of DOX-
loaded particles with IgG2b were prepared because of the availability or cost of these
antibodies.
The percent recovery, or yield achieved was in the range of 35 to 73%, which is
still lower than that achieved previously with PLGA nanoparticles. Recovery of blank
nanoparticles with antibodies, DOX-loaded nanoparticles, RHO-loaded nanoparticles or
ICG-loaded nanoparticles was not statistically different from that of blank nanoparticles
without antibody. Longer centrifugation times or faster centrifugation speed would have
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improved recovery; however, this was not possible because the Beckman J2-21
centrifuge was already being used at its maximum rated speed, and the already-extended
centrifugation times appeared to be causing mechanical problems in this instrument.
The size of the nanoparticles prepared with poly(vinyl alcohol) as surfactant
(blank, DOX-loaded and RHO-loaded particles) was consistently in the range of 140 -
190 nm and not statistically different from that of blank nanoparticles without antibody
before freeze drying. ICG nanoparticles, which were prepared with sodium cholate as the
surfactant, were significantly smaller. Most batches aggregated to between 1.2 and 2
times the initial size after freeze drying despite the use of the optimized freeze drying
conditions that were described previously. RHO-loaded nanoparticles with conjugated
IgG appeared to be almost 5 times as big as pre-dried nanoparticles. It is important to
note, however, that nanoparticle batches to which antibodies had been adsorbed or
conjugated were resuspended by pipetting instead of sonication prior to freeze drying.
This could have resulted in incomplete nanoparticle resuspension in the cryoprotectant
solution, and consequently in less than optimal freeze drying conditions. Also, it is worth
noting that the preliminary studies of optimization of nanoparticle freeze drying
conditions were performed in a smaller scale (~1 ml samples) while the batches presented
in Table 6.2 were at least 4 times larger. The increased sample size could have had a
negative impact on the speed of sample freezing, possibly allowing the separation of the
components and formation of trehalose-free nanoparticle-rich pockets which would have
led to particle aggregation.
No significant difference was observed in the morphology or surface
characteristics of the particles with the different loaded agents or types of antibodies, as
can be seen from scanning electron microscopy (SEM) images on Figures 6.5, 6.6, 6.7
and 6.8 for blank, doxorubicin-loaded, rhodamine-loaded and indocyanine green-loaded
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nanoparticles, respectively. SEM images of the batches in fact revealed the presence of
polymer aggregates, as shown for doxorubicin-loaded nanoparticles in Figure 6.6A.
However, these were far less numerous than the spherical nanoparticles that were all
around them when the magnification was increased, as seen in Figure 6.6B for the same
batch. Transmission electron microscopy images, as shown on Figure 6.9, confirm the
spherical shape of the particles. Both scanning and electron microscopy images suggest,
however, that the actual nanoparticle size is closer to 100 nm as opposed to 170 nm, as
measured with the ZetaPlus instrument. This is expected since this instrument reports an
effective diameter that is influenced by the diameter of the larger polymeric aggregates,
despite the fact that they are significantly outnumbered by the small nanoparticles.
The zeta potential of all batches, similarly to the size of the particles, was
determined to be mainly influenced by the type of surfactant used. All batches prepared
with poly(vinyl alcohol), including those loaded with agents and with or without
antibodies, were in the range of -5 to -12 mV, and not statistically different from blank
nanoparticles without antibody. ICG nanoparticles, prepared with sodium cholate, had a
more charged surface with a statistically different average of -15 mV. This is expected as
sodium cholate is an anionic surfactant derived from cholesterol.
6.3.3 Encapsulation of Chemotherapeutic and Imaging Agents
Loading of chemotherapeutic and imaging agents, as seen in Table 6.3, was very
different to that previously observed with PLGA nanoparticles. The calculated
doxorubicin loading was of only about 7% the desired amount regardless of antibody
conjugation, with an average loading of 0.2 wt.%. In comparison, the loading achieved
with PLGA nanoparticles was of about 80% of the desired amount at similar targeted
loadings, as presented in Table 3.2 of Chapter 3. Most of the drug partitioned to the
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water phase of the suspension upon nanoparticle precipitation and was subsequently
removed in the first few supernatants. Figure 6.10, however, shows how after the first
two or three washes the drug that had been encapsulated within the particles remained
entrapped instead of continuously leaching from them, as can be seen from the clear
doxorubicin color contrast between the pellet to that the supernatant.
Encapsulation of rhodamine similarly was reduced compared to that achieved in
PLGA nanoparticles. For the same targeted loading of 0.3 wt.%, the calculated loading
was 0.29 wt. % in PLGA nanoparticles compared to a maximum of 0.2 wt.% in PLA-
PEG nanoparticles. In addition, rhodamine appeared to continue leaching from the
particles as these were exposed to aqueous media during conjugation of antibodies, thus
resulting in a significantly lower loading of less than half that achieved without antibody
conjugation.
Possible reasons for the reduction in encapsulation efficiencies include the
reduction in nanoparticle size which significantly increases the surface area in contact
with the aqueous medium and available for agent diffusion. On the other hand, an ionic
interaction between the basic doxorubicin and the carboxylic acid groups of PLGA had
been hypothesized in Chapter 3. In PLA-PEG-COOH nanoparticles the carboxylic acid
end group is no longer associated with the core of the nanoparticles, but rather with the
terminal end of the surface brush-like PEG shell. Consequently, any such interaction
between doxorubicin and the polymer would have been lost. A similar theory could be
applied to rhodamine 6G which also contains a positively-charged protonated amine
group at physiological pH, as can be seen from Figure 4.1A in Chapter 4.
Loading of indocyanine green into PLA-PEG-COOH nanoparticles, on the other
hand, improved compared to that achieved with PLGA nanoparticles prepared with
identical protocols. Specifically, for the same targeted loading of 9.1 wt.%, PLGA
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nanoparticles were able to encapsulate only an average of 0.1 wt.% as shown on Table
4.3 of Chapter 4. PLA-PEG nanoparticles, on the other had, were able to encapsulate one
order of magnitude more ICG. It is possible that the increased hydrophilicitiy of the
nanoparticles as a result of the incorporation of PEG provided sufficient drive for such
different partitioning of ICG between the organic polymeric phase and the outer aqueous
phase.
6.3.4 In Vitro Release of Chemotherapeutic and Imaging Agents
The release of doxorubicin and rhodamine 6G from PLA-PEG–COOH
nanoparticles was investigated. Figure 6.11 shows the release profile obtained for
doxorubicin-loaded particles at physiological and acidic pH. As observed, an initial burst
release of only 10% of the drug was observed within the first three hours in both
conditions. After this, the release occurred at a nearly-constant rate for up to 4 days. No
significant differences were observed in the release of the drug in the different pH buffers
during the first 20 hours of release. Afterwards, statistically significant differences were
observed at the two pH values, with the drug releasing slightly faster at pH 7.4.
Results are very different from those obtained with PLGA nanoparticles, as
described in Section 3.4.3 and displayed in Figure 3.2 of Chapter 3. The release from
PLGA particles occurred at a significantly higher rate and was highly influenced by pH.
At pH 7.4, almost 50% of the drug had been released from PLGA nanoparticles within
one day, while less than half of that was released from PLA-PEG-COOH nanoparticles.
In pH 4.0, release from PLGA nanoparticles occurred very fast, with about 70% of the
drug being released within the first hour and about 93% during the first day. The release
rate from PLA-PEG-COOH nanoparticles at pH 6.0 cannot, however, be directly
compared to that of PLGA nanoparticles which was studied at pH 4.0. Nonetheless, the
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pH dependency of drug release from PLA-PEG-COOH nanoparticle appears to be less
significant.
In Chapter 3, the dependence of release on pH was suggested to be associated
with the interaction between the deprotonated carboxyl end groups of PLGA and the
protonated amine group of doxorubicin. As the pH was lowered, the carboxyl groups
would become protonated and the charge attraction between the polymer and the drug
would have been lost, thus permitting diffusion of the drug from the particles. With the
PLA-PEG-COOH nanoparticles, and as discussed above for the loading capacity of these
particles, the carboxyl groups are no longer present in the core of the particles but rather
on the surface at the terminal end of the PEG chains. Consequently, no such charge
attraction occurs and changes in pH do not affect the release of the drug so significantly.
Figure 6.12 shows the time release of rhodamine 6G from PLA-PEG
nanoparticles. Differences are observed in the release of rhodamine from particles
conjugated to antibodies compared to those that did not have antibody at physiological
pH. It is possible that more rapid release of the agent from particles without antibodies is
caused by the higher loading of rhodamine in these particles. As mentioned earlier,
rhodamine was observed to continuously leach out of the particles during all activation,
conjugation and purification steps, thus leading to lower rhodamine content in the
particles than in those that were not subjected to these steps. The loading was of 0.093
and 0.204 wt.% rhodamine in particles conjugated to antibody and without antibody,
respectively.
The release of rhodamine from PLA-PEG-COOH particles at pH 7.4 was
significantly faster than the release from PLGA nanoparticles which is summarized in
Figure 4.4 and discussed on section 4.3.1 of Chapter 4. Within the first 2 hours, between
40 and 50% of the agent was released from PLA-PEG-COOH nanoparticles, while less
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than 5% had been released from PLGA particles (Figure 4.4). Within 4 days, almost 90%
of the rhodamine was released from PLA-PEG-COOH particles, while only 30 to 45%
had been released from PLGA particles.
The rate of release of rhodamine from the same batch of PLA-PEG nanoparticles
conjugated to mouse IgG at pH 6 was found to be faster than at pH 7.4, with an initial
release of approximately 55% of the drug during the first 2 hours and 96% within 3 days.
From this release behavior and the fact that the agent was observed to continue leaching
during all preparation steps, it is possible that rhodamine was associated with the surface
and consequently with the PEG shell. As such, as the pH was lowered to 6.0, the charge
attraction between the positively-charged amine group of rhodamine and the carboxyl
groups of PLA-PEG-COOH would have lost some affinity, thus resulting in the moderate
release rate increase observed.
6.3.5 Conjugation of Antibodies to the Nanoparticles
An Elisa-based assay was used for the determination of antibody binding to
nanoparticles. A secondary antibody conjugated to horseradish peroxidase was reacted
with nanoparticles that had antibodies either adsorbed to their surface or conjugated to
the terminal hydroxyl groups of PEG. The oxidation of TMB into a soluble blue
compound, mediated by horseradish peroxidase, was used to determine the amount of
primary antibody associated with the nanoparticles. Figure 6.13 shows the result of
control experiments on the attachment of mouse IgG to blank nanoparticles. In the
presence of no primary antibody, the adsorption of secondary antibody and resulting
TMB oxidation was low. Blank nanoparticles to which IgG was adsorbed instead of
conjugated showed no significant difference compared to nanoparticles with no primary
antibody. Nanoparticles to which IgG was conjugated, on the other had, showed clear
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incorporation of the antibody, with an average of 319 ng attached per milligram of
nanoparticles, which is equivalent to a 23% incorporation efficiency based on the 50 g
of antibody that were used for conjugation to each batch of nanoparticles.
Figure 6.14 shows the results of conjugation of antibodies on blank, doxorubicin-
and rhodamine-loaded nanoparticles. As presented, no difference was observed in the
attachment of mouse IgG between blank, doxorubicin- or rhodamine-loaded
nanoparticles. However, conjugation of the isotype control IgG2b antibody and the anti-
FSHR mAb106-105 antibody to blank and doxorubicin-loaded nanoparticles was less
effective. Possible reasons could be differences in the quality of the primary antibodies
or dissimilar interaction between these primary antibodies and the secondary horseradish
peroxidase conjugated antibody. Nonetheless, conjugation of these antibodies is clear
compared to nanoparticles with no antibodies or with adsorbed primary antibody.
It is important to note that no interference from the absorption of doxorubicin or
rhodamine was observed. Doxorubicin absorbs light in the range of 480 to 550 nm, with
peak absorption at 480 nm. Rhodamine absorbs from 475 to 550 nm, with peak
absorption at 520 nm. As shown on Figure 6.15 for doxorubicin-loaded nanoparticles,
the concentration of nanoparticles that was used for quantification of the antibody was
too low for the absorption of the loaded agent to be detected and, consequently, for it to
interfere with the quantification of the antibody. Equivalent results were obtained with
rhodamine-loaded nanoparticles.
The number of antibodies per individual nanoparticle was calculated based on the
mass ratio of antibody-to-nanoparticle shown on Figure 6.14 and the mass of a single
nanoparticle. Using a nanoparticle density of 1.27 g/ml, based on poly(lactic acid), the
mass of a nanoparticle was calculated for three different average nanoparticle sizes: 100,
200 and 300 nm. Table 6.4 displays the average number of antibody molecules per
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nanoparticle. The number of antibodies per particle increases with the third power of the
nanoparticle diameter. With decreasing nanoparticle size, the number of nanoparticles
per batch increases drastically. Consequently, even small changes in nanoparticle size
result in significant variations in the number of antibodies per nanoparticle. For
nanoparticles of size below 100 nm, the antibody conjugated would not be enough for
each particle to present one on its surface. However, for particles of 200 nm in average,
from 2 to 7 antibodies could have been bound per nanoparticle, depending on antibody
incorporation efficiency. Since the average size of nanoparticles before freeze drying
was in the range of 150 to 200 nm, as determined by dynamic light scattering and
presented in Table 6.2, the average number of antibodies bound per nanoparticle was in
the range of 1 to 7 molecules. Although the use of higher amounts of antibody in the
conjugation would have resulted in better modification of the nanoparticles, this was not
possible as a result of monoclonal antibody availability.
6.4 CONCLUSIONS
This Chapter describes the preparation of nanoparticles using amphiphilic
copolymers of poly(lactic acid) and poly(ethylene glycol). Use of these copolymers was
identified as the best method for incorporation of poly(ethylene glycol) on the surface of
the nanoparticles in Chapter 5. Here, the preparation of PEGylated nanoparticles
incorporating surface-bound antibodies for the targeted delivery of chemotherapeutic and
imaging agents is reported.
Three main variables were optimized in the preparation of these nanoparticles:
recovery, freeze drying conditions and antibody conjugation. Recovery of nanoparticles
was achieved by increasing centrifugation time to account for decreased nanoparticle size
and dynamic surface layer. Aggregation of nanoparticles induced by freeze drying
224
processes was minimized with the use of trehalose as a cryoprotectant. Trehalose
minimizes mechanical stresses on the particles as a result of crystallization of water and
PEG on the surface of the nanoparticles by creating hydrogen bonds with PEG and
forming an amorphous matrix around the particles. Antibody conjugation was carried out
by activation of terminal carbolxylic acid groups on the surface of the nanoparticles using
carbodiimide chemistry. Conjugation of antibodies to the activated nanoparticles with up
to 30% incorporation efficiency was confirmed with an Elisa-like assay.
Encapsulation of the chemotherapeutic agent doxorubicin and the imaging agents
rhodamine 6G and indocyanine green within PEGylated nanoparticles was investigated
and compared to the results previously described with PLGA nanoparticles in Chapters 3
and 4. Clear differences were observed in the encapsulation capacity of the PEGylated
nanoparticles. Doxorubicin was encapsulated at a significantly lower loading, but the
release of this drug was better controlled at an almost linear rate over a period of 4 days
with a minimal burst of 10% during the first three hours. Rhodamine was also loaded
less efficiently but also appeared to be released from the particles at a faster rate than
from PLGA nanoparticles. Indocyanine green, on the other hand, was encapsulated
better in PEGylated nanoparticles compared to PLGA particles. Differences in loading
capacity and release profiles were suggested to be caused mainly by the decreased
particle size and the loss of agent-polymer charge attractions as a result of the relocation
of terminal carboxyl groups from the core in PLGA nanoparticles to the outer surface of
the particles in the PEGylated counterparts. The effect of loading and release parameters,
PEGylation and targeting antibody presentation on the surface of these nanoparticles on
their interaction with cancer cells is described in Chapter 7.
225
Table 6.1 Optimization of cryoprotection for PLA-PEG nanoparticles. *Size too large













0/1 178 * *
0.25/1 168 308 1.8
0.5/1 168 252 1.5
1/1 168 208 1.2
2/1 168 201 1.2
5/1 178 208 1.2
10/1 178 205 1.2
0/1 178 * *
0.25/1 168 1,557 9.3
0.5/1 168 386 2.3
1/1 168 343 2.0
2/1 168 279 1.7
5/1 178 251 1.4
10/1 178 225 1.3
0/1 171 * *
0.25/1 180 759 4.2
0.5/1 180 252 1.4
1/1 180 263 1.5
2/1 180 203 1.1
4/1 171 179 1.0
8/1 171 203 1.2
0/1 171 237 1.4
0.25/1 180 1,426 7.9
0.5/1 180 2,639 14.7
1/1 180 5,603 31.1
2/1 180 204 1.1
4/1 171 270 1.6
8/1 171 198 1.2
0/1 173 * *
0.25/1 170 10,280 60.4
0.5/1 170 288 1.7
1/1 170 375 2.2
2/1 170 222 1.3
4/1 173 161 0.9
8/1 173 169 1.0
0/1 173 2,044 11.8
0.25/1 170 2,678 15.7
0.5/1 170 1,903 11.2
1/1 170 407 2.4
2/1 170 209 1.2
4/1 173 182 1.1














TABLE 6.2 Characteristics of PLA-PEG nanoparticles (NPs). Abbreviations: poly(vinyl
alcohol) (PVA), sodium cholate (SC), doxorubicin (DOX), rhodamine 6G























Blank NPs No Antibody 0 PVA 57 ± 19 184 ± 30 305 ± 110 -9.9 ± 3.0
IgG Adsorbed 50 PVA 58 ± 12 176 ± 49 243 ± 18 -8.8 ± 4.0
IgG Conjugated 50 PVA 47 ± 14 175 ± 35 280 ± 57 -9.1 ± 3.2
mAb106-105 Conjugated 50 PVA 40 ± 17 138 ± 14 250 ± 46 -12.2 ± 3.4
IgG2b Conjugated 50 PVA 35 ± 4 151 ± 16 268 ± 59 -7.3 ± 1.0
DOX NPs No Antibody 0 PVA 64 ± 9.8 152 ± 5 312 ± 60 -7.5 ± 1.7
IgG Conjugated 50 PVA 69 ± 10 164 ± 9 218 ± 33 -8.6 ± 1.1
mAb106-105 Conjugated 50 PVA 63 ± 12 156 ± 6 301 ± 55 -5.6 ± 0.7
IgG2b Conjugated 50 PVA 78 161 289 -12.9
RHO NPs No Antibody 0 PVA 39 ± 8 160 ± 7 191 ± 5 -8.7 ± 0.2
IgG Conjugated 50 PVA 55 ± 10 191 ± 35 922 ± 161 -6.9 ± 1.7
ICG NPs No Antibody 0 SC 39.3 ± 7 139 ± 4 191 ± 19 -15.7 ± 5.0
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Table 6.3 Loading of chemotherapeutic and imaging agents within PLA-PEG-COOH













DOX NPs No Antibody 2.9 0.22
IgG Conjugated 2.0 0.20 ± 0.02
IgG Conjugated 2.9 0.18 ± 0.03
mAb106-105 Conjugated 2.9 0.23 ± 0.07
IgG2b Conjugated 2.9 0.2
RHO NPs No Antibody 0.2 ± 0.017
IgG Conjugated 0.09 ± 0.004
ICG NPs No Antibody 9.1 1.2 ± 0.158
0.3
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Table 6.4 Molecules of mouse IgG, mAb106-105 and IgG2b isotype antibodies bound
per individual nanoparticle as a function of nanoparticle size for blank and
doxorubicin-loaded nanoparticles. Data are based on the wt. % content of
antibodies in the nanoparticles, as calculated with the TMB assay, and using
a particle specific gravity of 1.27.
NP Size
(nm)
Blank DOX Blank DOX Blank DOX
100 0.78 0.89 0.24 0.46 0.33 0.30
200 6.23 7.14 1.92 3.69 2.67 2.39
300 21.03 24.08 6.49 12.45 9.01 8.06
Number of Antibody Molecules per Nanoparticles
IgG mAb106/105 IgG2b
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Figure 6.1 Schematic of chemical route for conjugation of antibodies to the surface of
poly(lactic acid)-co-poly(ethylene glycol) (PLA-PEG-COOH)
nanoparticles. Carboxylic acid groups on the terminal end of surface-
exposed PEG were activated to NHS esters using carbodiimide chemistry






Figure 6.2 Setup utilized for freeze drying of sterile nanoparticles. Red stopcock
valves were closed at all times unless the system was under vacuum which
assured one-directional flow from the sample to the freeze dryer. Valves
were closed and removed from the freeze dryer while maintaining the


















































Figure 6.3 (A) Effect of copolymer molecular weight on the size of the PLA-PEG
nanoparticles, the size of the particles remaining on the supernatants of
centrifugation, and the mass of dried combined supernatants (which includes
100 mg of surfactant). (B) Image of final nanoparticle suspension (left) and
combined supernatants (right) for batch prepared with copolymer of 53,400
g/mol molecular weight. Each batch was prepared with 100 mg of






















7.5 mg/ml NP, -80C
7.5 mg/ml NP, -196C
10mg/ml NP, -80C
10 mg/ml NP, -196C
12.5 mg/ml NP, -80C
12.5 mg/ml NP, -196C
15 mg/ml NP, -80C
15 mg/ml NP, -196C
Figure 6.4 Effect of the mass ratio of D-trehalose to nanoparticles (NP) on the size of
freeze dried particles. The y axis represent the ratio of the size of the
particles after being freeze dried compared to the pre-dried size. As the
ratio of trehalose to nanoparticles increases from 0.25 to 2.0, the size of the
particles nears the pre-dried size (size ratio closer to 1). No further
improvement was observed with trehalose/NP ratios greater than 2.
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Figure 6.5 Scanning electron images of blank PLA-PEG-COOH nanoparticles. (A)
Nanoparticles that were activated with EDC/NHS but not conjugated to an
antibody. (B) Nanoparticles with adsorbed mouse IgG. (C) Nanoparticles





Figure 6.6 Scanning electron images of doxorubicin-loaded PLA-PEG-COOH
nanoparticles. (A and B) Images of batch of particles conjugated to anti-
FSHR antibody mAb106-105. Image at low magnification shows the
presence of polymeric aggregates (A), which are numerically insignificant
compared to the smaller particles observed at high magnification (B). (C)
Nanoparticles conjugated to isotype control antibody IgG2b. (D)




Figure 6.7 Scanning electron microscopy images of rhodamine 6G-loaded PLA-PEG-
COOH nanoparticles.
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Figure 6.8 Scanning electron microscopy image of PLA-PEG-COOH nanoparticles
loaded with indocyanine green.
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Figure 6.9 Transmission electron microscopy images of blank PLA-PEG-COOH







Figure 6.10 Image of doxorubicin loaded nanoparticle pellet and supernatant showing





















DOX PLA-PEG-IgG NPs - pH 7.4
DOX PLA-PEG-IgG NPs - pH 6.0
Figure 6.11 In vitro release of doxorubicin from PLA-PEG-IgG nanoparticles at
physiological and acidic pH. Error bars represent the standard deviation
















PLA-PEG NPs - pH 7.4
PLA-PEG-IgG NPs - pH 7.4
PLA-PEG-IgG NPs - pH 6.0
Figure 6.12 In vitro release of rhodamine from PLA-PEG nanoparticles without
antibody or conjugated to mouse IgG as a model antibody at physiological
(pH 7.4) or acidic conditions (pH 6.0). Y bars represent the standard


























































Mass Antibody / Mass NPs
Antibody Incorporation
Figure 6.13 Efficiency of conjugation of mouse IgG as a model antibody on PLA-PEG-
COOH nanoparticles. Data are displayed as mass of antibody conjugated
per mass of nanoparticles and as percent antibody incorporated out of that














































Blank NPs - No Antibody
Blank NPs - mAb106-105
DOX NPs - mAb106-105
Blank NPs - IgG2b
DOX NPs - IgG2b
Blank NPs - IgG
DOX NPs - IgG
RHO NPs - IgG
Figure 6.14 Conjugation of antibodies to blank, doxorubicin- and rhodamine-loaded
















































DOX NPs + TMB
DOX NPs
Figure 6.15 Absorbance spectra of doxorubicin-loaded nanoparticles conjugated to anti-
FHSR mAb106-105 antibody (black) and of the same batch of nanoparticles
at the same concentration after reaction with TMB for antibody
quantification. The nanoparticle concentration is too low for the absorption
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CHAPTER 7
IN VITRO CELLULAR EVALUATION OF TARGETED
NANOPARTICLES
7.1 INTRODUCTION
Three cells lines were used as in vitro models for the evaluation of targeted
nanoparticles. The main criteria used for screening of these cell lines were expression of
the follicle stimulating hormone receptor (FSHR) and sensitivity or resistance to
chemotherapeutic agents such as doxorubicin. The cell lines chosen are described below.
7.1.1 Ovarian Cancer Cell Line NIH:OVCAR-3
OVCAR-3 cells are epithelial, adherent cells isolated in 1982 from the ascites of a
60-year old Caucasian female patient with poorly differentiated ovarian adenocarcinoma
(Hamilton, Young et al. 1983). This cell line grows in tightly interconnected colonies in
culture and is known to express androgen and estrogen receptors (Hamilton, Young et al.
1983). This cell line is known to be resistant to clinically chemotherapeutic drugs
including doxorubicin, cisplatin and melphalan at clinically-relevant concentrations of
0.03, 0.15 and 1.5 g/ml, respectively (Hamilton, Young et al. 1983). These
concentrations of chemotherapeutic agents are equivalent to 10% of the achievable peak
plasma levels of doxorubicin and cisplatin, and 3-fold more than the maximum
achievable plasma levels for melphalan. This cell line is one of the 60 human cancer cell
lines used by the National Cancer Institute to screen new anti-cancer drugs (Nishizuka,
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Charboneau et al. 2003) and has been suggested to be an appropriate model system for
the study of drug resistance in ovarian cancer.
OVCAR-3 cell line has been previously shown to express high levels of the
follicle stimulating hormone receptor by Southern immunoblot analysis and high levels
of FSHR mRNA by RT-PCR (Choi, Choi et al. 2004; Choi, Choi et al. 2006). This cell
line has also been shown to overexpress EGFR, K-Ras, HER-2/neu and c-myc oncogenes
(Choi, Choi et al. 2006).
7.1.2 Ovarian Cancer Cell Line Caov-3
Caov-3 cells are ovarian adenocarcinoma adherent cells of epithelial morphology
derived from a 54-year old caucasian female (ATCC). This cell line is known to be
sensitive to doxorubicin treatment (Fan, Twu et al. 1998; Sugiyama, Imai et al. 2005).
Reports of FSHR expression levels in Caov-3 cells in the literature have been
contradicting: Choi, et al., reported in 2004 that this cell line had high levels of the FSHR
protein at the translational level similar to OVCAR-3 cells by immunoblot, although the
data was not shown (Choi, Choi et al. 2004). The same group in 2006 reported that the
mRNA transcriptional level of FSHR produced by Caov-3 cells was less than 10% of that
of OVCAR-3 cells and SKOV-3 cells as determined by real-time PCR (Choi, Choi et al.
2006). According to an email discussion with Dr. K. C. Choi, the discrepancy could be a
result post-transcriptional regulation of FSHR, different culture conditions of Caov-3
during the studies, and of the quality of the anti-FSHR antibody used in their
investigation (Choi 2007). The antibody used by this group is the same mAb106-105
monoclonal antibody developed by the group of Dr. James Dias at the Wadsworth Center
(Albany, NY) that was utilized in the research presented here as a targeting agent for
delivery of nanoparticles to ovarian cancer cells.
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7.1.3 Breast Cancer Cell Line MDA-MB-231
MDA-MB-231 cells are epithelial adenocarcinoma cells derived from pleural
effusion of a 54-year old Caucasian female (Cailleau, Young et al. 1974; Cailleau, Olive
et al. 1978). As reported in previous accounts, FSHR expression is limited to cells of
ovarian origin (Richards and Midgley 1976; Kangasniemi, Kaipia et al. 1990; Simoni,
Gromoll et al. 1997; Meduri, Charnaux et al. 2002). Consequently, this cell line was used
as a control for studying the interaction of the targeted nanoparticles with cells not
expressing the target receptor. This cell line is also one of the 60 human cancer cell lines
used by the National Cancer Institute for screening of new anti-neoplastic drugs
(Nishizuka, Charboneau et al. 2003). This cell line is known to be sensitive to
doxorubicin treatment (Smith, Watson et al. 2006; Betancourt, Brown et al. 2007; Pero,
Shukla et al. 2007).
7.2 METHODS
7.2.1 Materials
The reagent 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) and formaldehyde (37%, formalin) were obtained from Sigma-Aldrich (Saint
Louis, MO, USA). Ethylenediamine-tetraacetic acid (EDTA) and dimethylsulfoxide
were purchased form Fisher Scientific (Waltham, MA, USA). Sodium azide was
obtained from ACROS Organics.
Blank or doxorubicin-loaded poly(lactic acid)-co-poly(ethylene glycol) (PLA-
PEG) nanoparticles with or without conjugated antibodies were prepared and
characterized as described in Chapter 6. Blank or doxorubicin-loaded poly(lactic-co-
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glycolic acid) (PLGA) nanoparticles with no targeting antibodies were prepared and
characterized as described in Chapter 3.
7.2.2 Cell Culture
Ovarian cancer cell lines were obtained from American Type Tissue Culture
(Manassas, VA, USA) while the MDA-MB-231 cell line was generously provided by Dr.
Suranganie Dharmawardane, formerly from the School of Biological Sciences of The
University of Texas at Austin. Caov-3 and MDA-MB-231 cells were cultured with
Dulbecco’s Modified Eagle’s Medium (DMEM, Mediatech, Manassas, VA, USA)
supplemented with 10% fetal bovine serum (Tissue Culture Biologicals, Tulare, CA,
USA), 10 mM HEPES buffer (Gibco, Carlsbad, CA, USA) and 1%
penicillin/streptomycin. NIH-OVCAR-3 cells were grown in RPMI medium
(Mediatech, Manassas, VA, USA) supplemented with 20% fetal bovine serum, 10 mM
HEPES buffer, 1% penicillin/streptomycin, and 0.01 mg/ml bovine insulin (Sigma, Saint
Louis, MO, USA). Cells were grown in T75 flasks in an incubator at 37°C and 5% CO2
atmosphere.
7.2.3 Determination of Target Receptor Expression by Cell Lines
The relative expression levels of the follicle stimulating hormone receptor
(FSHR) was determined on ovarian cancer cell lines Caov-3 and NIH:OVCAR-3. Breast
cancer cell line MDA-MB-231 was used as a control. For determination of FSHR
expression an immunocytochemical study was carried out. Cells were grown in T-75
flasks to near confluency, washed twice with 5 ml of DPBS without calcium or
magnesium ions (referred to as DPBS throughout this section), and once with a solution
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of 2mM EDTA in DPBS. Cells were then detached by incubation in EDTA solution.
Detached cells of each cell line were transferred to six separate 15-ml conical tubes at a
concentration of 300,000 cells per tube, centrifuged for 5 minutes at 500 x g to remove
EDTA and incubated at 4°C for 30 minutes in 1 ml of 5% goat serum (SIGMA, St. Louis,
Missouri, USA) in DPBS with 0.02% sodium azide (DPBS-SA) to block non-specific
sites. The presence of sodium azide prevents modification of the antibody-antigen
complex after recognition and binding.
Cells were then centrifuged and resuspended in 200 l of a solution of the
primary antibody mAb106-105 from murine origin (IgG2b isotype, generously provided
by Dr. James Dias from the Wadsworth Center, Albany, NY) at a concentration of 2.5
g/tube, mouse IgG2b (SIGMA, Saint Louis, Missouri, USA) as an isotype control at the
same concentration, or DPBS-SA as a negative control for 1 hour at 4°C. Each of these
primary antibody treatments were repeated in 2 of the conical tubes of each cell line.
Cells were then centrifuged, washed with DPBS-SA, centrifuged again and resuspended
in 200 l of secondary FITC-conjugated goat anti-mouse IgG (H+L) antibody (Biomeda,
Foster City, CA, USA) or DPBS-SA as a negative control and incubated at 4°C for 30
minutes. Cells were then centrifuged, washed with DPBS-SA, resuspended in DPBS-SA
with 2% formaldehyde, kept cold and analyzed soon after by flow cytometry
(FACSCalibur, Becton and Dickinson, Franklin, NJ, USA). All voltage and gain settings
were maintained constant during analysis to be able to do a comparative analysis of the
fluorescence associated with each sample.
The fluorescence levels of these three cell lines after exposure to the primary and
secondary antibodies were confirmed by confocal microscopy. Samples from the fixed
cells of the above study were mounted onto microscopy slides and observed with a Leica
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SP2 AOBS confocal fluorescence microscope while maintaining all microscope and
software settings constant for comparison between samples.
7.2.4 Determination of Therapeutic Efficacy of Targeted Nanoparticles
Each of the three cell lines was seeded at a concentration of 5,000 cells per well in
the central 60 wells of nine 96-well plates with 100 l of complete growth media. The
remaining 36 wells of each plate were filled with 200 l of DPBS to minimize loss of
moisture from the plates. Two days after seeding, the cell media was replaced with 100
l of complete media containing one of a series of formulations. These formulations
included blank or doxorubicin-loaded PLA-PEG nanoparticles conjugated to anti-FSHR
antibody mAb106-105, IgG2b control antibody or no antibody, blank and doxorubicin-
loaded PLGA nanoparticles, free doxorubicin in solution or unmodified media as a
control. Each formulation was repeated in 5 wells.
The concentration of nanoparticles was such that the doxorubicin content was
maintained constant between samples. Nanoparticle samples with no doxorubicin were
added at the same nanoparticle concentration as doxorubicin-loaded nanoparticles with
the same antibody. The mass of each nanoparticle formulation to be used was calculated
from the desired doxorubicin concentration, the known weight percent of doxorubicin in
each batch, and the nanoparticle-to-trehalose ratio that was determined for each batch.
Nanoparticles were first weighed, resuspended in 10 ml of cold sterile water and
centrifuged for 1 hour in a Beckman J2-21 refrigerated centrifuge (Beckman Instruments
Inc., Palo Alto, CA, USA) at 43,000 x g to remove excess trehalose. The nanoparticle
pellets were then resuspended in 0.6 ml of DPBS with Ca/Mg. A volume of 0.4 ml of
these suspensions was further diluted in 1.6 ml of DMEM media for the Caov-3 and
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MDA-MB-231 cells, while the remaining 0.2 ml were diluted in RPMI media for the
OVCAR-3 cells. The doxorubicin concentrations tested were 0.1, 1.0 and 10.0 g/ml.
Cells were incubated for 24 hours in these formulations, after which the media
was removed and the cells were washed three times with DPBS with Ca/Mg ions.
Complete growth media was then added to the cells and these were incubated for 2 days
to allow the drug to act as the cells attempted to replicate. After this incubation period,
10 l of 5 mg/ml MTT solution in DPBS with Ca/Mg was added and the cells were
incubated for 4 hours. After this incubation period, the cell media was removed by
inverting the plates and gently tapping them against paper towels. Then, 200 l of
dimethylsulfoxide were added to each well to solubilize formazan crystals produced by
live cells. After confirming solubilization of crystals by microscopy, the absorbance of
each well was read at 570 and 690 nm using a BioTek SynergyTM HT microplate reader
(Winooski, VT, USA). The absorbance difference at these two wavelengths was used to
determine the viability of the cells exposed to each formulation relative to control cells
not exposed to any formulation.
It should be noted that the PLA-PEG nanoparticle formulations used contained
doxorubicin-loadings in the range of 0.196 to 0.282 wt. % and nanoparticle-to-trehalose
ratios of 0.11 to 0.18 depending on the encapsulation efficiency and yield of each batch.
The PLGA batch, on the other had, had a doxorubicin content of 1.69 wt.% and no
trehalose. Nonetheless, the actual doxorubicin concentrations that the cells were exposed
to were maintained constant, as described above.
7.2.5 Microscopy Study of Interactions of Nanoparticles with Cells
Each of the cell lines was seeded at a concentration of 5,000 cells per well in 8-
welled Lab-TekTM chambered coverglass (Nalge Nunc International, Rochester, NY) in
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complete growth media and incubated at 37°C and 5% CO2 atmosphere for 4 days before
beginning the study to permit enough time for the cells to attach to the less-favorable
glass substrate and begin replicating. To begin the study, the media was removed and
replaced with complete media containing various nanoparticle or drug formulations.
Specifically, the six formulations tested were doxorubicin-loaded PLA-PEG
nanoparticles conjugated to mAb106-105 anti-FSHR antibody, IgG2b isotype control
antibody or no antibody, doxorubicin-loaded PLGA nanoparticles, free doxorubicin in
solution and free media as a control.
The concentration of nanoparticles was adjusted so that the doxorubicin
concentration was maintained at 10 g/ml in all the formulations. The mass of each
nanoparticle formulation to be used was calculated from the desired doxorubicin
concentration, the weight percent of doxorubicin in each batch, and the nanoparticle-to-
trehalose ratio of each batch. The PLA-PEG nanoparticle batches used had a doxorubicin
content of 0.18 to 0.22 wt. %, while the PLGA batch had a doxorubicin content of 1.69
wt.%. The PLA-PEG nanoparticle batches also had a nanoparticle-to-trehalose ratio in
the range of 0.14 to 0.18 by weight, while the PLGA nanoparticle batches contained no
trhalose. The desired mass of nanoparticles was resuspended in 10 ml of cold sterile
water and centrifuged for 1 hour at 43,000 x g to remove excess trehalose. The
nanoparticle pellets were then resuspended in the appropriate complete cell culture media
depending on the cell line, and added to the cells.
After 3 hours of cell exposure to the formulations, the media was removed, the
cells were washed three times, and complete growth media was added. Cells were
immediately imaged with a Leica SP2 AOBS confocal microscope utilizing the natural
fluorescence of doxorubicin to determine the interaction of the nanoparticles with the
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cells. All laser and detection settings were maintained constant during the study for
comparison of fluorescence intensities between formulations.
7.3 RESULTS
7.3.1 Expression of FSHR by Cell Lines
Figure 7.1 displays the results of immunocytochemical detection of FSHR
expression by the three cell lines to be used in these studies. In the control breast cancer
cell line MDA-MB-231, only minor increases in mean fluorescence intensities were
observed with exposure to FITC-conjugated secondary antibody, regardless of the type of
primary antibody, thus confirming the absence of the FSHR receptors on the surface of
these cells. In OVCAR-3 cells, slightly higher fluorescence was observed in all samples
exposed to the labeled secondary antibody; however, significantly higher fluorescence
was detected from the samples exposed to the anti-FSHR antibody and the secondary
antibody in comparison to all other samples and cell lines, thus confirming expression of
the target receptor, as expected based on prior reports (Choi, Choi et al. 2004; Choi, Choi
et al. 2006).
In Caov-3 cells, no significant difference was observed between all samples,
including those exposed to the anti-FSHR antibody, thus suggesting that the cells do not
express this receptor. This result is contrary previous reports of high expression levels of
FSHR that were determined by immunoblot (Choi, Choi et al. 2004). It is possible that
different expression levels are manifested based on cell culture conditions. In addition,
the fact that previous studies had observed low FSHR mRNA but high FSHR protein
levels could suggest that the expression of this receptor is modulated by the cells
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according to various stimuli and, consequently, the expression of this receptor varies with
time and conditions even in culture.
7.3.2 In Vitro Therapeutic Effect of Formulations
The MTT assay was used for determination of cell viability after exposure to
various nanoparticle formulations. This assay is based on the cleavage of the tetrazolium
ring of the MTT reagent by action of mitochondrial dehydrogenases of viable cells
(Mossman 1983). This cleavage results in the formation of formazan crystals which are
insoluble in aqueous solutions, but are soluble in acidified isopropanol or
dimethylsulfoxide. The concentration of soluble formazan, as determined
spectrophotometrically, is proportional to the number of live cells in the sample, thus
indicating the effect of the various formulations on cell growth. The MTT assay among
the few that can be used for determination the activity of doxorubicin-containing
formulations because the absorbance and fluorescence of this drug interferes with most
other cytotoxicity or live/dead assays.
Figures 7.3, 7.4 and 7.5 display the viability of the OVCAR-3, Caov-3 and MDA-
MB-231 cells after exposure to the various formulations. For all three cell lines, a
decrease in cell viability was observed with increased dose, including after exposure with
blank and doxorubicin-loaded nanoparticles. Significant reductions in cell viability by
doxorubicin-loaded nanoparticles compared to blank nanoparticles were observed for
most samples at the highest exposure concentration equivalent to 10 g/ml and in a few
samples at the intermediate concentration of 1.0 g/ml. No significant decrease in cell
viability was caused by the nanoparticles containing conjugated anti-FSHR antibody
mAb106-105 in any of the cell lines compared to nanoparticles with the control antibody
IgG2b or without an antibody at the highest dose, which is the dose at which the cell
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viability decreased caused by doxorubicin-loaded nanoparticles was significantly lower
than that caused by blank nanoparticles.
The reduced cell viability encountered after exposure to all nanoparticle
formulations could suggest that trace amounts of monomers, catalysts, solvents, antibody
conjugation reagents and trehalose could have remained in the formulations; however,
this hypothesis does not explain reduction in cell viability for every single formulation
since those batches without antibodies had not been exposed to the conjugation reagents
and those made with PLGA had not been exposed to trehalose. On the other hand, in this
study the concentration of nanoparticles used at the highest dose was in the range of 4.4
to 6.4 mg/ml for PLA-PEG batches as a result of their low doxorubicin content. This
concentration, and the number of particles that it represents, is quite high and possibly
resulted in reduction in cell viability as a result of mechanical shear stresses caused by
the Brownian motion of the colloids in suspension. Nonetheless, at this dose the effect of
doxorubicin on cell growth was observed, thus indicating the drug activity is maintained.
In this study, cells were exposed to the various formulations for 24 hours, in
contrast to the 2 hours used in the study presented in Chapter 3 (Figure 3.5). This longer
exposure time was chosen because of the slower rate of drug release observed with
doxorubicin-loaded PLA-PEG nanoparticles, which limited the amount of free drug to
less than 25% of the total during this incubation time at both pH 7.4 and 6.0 according to
the release studies described in Chapter 6. At the same time, however, this increased the
time that the cells were subjected to the unfavorable nanoparticle suspension, thus
resulting in cell death that is not associated with the action of the drug.
Despite these problems, the data show that no significant increase in cell death is
caused by the targeted doxorubicin-loaded nanoparticles on the cells expressing the target
FSH receptor. It is possible that the number of antibodies conjugated per nanoparticle is
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too low for favorable interaction of the nanoparticles with the target receptors. As
described in Chapter 6, the number of antibodies per nanoparticle was calculated to be in
the range of 1 to 7. In addition, the chemistry used for conjugation of the antibodies, as
described in Chapter 6, does not discriminate between the N-terminal and lysine amine
groups in the antibody (Hermanson 1996). As such, conjugation can occur at any one of
a number of locations in an antibody, which could result in blockage of the antigen
binding domain and consequent reduction in biological activity (Chapman 2002). The
binding potential of antibodies after random conjugation to poly(ethylene glycol) chains
was reported to decrease from 20 to 90% depending on the antibody type, number of
conjugations per antibody and PEG molecular weight, as reviewed previously (Chapman
2002). Conjugation to nanoparticles can, in addition, prevent proper antibody-receptor
recognition and binding as a result of steric hindrance by surrounding PEG chains.
7.3.3 Microscopy Study of Cell-Nanoparticle Interaction
Cells were imaged while live with a confocal microscope using the natural
fluorescence of doxorubicin to investigate the interaction of the PLA-PEG and PLGA
nanoparticles with ovarian and breast cancer cells. Figures 7.6, 7.7 and 7.8 display
images of the fluorescence associated with each sample after a 3 hour exposure to
doxorubicin-loaded PLA-PEG nanoparticles with anti-FSHR antibody mAb106-105
(PLA-PEG-mAb), with isotype control antibody IgG2b (PLA-PEG-IgG2b) or without an
antibody (PLA-PEG-NA), doxorubicin-loaded PLGA nanoparticles or free doxorubicin
in solution. As presented, in OVCAR-3 cells that express the FSHR receptor, a similar
low level of fluorescence is observed in cells exposed to PLA-PEG-mAb, PLGA
nanoparticles or free doxorubicin in solution. A slightly higher level of fluorescence was
observed in cells exposed to PLA-PEG-IgG2b nanoparticles. The fluorescence intensity
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of cells exposed to PLA-PEG-NA nanoparticles was, however, drastically higher than
with all other formulations.
In cells exposed to doxorubicin-loaded PLA-PEG nanoparticles, the distribution
of the fluorescence signal was limited to the cytoplasm of the cells, thus suggesting that
the drug is still associated with the nanoparticles. In cells exposed to PLGA
nanoparticles or doxorubicin solution, the drug was mostly associated with the nucleus of
the cells, as previously observed in studies described in Chapter 3 (Figures 3.6 and 3.7).
Nuclear localization requires, however, that the drug be dissociated from the
nanoparticles for transport across nuclear pores. These results agree with the drug release
behavior of PLA-PEG nanoparticles described in Chapter 5 which found no differences
in the release of the drug at physiological pH of 7.4 or acidic pH of 6.0 during the first
day and that from PLGA nanoparticles described in Chapter 3 (Figure 3.2) which found a
significantly accelerated at acidic pH. When the nanoparticles are endocytosed, exposure
to acidic conditions in the endolysosomal compartments leads to rapid release of the drug
from PLGA nanoparticles, but not so from PLA-PEG nanoparticles.
Similar increased fluorescence signal in addition to some nuclear fluorescence
was observed in Caov-3 and MDA-MB-231 cells exposed to PLA-PEG-NA nanoparticles
compared to those bound to the anti-FSHR mAb106-105 or IgG2b antibody. In addition,
increased nuclear localization in cells exposed to PLGA nanoparticles was observed in
comparison to cells exposed to free doxorubicin in both of these cell lines, as previously
described in Chapter 3 for the breast cancer cell line.
Results suggest that the conjugation of antibodies, whether mAb106-105 or
isotype control IgG2b, on the surface of the nanoparticles decreases their ability to
interact with the cells in comparison to PLA-PEG nanoparticles with no antibody. Zeta
potential measurements, presented in Chapter 6, did not show significant differences
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between these formulations. During conjugation of the antibody, the terminal carboxyl
groups of PEG are activated to their N-hydroxysuccinimide (NHS) ester, as shown on
Figure 6.1. After conjugation of the antibodies, all free NHS esters would by hydrolyzed
back to the carboxylic acid in the presence of water at neutral or higher pH. The half life
of these NHS esters has been reported to be in the order of less than 30 minutes at this pH
7-9 (Hermanson 1996; NektarTherapeutics 2005). The conjugations were carried out for
3 hours in PBS buffer pH 7.4 and further washes were done in this buffer. Consequently,
the actual surface chemistry of the particles conjugated to antibodies or without these
would not be significantly different
The hydrophilic surface PEG coating and the negatively charged end groups of
the PLA-PEG nanoparticles in theory would impede their uptake into the cells through
the hydrophobic and also negatively charged cell membrane. Consequently, some type of
active transport must be facilitating the uptake of the PEGylated nanoparticles into the
cytoplasm of the cells.
Similarly to what was observed from therapeutic efficacy studies described in the
previous section, the results show that no increased cell-nanoparticle interaction was
facilitated by the anti-FSHR antibody on the FSHR-positive cells. As described, it is
possible that the number and activity of the antibodies bound to the surface of the
nanoparticles are not sufficient to mediate active binding and/or transport into the cells.
7.4 CONCLUSIONS
Cellular studies described in this chapter evaluated the efficacy of targeted
PEGylated nanoparticles at interacting with cells expressing the target follicle stimulating
hormone receptor and causing decrease in cell growth compared to the free
chemotherapeutic agent doxorubicin and to non-targeted and non-PEGylated
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formulations. Cytotoxicity studies determined that no increased cell viability reduction
was caused by exposure to the targeted nanoparticles in comparison to non-targeted or
non-PEGylated nanoparticles. A reduction of cell viability compared to control was
observed after exposure to most of the formulations at the three doses tested possibly as a
result of shear forces on the cell by the colloids or the presence of trace non-
biocompatible compounds in the nanoparticles, although formulations including
doxorubicin caused higher reductions in cell viability than blank nanoparticles at
intermediate and higher doses, as expected. In vitro imaging studies also revealed that
the interaction of nanoparticles with cells was decreased in formulations that had been
conjugated to antibodies, regardless of the antibody type. No increased association of
targeted nanoparticles was seen in FSHR-positive OVCAR-3 cells. All results suggest
that the number of antibodies conjugated to the nanoparticles was not sufficient to permit
specific recognition, binding and transport of the targeted nanoparticles with the target
FSH receptor.
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Figure 7.1 Immunocytochemical determination of FSHR expression in model cell lines.
Data show clear expression of FSHR by OVCAR-3 cells.






















1 Anti-FHSR (mAb106-105) Yes
2 Anti-FHSR (mAb106-105) No
3 IgG2b control Yes




Figure 7.2 Fluorescence and corresponding differential interference contrast
microscopy images of (A) OVCAR-3 ovarian cancer cells, (B) Caov-3
ovarian cancer cells and (C) MDA-MB-231 breast cancer cells. The
intensity of fluorescence represents the expression of the follicle-







2 DOX - PLA-PEG-mAb106-105 NPs
3 DOX - PLA-PEG-IgG2b NPs
4 DOX - PLA-PEG NPs - No Antibody
5 Blank - PLA-PEG-mAb106-105 NPs
6 Blank - PLA-PEG-IgG2b NPs
7 Blank - PLA-PEG NPs - No Antibody
8 DOX - PLGA NPs
9 Blank - PLGA NPs
10 DOX solution
Figure 7.3 Viability of NIH:OVCAR-3 cells after exposure to blank and doxorubicin-
loaded PLA-PEG and PLGA nanoparticles with or without targeting
antibodies as determined by the MTT assay. Viability presented as a
fraction relative to control cells maintained in complete growth media
without nanoparticles or drug. Error bars represent the standard deviation
between 5 repetitions for each condition. * Significantly different from



























































2 DOX - PLA-PEG-mAb106-105 NPs
3 DOX - PLA-PEG-IgG2b NPs
4 DOX - PLA-PEG NPs - No Antibody
5 Blank - PLA-PEG-mAb106-105 NPs
6 Blank - PLA-PEG-IgG2b NPs
7 Blank - PLA-PEG NPs - No Antibody
8 DOX - PLGA NPs
9 Blank - PLGA NPs
10 DOX solution
Figure 7.4 Viability Caov-3 cells after exposure to blank and doxorubicin-loaded
PLA-PEG and PLGA nanoparticles with or without targeting antibodies as
determined by the MTT assay. Viability presented as a fraction relative to
control cells maintained in complete growth media without nanoparticles
or drug. Error bars represent the standard deviation between 5 repetitions
for each condition. * Significantly different from control. & Significantly




















































2 DOX - PLA-PEG-mAb106-105 NPs
3 DOX - PLA-PEG-IgG2b NPs
4 DOX - PLA-PEG NPs - No Antibody
5 Blank - PLA-PEG-mAb106-105 NPs
6 Blank - PLA-PEG-IgG2b NPs
7 Blank - PLA-PEG NPs - No Antibody
8 DOX - PLGA NPs
9 Blank - PLGA NPs
10 DOX solution
Figure 7.5 Viability MDA-MB-231 cells after exposure to blank and doxorubicin-
loaded PLA-PEG and PLGA nanoparticles with or without targeting
antibodies as determined by the MTT assay. Viability presented as a
fraction relative to control cells maintained in complete growth media
without nanoparticles or drug. Error bars represent the standard deviation
between 5 repetitions for each condition. * Significantly different from

















































Figure 7.6 Confocal microscopy images of OVCAR-3 cells exposed to doxorubicin-
loaded PLA-PEG nanoparticles with anti-FSHR mAb106-105 antibody (A),
IgG2b antibody (B), or no antibody (C), DOX-loaded PLGA nanoparticles





Figure 7.7 Confocal microscopy images of Caov-3 cells exposed to doxorubicin-loaded
PLA-PEG nanoparticles with anti-FSHR mAb106-105 antibody (A), IgG2b
antibody (B), or no antibody (C), DOX-loaded PLGA nanoparticles (D),







Figure 7.8 Confocal microscopy images of MDA-MB-231 cells exposed to
doxorubicin-loaded PLA-PEG nanoparticles with anti-FSHR mAb106-105
antibody (A), IgG2b antibody (B), or no antibody (C), DOX-loaded PLGA
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The need for improved therapies for the treatment of cancer is still great despite
decades of research. The development of engineered drug delivery systems is one of the
strategies that are currently being investigated for improvement of patient quality of life
during treatment and outcome after treatment. These systems promise to improve the
pharmacological behavior of anticancer drugs in vivo in order to improve the therapeutic
effect while minimizing dose-limiting side effects.
The systems developed in this research were designed for targeted and controlled
delivery of the chemotherapeutic agent doxorubicin to ovarian tumors. Specifically, the
design of this drug delivery carrier consisted of nanoparticles with a core of a
biodegradable polyester of the poly(lactic-co-glycolic acid) family and surface pendant
chains of functional poly(ethylene glycol) to which antibodies specific to the follicle
stimulating hormone receptor were conjugated. These nanoparticles were expected to be
superior to normal bolus administration of the drug because the use of nanoparticles
would improve the lifetime of the drug in the circulation, increase the accumulation of
the drug at the tumor site, increase the time that the tumor would be exposed to the drug,
and minimize the amount of drug able to enter healthy tissue as a result of the entrapment
of the drug within a macromolecular matrix. In addition, by use of targeting antibodies,
these particles were designed to be able to actively recognize and bind to the diseased
ovarian tissue.
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In the course of the research, the first studies were focused on the encapsulation
of the chemotherapeutic agent doxorubicin in the core of nanoparticles of poly(lactic-co-
glycolic acid). A nanoprecipitation method was successfully employed to this end,
leading to the preparation of spherical nanoparticles of size in the range of 200 nm with a
relatively high content of the drug compared to that achieved in a number of previously
reported formulations. The encapsulation of doxorubicin with this method proved to be
reproducible and efficient, thus maximizing the use of the drug. In vitro studies showed
that doxorubicin was released form these particles in a controlled and pH-dependent
manner. Under normal physiological conditions the drug would be more protected within
the core of the particles while in the more acidic tumor extracellular fluid and after
endocytosis into the cells, the nanoparticles would rapidly release the drug thus allowing
it to act on the cells. The pH dependency of the drug release was hypothesized to be
associated with charge interactions between positively charged amine groups of
doxorubicin and negatively charged terminal carboxyl groups of the polymer.
Studies of the interaction of these particles with breast cancer cells in vitro
showed that short exposure of the cells to the particles resulted in as much therapeutic
effect as the free drug at the same dose. These results were encouraging because in vivo
the amount of drug that would reach the tumor was expected to be significantly higher for
the nanoparticle-based formulation than for the drug alone. Microscopy studies with
these cells also showed that the drug was taken up by the cells faster and in a greater
amount when presented to them encapsulated within nanoparticles than when in solution.
The same nuclear localization of the drug within the cells was observed with both
formulations, thus confirming the activity of the drug even after encapsulation.
After having successfully synthesized nanoparticles loaded with a high payload of
the chemotherapeutic agent doxorubicin, the focus of the research was then to prepare
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nanoparticles loaded with imaging agents for in vitro and in vivo monitoring of the fate of
these formulations. For this purpose, the various formulations would need to have
similar physiochemical characteristics so very similar preparation methods were utilized.
The imaging agents rhodamine 6G, indocyanine green and gadopentetic acid were
encapsulated within poly(lactic-co-glycolic acid) nanoparticles. Rhodamine
encapsulation was achieved with high efficiency. Rhodamine-loaded nanoparticles were
optimal for fluorescence microscopy studies as they retained the fluorescent agent for
extended periods of time so that all significant fluorescence signal detected would be
associated with the particles during in vitro studies. Cellular studies also showed
improved intake of the agent by the cells when encapsulated within nanoparticles than
when in solution. Indocyanine green encapsulation was much less efficient than that of
doxorubicin of rhodamine as a result of its high hydrophilicity, but the content of
indocyanine green within nanoparticles was determined to be sufficient for detection of
the particles in animal studies. Confirmation of the encapsulation of the paramagnetic
and electron dense agent gadopentetic acid was challenging as a result of its unique
properties. Studies with inductively coupled plasma mass spectroscopy and energy
dispersive spectroscopy showed that incorporation of gadopentetic acid within
nanoparticles was low if any at all. Although alternative nanoparticles preparation
methods could have resulted in higher encapsulation efficiency indocyanine green or
gadopentetic acid, the need for preparation of imaging nanoparticles that had similar
properties to those of doxorubicin-loaded particles negated this option.
Having prepared particles with chemotherapeutic and imaging agents that could
be used in vitro, the next step of the research was to modify the surface of the
nanoparticles to improve their in vivo potential by incorporation of functional
poly(ethylene glycol) (PEG). Various methods were investigated to this end, including
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the use of polymer blends, the conjugation of pre-made polymers and the preparation of
copolymers by polymerization of the core polyester onto pre-made heterofunctional PEG.
The effectiveness of incorporation of PEG in formulations prepared with polymer blends
was highly dependent on the characteristics of the polymers. Incorporation of simple
functional PEG was minimal. Triblock copolymers of poly(propylene oxide) (PPO) and
PEG were, on the other hand, incorporated with up to 76% efficiency as a result of the
higher hydrophobicity of the central PPO domain. These two latter methods, however,
could not assure permanent modification of the particle surfaces since they relied on
physical association. Covalent conjugation of PEG to the terminal carboxyl groups of the
biodegradable polyester in solution was effective when the reaction conditions were
optimized. However, purification and recovery of the polymer proved to be challenging
as a result of the amphiphilic character of the copolymers synthesized. Conjugation of
PEG directly to the surface of the nanoparticles using the exposed carboxyl groups of the
core polyester was significantly less efficient, possibly as a result of inaccessibility of
these groups because of adsorbed surfactant. The most reproducible and efficient
method of preparation was the ring-opening polymerization of the polyester onto pre-
made heterofunctional PEG. These copolymers were synthesized reproducibly and in
high yields. Also, by varying the reagent amounts, the composition and molecular weight
of the copolymers was adjusted.
The encapsulation of the previously-discussed chemotherapeutic and imaging
agents in nanoparticles prepared with the copolymers was then assessed. In addition,
targeting antibodies were conjugated to the terminal carboxyl groups of PEG on the
surface of these nanoparticles. All formulations were significantly different than those
solely prepared with poly(lactic-co-glycolic acid). The encapsulation efficiency of
doxorubicin and rhodamine decreased, possibly as a result of significant decrease in the
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size of the nanoparticles and translocation of the negative charge of the polymer terminal
groups from the core of the particles to the terminal end of the PEG chains on the surface
of the particles. However, the release of doxorubicin from the modified formulation was
better controlled. Rhodamine, on the other hand, was found to escape more easily from
the nanoparticles prepared with the copolymers. Encapsulation of indocyanine green in
nanoparticles made with the copolymer was increased, possibly as a result of the higher
hydrophilicity of the particles as a result of the presence of poly(ethylene glycol).
Conjugation of targeting or control antibodies to the surface of the nanoparticles was
successfully confirmed by an Elisa-like assay.
The interaction of targeted nanoparticles with or without the drug was evaluated
in the ovarian cancer cell lines OVCAR-3 and Caov-3, in addition to the MDA-MB-231
breast cancer cells used for evaluation of the unmodified doxorubicin and rhodamine
nanoparticles. These studies showed that the nanoparticles containing the targeting
antibodies did not result in improved interactions or therapeutic effect than nanoparticles
without these antibodies, possibly because the small number of antibodies conjugated per
nanoparticle were not sufficient to mediate active recognition and binding to the target
receptor. In addition, these studies suggested that the nanoparticle formulations caused
reduction of cell viability in the absence of the chemotherapeutic drug, possibly because
of negative mechanical or chemical interaction of the nanoparticles with the cells.
Future improvements in the development of this targeted drug delivery system for
ovarian cancer should address the physiochemical characteristics of the nanoparticle
formulation that could be interfering with cell viability. In addition, to achieve the
targeting potential of the nanoparticles, further studies will need to investigate the effect
of increased targeting agent presentation on their interactions with target cells. Also, the
effect of the choice of targeting agent between antibodies, antibody fragments, targeting
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peptides and aptamers on the interaction of the nanoparticles with the in vitro models of
tumors should be studied.
The present research contributed to the understanding of key parameters in the
preparation of polymeric nanoparticles for therapeutic and imaging purposes in biological
systems. In addition, it demonstrated the significant differences in the interaction of
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